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Abstract 
Pluripotency is defined as the capacity to give rise to all cell types of the embryo proper. It arises in the 
early mammalian embryo but is lost after a short period of time as cells differentiate and become 
committed to different lineages. Prior to implantation, mouse epiblast cells enter the pluripotent naïve 
state, which can be captured in vitro in the form of embryonic stem cells. These cells are characterized 
by a capacity for indefinite self-renewal, and the ability to re-enter normal development upon being 
returned to the naïve epiblast. A complex transcription factor network promotes this state. 
Overexpression of one of many of these factors leads to stabilisation of the naïve state, with enhanced 
self-renewal and reduced spontaneous differentiation. However, the transcription factor Oct4 must be 
maintained within a tight window of expression; depletion results in extraembryonic differentiation, 
while overexpression also results in exit from pluripotency. 
Oct4 was identified as a protein expressed in the early embryo and in germ cells, and was subsequently 
discovered to be essential for the establishment of the naïve epiblast. In vitro studies determined that 
loss of Oct4 in ESCs induced trophoblast differentiation. Meanwhile, overexpression of Oct4 led to 
differentiation of ESCs, and constitutive expression of Oct4 was not sufficient to replace any of the 
extrinsic factors required for ESC self-renewal. Despite these dramatic phenotypes, the essential role 
of Oct4 remains unclear, further complicated by the finding that a reduced level of Oct4 promotes self-
renewal at the expense of differentiation capacity. 
In this work, I generated a novel Oct4 fusion protein capable of rapid inducible degradation in order 
to study the immediate responses to removal of Oct4. This system utilizes the auxin responsive 
degradation domain of the Arabidopsis thaliana IAA17 protein to recruit a transgenic F-box protein 
Tir1 on addition of the small molecule auxin to the culture medium. Subsequent ubiquitination by the 
endogenous SCF complex leads to rapid proteolytic degradation of the Oct4 fusion protein, resulting 
in loss of detectable protein in as little as two hours. This system allows the study of immediate 
responses to loss of Oct4 in contrast to conventional depletion systems in which Oct4 levels decay over 
a protracted period making it difficult to disentangle direct and indirect effects. 
I established that several pluripotency-associated genes require Oct4 for their transcription. RNA 
levels of these factors decrease rapidly on depletion of Oct4, prior to significant changes in the 
expression of other key pluripotency factors such as Nanog and before protein levels of other factors 
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can change dramatically. Furthermore, I established that the presence of Oct4 antagonises chromatin 
binding by Nanog, revealing a possible mechanism by which increased Oct4 levels are detrimental to 
the naïve state. Together, these findings may be sufficient to explain the simultaneous requirement 
for, and antagonistic activity of, Oct4 in naïve pluripotent cells. 
I also found that an ESC level of Oct4 facilitates cell identity transitions. Cells constitutively expressing 
Oct4 and differentiated in vivo could be reverted to naïve pluripotency in vitro through the application 
of defined naïve pluripotency growth conditions. Additionally, in the course of these experiments I 
examined the phenotypic abnormalities that occur in mouse embryonic development under 
continuous expression of Oct4. In keeping with previous work, we observed abnormalities in limb 
development and in the skin. We also observed exencephaly in a number of embryos. 
In conventional exit from pluripotency, female cells must inactive an X chromosome in order to 
balance X-linked gene expression between males and females. This is achieved via expression of Xist 
from a single X chromosome, where it orchestrates chromosome-wide silencing. I show that Oct4 
plays an important role in the regulation of Xist during the exit from pluripotency. I find that, in the 
absence of Oct4 or in extraembryonic differentiation induced by other methods, such as 
overexpression of Cdx2 or Gata6, downregulation of Xist does not occur in male cells resulting in 
persistent high levels of Xist expression. Normally, Oct4 expression persists after the downregulation 
of most naïve transcription factors during early differentiation. I propose that this allows Oct4 to 
antagonise expression of the Xist, and thus ensure proper control over X chromosome inactivation. 
Together this work focuses on the dual roles of Oct4 in regulating both pluripotency and 
differentiation. I address the contradictory phenotypes relating to altered expression of Oct4, and 
establish a unifying theory to explain them. I put forward evidence that Oct4 promotes cell fate 
transitions by regulating naïve transcription factors. I propose that the environment plays a key role 
in determining cell identity, while Oct4 acts to maintain plasticity by preventing cells from being 




Acknowledgements ........................................................................................................................................ I 
Abstract .......................................................................................................................................................... II 
Contents .......................................................................................................................................................IV 
List of Figures ............................................................................................................................................ VII 
List of Abbreviations ................................................................................................................................... IX 
List of Tables ................................................................................................................................................. X 
List of Equations ........................................................................................................................................... X 
List of Appendices ........................................................................................................................................ X 
Chapter 1: Introduction ................................................................................................................................ 1 
1.1. Pluripotency and early mouse development .................................................................................... 1 
1.1.1. The early mouse embryo ............................................................................................................ 1 
1.2. Studying pluripotency in vitro ........................................................................................................... 4 
1.2.1. Establishing embryonic stem cells ............................................................................................. 4 
1.2.2. The ESC signalling environment .............................................................................................. 5 
1.2.3. Alternative pluripotent identities .............................................................................................. 6 
1.2.4. Current ESC culture conditions ................................................................................................ 8 
1.2.5. Reprogramming to naïve pluripotency .................................................................................. 11 
1.3. The naïve transcriptional network ................................................................................................. 12 
1.3.1. Signalling and transcription regulation .................................................................................. 12 
1.3.2. Previous models explaining the activity of Oct4 in naïve pluripotency .............................. 14 
1.4. X chromosome inactivation ............................................................................................................ 16 
1.4.1. Imprinted XCI ........................................................................................................................... 17 
1.4.2. Elements involved in counting, choice, and initiation of XCI ............................................. 18 
1.5. Aims of this work ............................................................................................................................. 21 
Chapter 2: Materials and Methods ............................................................................................................. 23 
2.1. Cell Culture ....................................................................................................................................... 23 
2.1.1. Culture conditions .................................................................................................................... 23 
2.1.2. Passaging and freezing .............................................................................................................. 24 
2.1.3. Cell lines .................................................................................................................................... 25 
2.1.4. Cell transfection ........................................................................................................................ 25 
2.1.5. NSC Reprogramming ............................................................................................................... 26 
2.1.6. Reprogramming somatic cells from E8.5 embryos ................................................................ 26 
2.1.7. NSC and MEF derivation ......................................................................................................... 26 
  V 
2.2. Molecular Biology ............................................................................................................................ 27 
2.2.1. Plasmids and cloning ................................................................................................................ 27 
2.2.2. RT-qPCR and High Throughput RNA Sequencing .............................................................. 28 
2.2.3. List of primers and Taqman probes ........................................................................................ 28 
2.2.4. Chromatin Immunoprecipitation (ChIP) ............................................................................... 30 
2.2.5. Protein extraction and Western blotting ............................................................................... 31 
2.2.6. Histology .................................................................................................................................... 31 
2.3. Bioinformatic analysis ...................................................................................................................... 32 
2.3.1. ChIP-seq and RNA-seq alignment and visualization ............................................................ 32 
2.3.2. RNA-seq statistical analysis ..................................................................................................... 33 
2.3.3. ChIP-seq analysis ...................................................................................................................... 33 
Chapter 3: Establishing the reprogramming capacity of fixed-Oct4 cells after in vivo differentiation 34 
3.1. Introduction ...................................................................................................................................... 34 
3.1.1. Generating cells with a fixed ESC level of Oct4 ..................................................................... 35 
3.1.2. Cells with an ESC level of Oct4 differentiate and reprogram efficiently in vitro ................ 35 
3.2. Results ............................................................................................................................................... 36 
3.2.1. Fixed-Oct4 cells are able to differentiate in vivo and integrate well into E8.5 chimeras .... 36 
3.2.2. In vivo-differentiated fixed-Oct4 cells reprogram efficiently ................................................ 39 
3.2.3. Constitutive Oct4 expression causes several severe malformations in E12.5 chimeras ..... 44 
3.3. Discussion ......................................................................................................................................... 49 
Chapter 4: Loss of Oct4 reveals that it is both antagonistic to and necessary for expression of the naïve 
transcription factor network ........................................................................................................... 55 
4.1. Introduction ...................................................................................................................................... 55 
4.2. Results ............................................................................................................................................... 56 
4.2.1. Studying Oct4 depletion using a Lox-Cre system .................................................................. 56 
4.2.2. Establishing a novel system to study the immediate effects of loss of Oct4 ........................ 62 
4.2.3. Using rapid depletion to probe the essential function of Oct4 in ESCs............................... 68 
4.2.4. Studying the role of Oct4 in the binding of other transcription factors to DNA ............... 71 
4.2.5. Global analysis of Nanog distribution following loss of Oct4 .............................................. 73 
4.2.6. Studying the epigenetic impact of loss of Oct4 ...................................................................... 79 
4.3. Discussion ......................................................................................................................................... 80 
4.3.1. Conventional systems for depletion of Oct4 pass through an Oct4-low state .................... 81 
4.3.2. DNA binding of pluripotency factors is affected immediately following loss of Oct4 ....... 82 
4.3.3. Oct4 is required for transcription of key pluripotency factors ............................................. 85 
4.3.4. Exit from pluripotency following loss of Oct4 follows a non-conventional trajectory ..... 87 
VI  
4.3.5. Exploring the mechanistic properties of Oct4 ....................................................................... 88 
Chapter 5: Exit from naïve pluripotency induces expression of Xist, which is misregulated in 
extraembryonic differentiation ....................................................................................................... 89 
5.1. Introduction ...................................................................................................................................... 89 
5.1.1. A new model for XCI ............................................................................................................... 90 
5.2. Results ............................................................................................................................................... 91 
5.2.1. Generating cell lines to study XCI in extraembryonic differentiation from ESCs ............. 93 
5.2.2. Extraembryonic differentiation from male mouse ESCs results in Xist upregulation ....... 95 
5.2.3. Oct4 plays a direct role in repression of Xist ........................................................................ 100 
5.3. Discussion ....................................................................................................................................... 103 
5.3.1. Xist is misregulated in male cells following depletion of Oct4 ........................................... 103 
5.3.2. Xist expression is a common feature of extraembryonic differentiation from ESCs ....... 105 
5.3.3. Oct4 overexpression prevents Xist upregulation ................................................................ 106 
Chapter 6: General Discussion ................................................................................................................. 108 
6.1.1. Transcriptional regulation by Oct4 ....................................................................................... 108 
6.1.2. Oct4 as a reprogramming factor ............................................................................................ 111 
6.1.3. Oct4 in pluripotency and differentiation .............................................................................. 112 
6.1.4. Control of Xist repression by Oct4 and in extraembryonic differentiation ...................... 114 
6.1.5. In summary.............................................................................................................................. 119 
6.1.6. On the role of Oct4 ................................................................................................................. 119 
References .................................................................................................................................................. 121 
Appendix A ................................................................................................................................................ 158 
Appendix B ................................................................................................................................................. 166 
Appendix C................................................................................................................................................. 167 
 
  
  VII 
List of Figures 
Figure 1.1 Mouse embryogenesis from fertilization to early post-implantation ..................................... 2 
Figure 1.2 Timeline of key discoveries relating to naïve pluripotency in mouse .................................... 5 
Figure 1.3 Summary of exogenous signals used to maintain naïve and primed pluripotency ............... 9 
Figure 1.4 Outline of the processes of imprinted X inactivation, reactivation, and random XCI ....... 18 
Figure 3.1 Fixed-Oct4 PSCs can be differentiated in vitro and revert to naïve pluripotency on media 
switch ..................................................................................................................................... 36 
Figure 3.2 Generating fixed-Oct4 chimeric embryos ............................................................................... 37 
Figure 3.3 Cryosections and immunofluorescence of E8.5 chimeras (data from Hannah Stuart) ....... 39 
Figure 3.4 Emerging iPS colonies from fixed-Oct4 cells differentiated in vivo ...................................... 42 
Figure 3.5 Retroviral transgenes remain silent during fixed-Oct4 reprogramming ............................. 43 
Figure 3.6 Analysis of expression of pluripotency genes in chimeric embryos and iPSCs ................... 44 
Figure 3.7 Fixed-Oct4 cells contribute efficiently to E12.5 embryos ...................................................... 45 
Figure 3.8 E12.5 fixed-Oct4 chimeric embryos show a range of defects, often with partial penetrance
 ................................................................................................................................................ 48 
Figure 4.1 Oct4 is depleted from Oct4F/- cells following Cre activation ................................................ 57 
Figure 4.2 Analysis of transcriptional changes following loss of Oct4 in Oct4F/- ESCs ........................ 58 
Figure 4.3 Comparison of transcriptional changes following loss of Oct4 in Oct4F/- ESCs vs Oct4 
TetOFF ESCs ......................................................................................................................... 61 
Figure 4.4 Designing and testing a degradable Oct4-AID fusion protein .............................................. 63 
Figure 4.5 Establishing Oct4-AID dependent ESCs (Oct4-AID ESCs) .................................................. 65 
Figure 4.6 Establishing Oct4-AID dependent iPSCs (Oct4-AID iPSCs) ................................................ 67 
Figure 4.7 Profiling transcriptional changes in Oct4-AID ESCs and iPSCs following depletion of 
Oct4 ........................................................................................................................................ 69 
Figure 4.8 Global transcriptional changes in Oct4-AID ESCs reveals non-conventional exit from 
pluripotency ........................................................................................................................... 70 
Figure 4.9 Oct4 affects the binding of other pluripotency factors to the genome ................................. 72 
Figure 4.10 Nanog binding increases at some loci following Oct4-AID depletion in Oct4-AID iPSCs
 ................................................................................................................................................ 73 
Figure 4.11 Nanog genomic occupancy at key pluripotency regulatory elements ................................ 74 
Figure 4.12 Global analysis of Nanog binding sites .................................................................................. 76 
Figure 4.13 Nanog protein is more stable in the presence of Oct4-AID ................................................ 78 
Figure 4.14 Changes in active histone modification H3K27ac following Oct4 depletion in Oct4-AID 
ESCs........................................................................................................................................ 79 
Figure 4.15 Changes in enhancer RNA expression following Oct4 depletion in Oct4-AID ESCs ...... 80 
VIII  
Figure 4.16 A model of the relationship between Oct4 protein level and expression of a set of 
pluripotency genes ................................................................................................................ 86 
Figure 5.1 Schematic of the conventional model for XCI and our prospective model for XCI ........... 90 
Figure 5.2 Xist transcription is induced to high and sustained levels in male ESCs following depletion 
of Oct4 .................................................................................................................................... 92 
Figure 5.3 Following deletion of Oct4 in ESCs, trophoblast stem cells can be captured in vitro ......... 93 
Figure 5.4 Experimental design to generate cell lines capable of induced extraembryonic 
differentiation ........................................................................................................................ 94 
Figure 5.5 Characterizing cell lines for inducible extraembryonic differentiation ................................ 95 
Figure 5.6 RNA-sequencing analysis of iGata6 and iCdx2 differentiation ............................................. 97 
Figure 5.7 Expression analysis of iGata6 and iCdx2 cells ......................................................................... 98 
Figure 5.8 Expression within the XIC during extraembryonic and embryonic differentiation ........... 99 
Figure 5.9 Oct4 expression in extraembryonic and EB differentiation, and Oct4 binding sites within 
the XIC ................................................................................................................................. 100 
Figure 5.10 Overexpression of Oct4 in male ESCs results in differentiation with repression of Xist
 .............................................................................................................................................. 102 
Figure 6.1 A potential role for Oct4 in establishing enhancer-promoter interactions ....................... 109 
Figure 6.2 Models of mechanisms by which Oct4 overexpression may induce repression ................ 110 
Figure 6.3 A model for regulation of the XIC during male ESC differentiation ................................. 115 
Figure 6.4 A model for the dysregulation of Xist on deletion of Oct4 ................................................. 116 
Figure 6.5 A speculative model of the mechanism of XCI ..................................................................... 117 
  
  IX 
List of Abbreviations 
2i Combined Chiron and PD03 
4-OHT Synthetic ER agonist 4-hydroxytamoxifen 
A-P Anterior-posterior axis 
AID Auxin inducible degron 
Bsd Blasticidin S or the blasticidin resistance gene 
CAG A synthetic constitutive promoter 
ChIP Chromatin immunoprecipitation 
ChIP-qPCR ChIP followed by qPCR analysis 
ChIP-seq ChIP followed by NGS and downstream analysis 
Chiron Pharmacological GSK3 inhibitor CHIR99021 
CreERT2 Fusion protein of Cre and G400V/M542A/L544A triple mutant human ER 
DAPI 4′,6-diamidino-2-phenylindole, a fluorescent DNA stain 
DMSO Dimethyl sulfoxide 
Dox Doxycycline, a tetracycline derivative 
E Embryonic day (e.g. E4.5 is 4.5 days into embryonic development) 
EGC Embryonic germ cell 
EpiLC EpiSC-like cell 
EpiSC Epiblast stem cell 
ESC Embryonic stem cell 
F Floxed allele 
FCS Fetal calf serum 
FDR False discovery rate 
Floxed Flanked by LoxP sites 
GOI Gene of interest 
H&E Haematoxylin and eosin 
Hyg Hygromycin B 
IAA Indole acetic acid, an auxin plant hormone 
IF Immunofluorescence 
iPSC Induced pluripotent stem cell 
MEF Mouse embryonic fibroblast 
NGS Next generation high throughput sequencing 
NSC Neural stem cell 
qPCR Real time quantitiative PCR 
PB piggyBac transposon 
PCR Polymerase chain reaction 
PD03 Pharmacological MEK1/2 inhibitor PD0325901 
Pre-iPSC Reprogramming intermediate, precursors to iPSCs 
Puro Puromycin 
RNA-seq NGS of RNA 
RT-qPCR Reverse transcriptase qPCR 
rtTA Reverse-tTA 
SL Serum-based media supplemented with LIF 
X  
TRE Tetracycline response element, a series of TetO elements followed by a minimal 
CMV promoter; active when tTA or rtTA is bound. 
TSC Trophoblast stem cell 
tTA Tetracycline responsive transactivator, a fusion protein of TetR and VP16 
XCI X chromosome inactivation 
XIC X inactivation centre 
ZPA Zone of polarizing activity 
List of Tables 
Table 2.1 List of plasmids used in this thesis ............................................................................................. 27 
Table 2.2 Pre-designed taqman probes ...................................................................................................... 28 
Table 2.3 Custom Taqman probes ............................................................................................................. 29 
Table 2.4 RT-qPCR Sybr primers .............................................................................................................. 29 
Table 2.5 ChIP qPCR primers .................................................................................................................... 29 
Table 2.6 List of antibodies used in ChIP experiments ............................................................................ 31 
Table 2.7 Antibodies used for Western Blotting ...................................................................................... 31 
Table 3.1 List of E8.5 embryos harvested showing their chimerism and reprogramming capacity .... 41 
Table 3.2 Score of malformations by embryo and summary of malformations..................................... 47 
List of Equations 
Equation 1: Exponential decay equation .................................................................................................... 79 
Equation 2: Natural log of Equation 1 ....................................................................................................... 79 
Equation 3: Relationship of half-life and decay constant ......................................................................... 79 
List of Lists 
List of Appendices 
Appendix A: Unbiased lists of most differentially expressed genes following induction of iCdx2 and 
iGata6 ESCs. 
Appendix B: Published crystal structures of Oct4 and Sox family proteins bound to DNA and of the 
IAA-AID-SCF complex interaction. 
Appendix C: Publications arising from this work; ‘Reprogramming human cells to naïve 
pluripotency: how close are we?’
 
  
 Introduction 1 
 
Chapter 1: Introduction 
1.1. Pluripotency and early mouse development 
Development is often seen as a gradual restriction in fate potential. Embryogenesis begins with a 
fertilized oocyte, a single zygote with the potential to form every cell of a new organism and all of the 
extraembryonic tissue required to support embryonic growth. Over time, groups of cells differentiate, 
heading down paths limited to extraembryonic identities, while others lose this capacity but maintain 
the potential to contribute to the embryo proper; these are pluripotent cells. As development continues 
cells are segregated into major cell types, the three germ layers and the germ line, where they continue 
to differentiate, gradually losing their potency as they become specialized and adopt specific roles 
around the body. This is wonderfully captured in the concept of Waddington’s landscape 
(Waddington, 1957), a mountain face with peaks and troughs that direct a rolling ball to one of several 
end points; a model of growing epigenetic constraints that direct cells to their identities and stably hold 
them there. 
1.1.1. The early mouse embryo 
Mammalian development has been best characterized in mouse. This is a model system adopted for 
ease of handling and rapid reproductive cycle, and reinforced by the development of techniques that 
allow us to probe the intricacies of development in detail. The earliest stages of mouse development 
are characterized by cleavage divisions of the totipotent zygote (E0, Figure 1.1) to generate a morula 
(~E2.0, Figure 1.1). 
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The zygotic genome is activated early in mouse, perhaps in the zygote itself (Aoki et al., 1997; Bouniol 
et al., 1995); nonetheless, large quantities of maternally derived mRNAs are present to direct these 
initial divisions (Hamatani et al., 2004). After three cycles of cell division, the eight-cell embryo begins 
to undergo compaction (Ducibella et al., 1977; Pratt et al., 1982). Cells obtain apical-basal polarity 
(Ducibella et al., 1977; Vinot et al., 2005) and adhere tightly together (Ducibella and Anderson, 1975; 
Vestweber et al., 1987) (~E2.5, Figure 1.1, inset), and as cells continue to divide the inner cells become 
surrounded by basolateral domains (Hirate and Sasaki, 2014). Cells on the outside of the embryo 
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differentiate towards trophectoderm through the combined activity of YAP/TAZ and the 
transcription factor Tead4, while inner cells remain undifferentiated as their close contact leads to 
activation of the Hippo pathway and degradation of YAP/TAZ (Hirate et al., 2013; Nishioka et al., 
2009, 2008; Yagi et al., 2007). Consequently, the outer cells upregulate trophoblast factors Cdx2 and 
Eomes while silencing Oct4 (Nishioka et al., 2009; Niwa et al., 2005), while expression of Oct4, Sox2, 
Nanog, Pdgfrα and Gata6 become more restricted to the inner cells (Kang et al., 2013; Le Bin et al., 
2014; Wicklow et al., 2014), now forming the inner cell mass (ICM) as a blastocoel-filled lumen opens 
within the embryo (Figure 1.1, inset). At this point, antagonistic regulation between Oct4 and Cdx2 
cements this first fate decision (Dietrich and Hiiragi, 2007; Niwa et al., 2005). 
As the ICM matures, the cells begin to adopt different fates with mutually exclusive expression of 
Nanog and Gata6, marking cells of the presumptive naïve epiblast and hypoblast respectively (Schrode 
et al., 2014; Yamanaka et al., 2010) (~E4.0, Figure 1.1, inset). A mixture of cell sorting and selective 
apoptosis leads to segregation of these cells (Meilhac et al., 2009; Plusa et al., 2008) such that the 
hypoblast overlies the naïve epiblast, which is in direct contact with the trophectoderm. At around 
this time, the zona pellucida is shed and embryos are suitable for implantation. If the previous litter 
has not yet been weaned, signals from the mother can induce embryonic diapause at this point, 
arresting development prior to implantation (Mantalenakis and Ketchel, 1966; Weitlauf and 
Greenwald, 1968). Upon implantation (~E5.0, Figure 1.1), the epiblast undergoes dramatic 
morphological, epigenetic and transcriptional changes. Cells begin to polarize and generate a single 
layered epithelium as a central lumen forms which will become the pro-amniotic cavity (Bedzhov and 
Zernicka-Goetz, 2014; Coucouvanis and Martin, 1995) (~E5.5, Figure 1.1). Shortly after this, the 
visceral endoderm formed from the differentiating hypoblast gains axial polarity, establishing the distal 
and subsequently anterior visceral endoderm (Beddington and Robertson, 1999; Takaoka et al., 2011, 
2006). Signalling from this anterior-specifying region and the overlying trophectoderm lead to 
differentiation of the posterior epiblast into the primitive streak (Tam and Behringer, 1997; Williams 
et al., 2012), characterized by a transition to a multi-layered epithelium. At this site epiblast cells 
undergo an epithelial to mesenchymal transition and ingress, passing through the streak and 
segregating into mesoderm and endoderm while the ectoderm remains on the exterior in the process 
of gastrulation (Lawson and Pedersen, 1987; Quinlan et al., 1995; Tam and Beddington, 1987; Tam 
and Behringer, 1997). As they become determined in their new identity, these cells lose their ability to 
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contribute to other germ layers, and hence lose their pluripotency (Beddington et al., 1992; Carey et 
al., 1995; Kanatsu and Nishikawa, 1996; Tam et al., 1997). 
1.2. Studying pluripotency in vitro 
It was predicted that cells of the pre-implantation mouse embryo might be pluripotent when it was 
demonstrated that small numbers of isolated blastomeres injected into the blastocoel of a recipient 
embryo could contribute to all germ layers of the subsequent embryo, generating chimeric offspring 
(Gardner, 1968). Both pre- and post-implantation embryos can generate tumours containing cells 
from all three germ layers as well as proliferating undifferentiated cells – teratocarcinomas - on transfer 
to the testes of adult mice (Stevens, 1970). Single carcinoma cells derived from teratocarcinomas can 
regenerate tumours containing various somatic tissues, demonstrating functional pluripotency at a 
cellular level (Kleinsmith and Pierce, 1964). These tumours can also form spontaneously from 
primordial germ cells (Stevens, 1967), particularly in certain inbred mouse lines (Stevens and Hummel, 
1957; Stevens and Little, 1954). This led to the capture of pluripotency in vitro in the form of embryonic 
carcinoma cells (ECCs) (Finch and Ephrussi, 1967; Rosenthal et al., 1970). Incredibly, these cells can 
contribute to normal, non-tumorous mice on microinjection into blastocysts (Papaioannou et al., 
1975; Stewart and Mintz, 1981). 
1.2.1. Establishing embryonic stem cells 
By studying conditions that favour the self-renewal rather than differentiation of ECCs, environments 
favourable for derivation of pluripotent cell cultures direct from mouse blastocysts were developed, 
yielding embryonic stem cells (ESCs) (Evans and Kaufman, 1981; Martin, 1981). 
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On introduction into blastocysts, these cells could re-enter normal development and contribute to all 
three germ layers plus the germ line (Bradley et al., 1984). These cells possess a robust, highly 
redundant transcriptional network that maintains their pluripotent character (Niwa, 2018). They are 
a powerful model system for studying general principles of mammalian cell biology and cell fate 
transitions since they can be readily expanded to large numbers and can self-renew indefinitely 
without needing to be immortalized or transformed. 
1.2.2. The ESC signalling environment 
For a long time, mouse ESCs were maintained in cytokine-rich serum-based medium on a feeder layer 
of mouse embryonic fibroblasts (MEFs) (Evans and Kaufman, 1981), or in ECC-conditioned medium 
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(Martin, 1981). Investigations into the factors involved in ESC self-renewal in these conditions 
uncovered the cytokine LIF (Smith et al., 1988; Williams et al., 1988), which enabled propagation of 
mouse ESCs in the absence of feeders in serum-based media supplemented with LIF (SL). This ligand 
binds to LIFR with GP130, resulting in activation of the intracellular kinase JAK. JAK phosphorylates 
STAT3, inducing dimerization leading to nuclear translocation whereupon it acts as a pluripotency-
promoting transcription factor (Figure 1.3) (Matsuda et al., 1999; Niwa et al., 1998). It can be shown 
that the JAK/STAT3 pathway is the major role of this cytokine since Stat3 knockout cells show little 
response to addition of LIF and Stat3Y705F mutants which cannot be phosphorylated by JAK are not 
capable of self-renewal in SL conditions (Huang et al., 2014), while constitutively active STAT3 can 
maintain ESCs in the absence of LIF (Huang et al., 2014; Matsuda et al., 1999). 
Further studies found that BMPs contribute to pluripotency and permit self-renewal of ESCs in serum-
free media containing LIF (Ying et al., 2003). It appears that BMP signalling via SMAD1 and SMAD5 
results in upregulation of Id1 and Id3 which inhibit neural differentiation (Figure 1.3) (Hollnagel et 
al., 1999; Ying et al., 2003). Overexpression of these Id genes is sufficient for ESC self-renewal in 
serum-free media containing LIF alone (Ying et al., 2003). Interestingly, conventional BMP-
SMAD1/4/5 signalling appears to be entirely disposable for the maintenance of mouse ESCs (Gomes 
Fernandes et al., 2016), with the transcription activation properties of SMAD1 being extinguished by 
interaction with Klf4 (Morikawa et al., 2016). Instead, a major role of Bmp signalling appears to be 
through activation of Mek5, which activates Erk5 resulting in upregulation of the naïve factor Klf2 
(Morikawa et al., 2016). 
1.2.3. Alternative pluripotent identities 
As described above, teratocarcinomas can arise from germ cells in mouse embryos (Stevens, 1967), 
suggesting that these cells are either already pluripotent or can readily convert to a pluripotent state. 
Subsequent work has shown that primordial germ cells  (PGCs) themselves are not pluripotent, 
differentiating only to gametes, and cannot integrate into mouse blastocysts (Matsui, 1998). However, 
they express many pluripotency-associated factors (Kurimoto et al., 2008), and rapidly convert to a 
pluripotent identity when cultured in serum-based medium supplemented with FGF, SCF and LIF 
(Matsui et al., 1992, 1991; Resnick et al., 1992). 
Meanwhile, there was significant work put into identifying conditions that could maintain long-term 
self-renewing human ESCs. Pluripotent stem cells (PSCs) were derived from non-human primates 
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using serum-based medium with or without human LIF, and required a feeder layer of MEFs for self-
renewal (Thomson et al., 1996, 1995). Utilizing the experience and knowledge gained from working 
with these primate PSCs, human PSC lines were derived from frozen embryos shortly afterwards 
(Thomson et al., 1998). All of these primate cell lines were very distinct from mouse ESCs, however. 
On explanting embryos in culture, the ICM forms a distinctive domed structure, with cells maintaining 
close contact in a 3-dimentional arrangement. As mouse ESC lines are established, the colonies return 
to this domed morphology after each passage. The primate lines, however, all form a flat epithelium 
without such tight contact between individual cells (Thomson et al., 1998, 1996, 1995). Pluripotent 
human EGCs were established from PGCs, and showed a compacted, rounded morphology more 
reminiscent of mouse ESCs (Shamblott et al., 1998); however, poor derivation and differentiation 
efficiencies limited their use (Turnpenny et al., 2003). 
There were also significant differences in signal requirements between mouse ESCs and primate PSCs. 
As described above, mouse ESCs are dependent on LIF and BMPs to maintain their identity, whereas 
primate PSCs are unresponsive to LIF (Dahéron et al., 2004; Humphrey et al., 2004) and differentiate 
to trophectoderm on BMP induction (Xu et al., 2002). Instead, human PSCs are reliant on the TGFβ-
family ligands Activin A or Nodal and bFGF for their maintenance (Figure 1.3) (Amit et al., 2004; 
Beattie et al., 2005; James et al., 2005; Vallier et al., 2005; Wang et al., 2005; C. Xu et al., 2005; R.-H. 
Xu et al., 2005). Activin-Nodal signalling contributes to the proliferation of mouse ESCs but is not 
essential (Ogawa et al., 2007), while autocrine FGF signalling is important in their exit from 
pluripotency (Kunath et al., 2007) and blockade of downstream MEK/ERK signalling favours their 
self-renewal (Figure 1.3) (Burdon et al., 1999). 
Initially, it was assumed that this was the result of species differences. The post-implantation mouse 
embryo is unusual in forming an egg-cylinder instead of the bilaminar disk seen in most mammalian 
embryos, so a level of signal divergence is not unexpected. However, the derivation of mouse 
pluripotent cell lines with properties highly reminiscent of primate PSCs from the post-implantation 
mouse epiblast suggested that this was not the case. Cells dependent on FGF and Activin/Nodal and 
forming flattened colonies were readily derived from post-implantation mouse embryos, and were 
termed EpiSCs (Brons et al., 2007; Tesar et al., 2007); these are also known as primed cells, as their 
expression of lineage markers implies that they are primed for differentiation. Like primate cells, these 
were unresponsive to LIF (Figure 1.3), and EpiSCs showed similar transcriptional responses to human 
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PSCs on signal inhibition (Tesar et al., 2007). Furthermore, it was demonstrated that cells of the pre-
implantation mouse embryo could be captured in vitro as EpiSCs (Najm et al., 2011) as the epiblast cells 
differentiate until they reach a post-implantation like identity. This can be recapitulated in the efficient 
differentiation of mouse ESCs to EpiSCs by changing growth conditions (Guo et al., 2009). Together, 
this showed that it was possible that primate pre-implantation epiblast cells had converted to a post-
implantation state, and this was the cause for some the differences between primate PSCs and mouse 
ESCs.  
1.2.4. Current ESC culture conditions 
Following research into the role of various signalling cues in the self-renewal of mouse ESCs described 
above, defined culture conditions for their maintenance in the absence of differentiation were 
developed. Relying on two pharmacological inhibitors – PD03, a MEK1/2 inhibitor, and Chiron, a 
GSK3 inhibitor – and LIF (Figure 3.1), this permits growth of ESCs in the absence of serum or feeders 
with little to no background differentiation (Ying et al., 2008). These conditions also allowed 
derivation of ESCs from genetic backgrounds that were previously considered non-permissive as they 
rarely, if ever, yielded self-renewing cell lines in conventional growth conditions (Nichols et al., 2009). 
Further, 2iL conditions allowed derivation of naïve rat ESCs for the first time (Buehr et al., 2008; Li 
et al., 2008). 
As described above, autocrine FGF signalling through MEK/ERK plays a significant role in the 
spontaneous differentiation of ESCs, and blocking this pathway with PD03 increases the propensity 
of cells to self-renew (Figure 1.3). LIF positively regulates naïve gene expression through activation 
of Stat3. By inhibiting GSK3, Chiron prevents the degradation of β-catenin. β-catenin is not essential 
for the maintenance of the naïve identity (Andersson-Rolf et al., 2017; Raggioli et al., 2014; Wray et 
al., 2011). However, it does inhibit the repressive Tcf3-Groucho complex which otherwise antagonises 
self-renewal (Figure 1.3) (Pereira et al., 2006). Additionally, β-catenin is required for cell adhesion and 
genomic stability (Andersson-Rolf et al., 2017; Raggioli et al., 2014). In other contexts, GSK3 also 
regulates mTORC1/2, but in mouse ESCs it appears that GSK3 does not affect mTORC activity 
(Sanchez-Ripoll et al., 2013), while mTORC1 may play a role in regulating GSK3 activity downstream 
of Akt (Li et al., 2018). 
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In addition to providing an environment for robust self-renewal of ESCs, 2iL resolves an issue that 
was ever present in conventional ESC culture systems; cellular heterogeneity. In SL conditions, there 
is significant cell to cell variation in the expression of many pluripotency genes including Nanog 
(Chambers et al., 2007; Hatano et al., 2005), Esrrb (van den Berg et al., 2008) and Rex1 (Toyooka et 
al., 2008). A fraction of cells lose expression of Nanog due to the onset of differentiation, but others 
only transiently downregulate Nanog and then gradually return to a Nanog-high state (Chambers et 
al., 2007; Filipczyk et al., 2015). While in a Nanog-low state, however, cells have an increased 
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propensity to differentiate (Chambers et al., 2007; Kalmar et al., 2009), and may be biased in their 
differentiation (Canham et al., 2010; Singh et al., 2007). This is particularly troubling since expression 
of pluripotency genes appears to be relatively consistent between naïve epiblast cells in the mouse 
embryo (Guo et al., 2010). 2iL culture increases the level of Nanog and other pluripotency factors at a 
population level, partly by greatly reducing the amount of heterogeneity in their expression (Hastreiter 
et al., 2018; Kumar et al., 2014; Marks et al., 2012; Wray et al., 2011). 
Mouse ESCs cultured in 2iL conditions also more closely mirror the epigenetic and transcriptional 
state of the naïve epiblast than cells grown in SL. In vivo these cells are characterized by global DNA 
hypomethylation (Howlett and Reik, 1991; Lane et al., 2003; Smith et al., 2012), almost entirely lacking 
5-methylcytosine except at imprinted loci (Hanel and Wevrick, 2001; Reik and Walter, 2001). 
However, ESCs in SL show a significantly higher level of DNA methylation (Leitch et al., 2013). This 
is reverted to embryo-like levels of hypomethylation when cells are grown in 2iL medium (Leitch et 
al., 2013; Sim et al., 2017). More recently, RNA-sequencing has been performed on early mouse 
embryos and ESCs maintained in different conditions. Cells grown in 2iL closely resemble the 
preimplantation naïve epiblast, whereas SL cultured cells are far more heterogeneous and fail to 
reliably cluster with any single embryonic identity, more closely matching a post-implantation identity 
(Boroviak et al., 2015, 2014). 
Interestingly, there have been recent reports of culture environments that support the growth of 
totipotent cells. However, it appears that these are most similar to ESCs with broader differentiation 
capacity induced by a more permissive epigenetic environment rather than recapitulating early 
embryonic identities in vitro (Yang et al., 2017). 
More recently, conditions have been developed for the propagation of human PSCs in a state that 
much more closely resembles the pre-implantation embryo (Guo et al., 2016; Takashima et al., 2014; 
Theunissen et al., 2016, 2014). However, it remains unclear whether these conditions are optimal and 
how closely they recapitulate their in vivo counterparts (Bates and Silva, 2017). Interestingly, recent 
single-cell RNA sequencing data appears to show that a naïve compartment does exist within the pre-
implantation embryo in rhesus monkey (D. Liu et al., 2018) and human (Stirparo et al., 2018), 
suggesting that these naïve-like human PSCs may be biologically relevant. Nonetheless, mouse ESCs 
still present a more attractive model system for studying naïve pluripotency factors and cell fate 
transitions for the time being. 
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1.2.5. Reprogramming to naïve pluripotency 
In a landmark discovery, Takahashi and Yamanaka found that somatic cells could be reprogrammed 
back to a pluripotent identity in 2006. Overexpression of four factors – Oct4, Sox2, Klf4 and cMyc – 
was sufficient to convert fibroblasts to an induced pluripotent identity (Takahashi and Yamanaka, 
2006), leading to the name iPSCs. While the original report did yield pluripotent cells, as indicated by 
the generation of tissues representing all three germ layers in teratomas, they were clearly distinct 
from ESCs; they continued to express retroviral transgenes to high levels, they only partially reverted 
to an ESC epigenome, and most lines lacked expression of key naïve markers such as Nanog and Rex1. 
The following year, it was reported that selection for the small fraction of cells that upregulated Nanog 
was sufficient to produce iPSCs with more ESC-like characteristics (Okita et al., 2007). Most of these 
cell lines were transgene independent as retroviruses were silenced on complete reprogramming. 
These naïve iPSCs were competent to generate chimeras and even contributed to the germ line. Since 
then, a large amount of effort has been put into developing protocols and identifying additional 
transgenes that contribute to more efficient derivation of iPSC lines, as well as finding alternative 
reprogramming cocktails and genes essential to the reprogramming process. Interestingly, the most 
irreplaceable factor appears to be Oct4, which is used itself or replaced by a factor that directly induces 
Oct4 in the majority of reprogramming cocktails (Radzisheuskaya and Silva, 2014). 
Generally, somatic cell reprogramming is a highly inefficient process. One factor that contributes to 
this is the fact that the majority of cells stall at a stable, highly proliferative state prior to entering the 
naïve state. Application of 2iL greatly improves the efficiency of conversion of these pre-iPS 
intermediates to bona fide naïve iPSCs (Silva et al., 2008). 
It is also possible to reprogram primed EpiSCs back to naïve pluripotency. This is a simpler process, 
likely owing to the more similar identities of the two cell types; both naïve iPSCs and primed EpiSCs 
express key pluripotency factors such as Nanog and Oct4. While it has been reported that EpiSCs can 
revert to a naïve identity of culture in 2iL conditions (Bao et al., 2009), this appears to be a peculiarity 
of a small number of cell lines. More often, it is reported that overexpression of one of many single 
naïve transcription factors is sufficient to achieve reprogramming of these cells (Gillich et al., 2012; 
Guo et al., 2009; Guo and Smith, 2010; Hanna et al., 2009; Silva et al., 2009; Zhang et al., 2016), 
however. Alternatively, activation of Stat3 signalling, which is typically inactive in EpiSCs, or chemical 
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alteration of the epigenetic landscape can mediate this identity change in mouse cells (Murayama et 
al., 2015; Ware et al., 2014; Yang et al., 2010; Zhang et al., 2016). 
1.3. The naïve transcriptional network 
1.3.1. Signalling and transcription regulation 
The state of naïve pluripotency in mouse is maintained by a complex, highly redundant and 
interconnected transcriptional network. A plethora of transcription factors regulate the expression of 
one another to create a semi-stable network while repressing factors that would induce differentiation. 
As we have seen, in SL conditions secretion of FGF4 is a key role in the induction of differentiation. 
However, in the presence of MEK inhibitor, stimulation of LIF/STAT3 or WNT/β-catenin signalling 
is sufficient to maintain the self-renewal of undifferentiated ESCs. Knockout studies revealed a triad 
of factors that are required for the establishment of the naïve epiblast in vivo; Oct4, Sox2 and Nanog 
(Chambers et al., 2003; Mitsui et al., 2003).  
Nanog is a homeodomain transcription factor. When overexpressed, ESCs are capable of self-renewal 
in the absence of LIF. However, Nanog is not the primary downstream effector of LIF/STAT3 
signalling as demonstrated by the fact that hyperactivation of STAT3 does not affect Nanog 
expression, while constitutive Nanog expressing ESCs self-renew more effectively in the presence of 
LIF. It has been shown that Nanog acts synergistically with activated STAT3 to induce the 
pluripotency factor Klf4 (Hall et al., 2009; Li et al., 2005; Stuart et al., 2014). Nanog null ESCs can be 
maintained, albeit with significantly impaired self-renewal and a greater propensity for differentiation 
(Chambers et al., 2007). The transcription factor Esrrb appears to be downstream of Nanog. 
Constitutive expression of Esrrb rescues the proliferative and self-renewal defects of Nanog-/- ESCs 
and maintains self-renewal in the absence of LIF when overexpressed, mirroring the activity of Nanog 
(Festuccia et al., 2012).  Like Nanog, Esrrb-/- cells can be maintained in the presence of LIF. Esrrb is a 
major effector downstream of GSK3 inhibition in mediating enhanced self-renewal. GSK3 forms part 
of the destruction complex that leads to degradation of β-catenin. A major function of β-catenin in 
ESCs is to inactivate the negative pluripotency regulator TCF3 by competing with the repressor 
Groucho for binding. TCF3 binds directly to Esrrb enhancer elements, Esrrb overexpression rescues 
differentiation induced by overexpression of TCF3, and Esrrb is permissive for self-renewal in the 
absence of the GSK3 inhibitor Chiron, while Esrrb-/- cells cannot maintain naïve pluripotency in 
media containing Chiron and only one of LIF or PD03 (Martello et al., 2012). Additionally Klf2, 
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Nanog, Nr0b1 and Tcfcp2l1 appear to be repressed by TCF3, and are thus responsive to treatment 
with Chiron (Martello et al., 2012). Tcfcp2l1 is also strongly responsive to LIF (Martello et al., 2013) 
as well as to PD03 (Ye et al., 2013), and overexpression of Tcfcp2l1 is sufficient to maintain naïve 
pluripotency in serum based media lacking any of the 2iL components (Ye et al., 2013). Notably, 
however, neither Oct4 nor Sox2 show strong, direct responses to any of these signals. 
Both Oct4 and Sox2 are essential for the establishment of the naïve pluripotent epiblast in vivo (Avilion 
et al., 2003; Nichols et al., 1998) and for maintaining naïve ESCs in vitro (Avilion et al., 2003; Masui et 
al., 2007; Niwa et al., 2005, 2000). In the absence of either factor, mouse ESCs differentiate to a 
trophoblast-like identity (Masui et al., 2007; Niwa et al., 2000). Oct4 is a POU-class transcription 
factor, and binds to DNA via a homeodomain and a POU-specific domain, while Sox2 is an HMG-box 
transcription factor. They co-bind many genomic loci, interacting primarily in the presence of DNA 
(Fong et al., 2011; Kuroda et al., 2005; Lam et al., 2012; Merino et al., 2014). Notably, Sox2 binds to 
the minor groove, inducing a bending of the DNA which appears to play a functional role in the 
regulatory ability of Sox2 (Scaffidi and Bianchi, 2001). It has been suggested that Sox2 is important for 
maintaining expression of Oct4 via inducing positive regulators such as Nr5a2 and repressing negative 
regulators such as Nr2f2 (Masui et al., 2007). This is was reinforced by the discovery that constitutive 
expression of Oct4 can rescue Sox2-/- ESCs (Masui et al., 2007). The Oct4 enhancer is also bound by a 
large array of naïve transcription factors, implying highly redundant regulation (Chen et al., 2008; 
Young, 2011), which may explain why it is relatively insensitive to changes in expression of most 
individual pluripotency factors. Oct4 and Sox2 physically interact on DNA at many regulatory 
elements. Interestingly, some single-molecule imaging work has been performed examining the 
interactions of Oct4 and Sox2 with DNA both individually and together (Chen et al., 2014). This work 
found a limited effect of Oct4 on Sox2 DNA binding kinetics. However, in cells coexpressing Oct4 and 
Sox2, Oct4 spent a greater fraction of time bound at Oct4-specific binding sites versus non-specific 
binding relative to cells expressing Oct4 alone. Chen et al. interpret this as indicating ordered binding, 
with Sox2 recruiting Oct4 to their cooccupied loci. However, this view has recently been questioned 
(Biddle et al., 2019), with Biddle et al. reanalysing the data of Chen et al. and arriving at the conclusion 
that the interactions of Oct4 and Sox2 with DNA are more complex. While increased Sox2 does lead 
to increased binding of Oct4, increased Oct4 levels actually reduce the overall binding of Sox2 to DNA. 
They conclude that Oct4 and Sox2 may bind cooperatively at some loci and competitively at others, or 
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that energy expenditure may be required to explain the interaction of Oct4 and Sox2 with DNA; this 
might suggest, for example, that chromatin modifiers or nucleosome remodelling could play an 
important role in the way that Oct4 and Sox2 are recruited to the genome. 
Co-binding of Oct4 and Sox2 is known to promote expression of some pluripotency factors such as 
Nanog and Klf4, but also negative regulators such as Fgf4 (Ambrosetti et al., 1997), while Oct4 and 
Nanog induce expression of Tcf3 (Yi et al., 2008). However, overexpression of either Oct4 or Sox2 
promotes differentiation seemingly by destabilising the naïve network itself since their direct targets 
become rapidly downregulated (Ben-Shushan et al., 1998; Boer et al., 2007; Kopp et al., 2008; Niwa et 
al., 2000; Thorold W. Theunissen et al., 2011). 
1.3.2. Previous models explaining the activity of Oct4 in naïve pluripotency 
Despite years of study, it remains unclear exactly how Oct4 regulates and is required for naïve 
pluripotency. A large number of phenotypes have been documented following altered expression of 
Oct4 and its partners but as yet the progression from wild-type cells following perturbations, and how 
these disparate phenotypes relate to one another, remain relatively unexplored and poorly understood. 
Loss of Oct4 is incompatible with establishing (Nichols et al., 1998) or maintaining (Niwa et al., 2000) 
naïve pluripotency, with cells exhibiting differentiation to a trophectoderm identity. Unlike factors 
such as Nanog and Esrrb, Oct4 does not contribute to a more robust pluripotency network on 
overexpression (Niwa et al., 2000). Instead cells are forced into differentiation. Furthermore, unlike 
these more conventional pluripotency factors, constitutive expression of Oct4 cannot prevent 
differentiation induced by removal of exogenous pluripotency signals such as LIF (Niwa et al., 2000). 
Therefore, it does not appear that Oct4 is simply acting downstream of cytokines to promote the 
maintenance of pluripotency, instead having a more complicated role. 
It has previously been proposed that Oct4 may have an as-yet-unidentified partner, present at 
sufficiently low levels that in wild-type cells it is recruited to and activates a core set of pluripotency 
genes, but on overexpression of Oct4 it is spread too thinly across the genome as a result of Oct4 
leading it to novel binding sites (Chambers, 2004; Niwa et al., 2002). As a result, expression of the core 
naïve factors is quenched and cells cannot maintain pluripotency. With this in mind, it is interesting 
to note that overexpression of Nanog is sufficient to rescue self-renewal in mouse ESCs overexpressing 
Oct4 to a modest level (Thorold W. Theunissen et al., 2011), a phenotype associated with this 
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hypothetical partner. Additionally, recent work has demonstrated enhanced self-renewal at the 
detriment of differentiation capacity in cells with reduced Oct4 levels (Karwacki-Neisius et al., 2013; 
Radzisheuskaya et al., 2013). This also matches predictions of such a model. 
However, other models for the mechanism by which Oct4 maintains naïve pluripotency do exist. 
Notably, one model that successfully predicted the outcome of several reprogramming strategies 
proposes that pluripotency exists in a somewhat precarious state maintained by the balanced 
expression of a cohort of antagonistic lineage specifiers (Loh and Lim, 2011). It has been noted that 
overexpression of Oct4 causes mesendodermal differentiation (Niwa et al., 2000; Thomson et al., 
2011). On the other hand, it has been shown that Sox2 acts to inhibit the formation of mesendoderm, 
while overexpression induces differentiation towards neural lineages (Thomson et al., 2011). 
Evidence in favour of this model comes from reprogramming assays in which it has been shown that 
alternative mesendoderm specifiers or depletion of key ectodermal genes can replace exogenous Oct4 
(Shu et al., 2013). Conversely, Sox2 can be replaced by other ectodermal specifiers. This culminated in 
the establishment of a novel cocktail of Gata6, Gmnn, Klf4 and cMyc which was capable of inducing 
somatic cell reprogramming (Shu et al., 2013). Of course, in the latter stages of reprogramming 
endogenous Oct4 and Sox2 are expressed, and since these are required in iPSCs it is impossible to test 
whether they are required for the final establishment of the naïve identity. 
However, some of the phenotypes described above do appear to be evidence against such a model. For 
one, expression of alternative lineage specifiers has not been shown to rescue differentiation induced 
by knockout of Oct4 or Sox2. On the contrary, it has been demonstrated that Oct4 itself can rescue 
self-renewal on knockout of Sox2 (Masui et al., 2007), though it is possible that other lineage specifiers 
are present to counteract Oct4 in this scenario. Furthermore, it has been demonstrated that ESCs can 
readily differentiate to alternative identities following overexpression of Oct4, and that the culture 
conditions may be the main driving factor behind fate choice in these cells (Shimozaki et al., 2003; 
Simandi et al., 2016). Nonetheless, this model has not been entirely dismissed, and notably there is 
some preliminary evidence that natural fluctuations in the relative levels of Oct4 and Sox2 may impact 
cell fate decisions (Strebinger et al., 2018). Thus it is possible that the antagonistic role of pluripotency 
factors in lineage specification may contribute to the mechanism of pluripotency maintenance. 
Alternatively, it may be that this model closer matches the regulation of more advanced state of primed 
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pluripotency in which heterogeneous expression of lineage markers is commonly observed (Song et 
al., 2016; Tsakiridis et al., 2014). 
It is interesting to observe that pluripotency appears to be regulated differently in other contexts. Prior 
to the establishment of the naïve epiblast, totipotent cells express many pluripotency factors such as 
Oct4 and Nanog but regulation of their expression differs. Knockout of either of these factors does not 
impair initial expression of the other in the early ICM (Le Bin et al., 2014), suggesting that their co-
regulation is not yet established. However, cells lacking either factor fail to specify a naïve epiblast 
(Mitsui et al., 2003; Nichols et al., 1998). It may be that expression of these genes is more tightly linked 
to proliferation prior to the establishment of the blastocyst, though studies of the transcriptional 
network in blastomeres of the morula are lacking due to the absence of an in vitro model. 
The regulation of pluripotency and the nature of the underlying transcription factor network is poorly 
described in post-implantation-like EpiSCs, but it is known that Oct4 expression is driven by a 
different enhancer element than in naïve cells (Choi et al., 2016; Tesar et al., 2007; Yeom et al., 1996). 
The functional consequences and differences in regulation as a result of this enhancer switch remain 
unclear, however. It appears that by E7.5, Sox2 is not required for expression of Oct4 (DeVeale et al., 
2013). Additionally, Oct4 appears to have a different function in the post-implantation embryo than 
in naïve cells, promoting proliferation of the primitive streak and reducing p53 expression while 
promoting mesodermal over neural differentiation (DeVeale et al., 2013). 
1.4. X chromosome inactivation 
Perhaps the most striking example of the unique transcriptional and epigenetic landscape of naïve 
pluripotent cells is the presence of two active X chromosomes in females. In order to achieve equal 
expression of X-linked genes in males and females, most female cells inactivate one X chromosome. 
In cells of the early embryo, prior to establishment of the naïve epiblast, and later in the 
extraembryonic tissues the paternal X chromosome is always silenced (Figure 1.4). However, cells in 
the embryo proper display inactivation of either the maternal or paternal X, with the inactive 
chromosome being chosen individually in each cell around the time of implantation (Figure 1.4). 
Studies of XXX and XXXX individuals indicate that all but one X chromosome is inactivated, and 
similarly XXY males randomly inactivate one X chromosome (Grumbach et al., 1963). This 
demonstrates that cells possess a capacity to ‘count’ X chromosomes in order to determine whether 
random X chromosome inactivation (XCI) needs to occur. Analysis of tetraploid cells reveals that these 
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maintain two active and two inactive X chromosomes (Webb et al., 1992), leading the hypothesis that 
cells maintain a number of active X chromosomes equal to half their ploidy; two sets of autosomes are 
present for each active X chromosome. 
The X inactivation centre (XIC) is a region of the X chromosome that must be present on multiple 
chromosomes in order for XCI to occur. Studies of cells with X chromosome truncations or deletions 
found that absence of this specific region led to a failure to inactivate an X chromosome in females 
(Rastan and Robertson, 1985). Interestingly, this region harbours an unusual gene, Xist, which is 
specifically expressed from the inactive X chromosome in differentiated cells (Borsani et al., 1991; 
Brockdorff et al., 1991). Xist is a long non-coding RNA (lncRNA) (Brockdorff et al., 1992) which is 
weakly expressed in ESCs but becomes strongly upregulated on their differentiation, specifically from 
the allele of the presumptive inactive X. As it becomes highly expressed, Xist RNA coats the entire X 
chromosome from which it is transcribed (Clemson et al., 1996). Deletion of Xist shows that it is 
absolutely required for silencing in cis, though Xist+/- female cells still inactivate the wild-type 
chromosome (Penny et al., 1996). 
1.4.1. Imprinted XCI 
It appears that regulation of non-random XCI is relatively straightforward. Initially on fertilization, 
all chromosomes are inactive until zygotic genome activation (Figure 1.4). However, the maternal Xist 
locus is imprinted and thus remains silent when transcription begins globally (Goto and Takagi, 2000; 
Kay et al., 1994). In males, Xist is therefore not expressed and the X chromosome remains active. 
Meanwhile in female cells, Xist is expressed from the paternal X chromosome resulting in silencing of 
the paternal X in all cells of the early embryo as described above (Figure 1.4). This non-random 
silencing persists throughout the tophectoderm and extraembryonic endoderm. However, the paternal 
X becomes reactivated in the naïve epiblast (Silva et al., 2009), resulting in cells with two active X 
chromosomes (Figure 1.4). At the same time, the imprints that silenced the maternal Xist locus are 
removed. This sets the stage for random XCI which occurs during implantation; the regulation of this 
process is far more complex and poorly understood. 
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1.4.2. Elements involved in counting, choice, and initiation of XCI 
Integration of multiple copies of a 450kb region, including the Xist locus, into an autosome in male 
ESCs was sufficient to induce early events of XCI upon their differentiation, with expression of Xist 
 Introduction 19 
being induced from both the endogenous and transgenic loci in a large fraction of cells (Lee et al., 
1996). It is worth noting that differentiating female cells only express Xist from a single locus, that of 
the chromosome undergoing XCI; however, there are multiple tandem integrations of the XIC in this 
system. By analogy to individuals with trisomy or tetrasomy X, the multiple XIC integrations appear 
to be counted separately leading to expression from several transgenic Xist loci as well as the 
endogenous locus. This demonstrates that the XIC contains elements required for counting. 
Remarkably, multiple autosomal integrations of a far smaller transgene consisting of the Xist locus and 
a total of 15kb of flanking sequences was also capable of inducing transgenic and endogenous Xist 
expression (Herzing et al., 1997). Additionally, these cells demonstrated local silencing of markers 
within the transgene demonstrating that Xist can induce gene inactivation in cis. 
Once counting has occurred and it has been determined that XCI should occur, a choice must be made 
such that one, and only one, X chromosome is inactivated in female cells. Offspring of mice from 
different genetic backgrounds show a bias in the choice of X to silence. This is conventionally defined 
as the inheritance of different X-linked alleles at the X-chromosome controlling element (Xce). 
Different alleles have different strengths such that a chromosome carrying the Xcea allele is more likely 
to be inactivated than one carrying Xceb, while a chromosome carrying Xced is the least likely to be 
inactivated. Phenotypically, this results in up to 75% of cells inactivating the X chromosome 
harbouring the weakest (Xcea) allele in Xcea/c heterozygous mice (Fowlis et al., 1991). Genetic mapping 
of the Xce locus has not revealed a single polymorphic gene, but instead a broad, repetitive region 
several hundred kb downstream of the Xist locus (Calaway et al., 2013; Simmler et al., 1993). It has 
been suggested that the cause of bias between different Xce alleles is the result of copy number variance 
for a trans-acting factor that regulates the initiation of XCI (Calaway et al., 2013), though this has not 
been demonstrated. 
Three lncRNAs are located within the XIC on the opposite strand to Xist. Xite and Tsx are located 
~20kb and ~36kb downstream of Xist respectively, whereas the antisense Tsix transcript overlaps Xist 
and extends beyond the gene in both directions. Xite and Tsx both positively regulate Tsix. Knocking 
out Xite reduces Tsix expression in cis; Expression of Xite does not appear to be required for this effect, 
so it may act as a conventional enhancer element (Ogawa and Lee, 2003). Similarly, knockout of Tsx 
results in reduced expression of Tsix in undifferentiated and differentiating ESCs (Anguera et al., 
2011). Deletion of a 65kb region distal to exon 6 of Xist effectively knocks out Tsx, Xite and Tsix. 
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Differentiating female cells carrying this deletion on one X chromosome still results in upregulation 
of Xist and XCI; however, the chromosome harbouring the deletion is always chosen for inactivation 
(Clerc and Avner, 1998). However, after reintroducing Tsix and the 3’ end of Xist to these cells, they 
still do not undergo random inactivation upon differentiation (Morey et al., 2001); they still always 
inactivate the chromosome carrying a now smaller deletion, suggesting that elements involved in 
choice are contained within this deletion region. That said, a small targeted deletion of ~4kb at the 
Tsix transcriptional start site is sufficient to induce non-random X inactivation (Lee and Lu, 1999), 
demonstrating that both Tsix and other factors in the region have this effect. Integration of a YAC 
carrying an extensive region including the  XIC, but with a ~3kb deletion at the Tsix transcription 
start site, into male ESCs also induces non-random inactivation on differentiation (Debrand et al., 
1999), with the autosome carrying the mutant XIC always being coated by Xist. Additionally, cells 
carrying the full 65kb deletion have a tendency to lose a significant portion of the wild-type X 
chromosome, resulting in a truncated chromosome lacking the XIC. Despite being effectively XO, 
these cells still undergo XCI implying that the counting mechanism is also broken (Morey et al., 2001). 
The same precocious X inactivation is observed in male cells carrying the 65kb deletion (Morey et al., 
2004). This is not the case in male cells with the small Tsix inactivating deletion; as in wild-type cells, 
these silence Xist on differentiation (Lee and Lu, 1999). However, reintroducing a 37kb section, 
restoring the 3’ end of Xist, the Tsix start site, and Xite, into cells carrying the 65kb deletion restores 
normal counting (Morey et al., 2004). Altogether, the regulation of this region is unclear, and the 
precise role of each component has yet to be reliably described. 
Oct4, Nanog and Sox2 all bind within intron 1 of Xist (Navarro et al., 2008). Knockout of Nanog in 
male ESCs results in mild upregulation of Xist, though not to levels seen during X inactivation 
(Navarro et al., 2008). However, knockout of Oct4 results in upregulation of Xist to levels seen in 
differentiating female ESCs (Navarro et al., 2008). Despite this, removal of Xist intron 1 has little to 
no impact on the ability of cells to properly undergo XCI (Minkovsky et al., 2013), and siRNA 
knockdown of Oct4 appears to have only a mild effect of Xist expression (Donohoe et al., 2009; 
Minkovsky et al., 2013). There is some evidence that Oct4 and Sox2 bind within Tsix regulatory 
elements (Donohoe et al., 2009). Knockdown of Oct4 reduces expression of Tsix, while Sox2 
knockdown increases expression (Donohoe et al., 2009). It appears that loss of Oct4 prevents pairing 
of X chromosomes in female cells, allowing a small number of cells to initiate XCI from both 
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chromosomes (Donohoe et al., 2009). However, the manner in which Oct4 achieves this, and exactly 
how binding of Oct4 affects Xist expression is unclear. Interestingly, X-reactivation also occurs in 
PGCs which, as previously discussed, possess a latent capacity for pluripotency and express many 
naïve-associated genes. However, it is unclear how this is regulated. 
1.5. Aims of this work 
Oct4 is present in embryonic development from the oocyte through to gastrulation. The level of Oct4 
is tightly controlled within the embryo, and fluctuates very little prior to the exit of cells from 
pluripotency (Joo et al., 2014; Rosner et al., 1990; Torres-Padilla and Chambers, 2014). It is unclear 
why this specific level has been adopted; evidence shows that a reduced level of Oct4 is optimal for the 
self-renewal of naïve pluripotent cells in vitro (Karwacki-Neisius et al., 2013; Radzisheuskaya et al., 
2013). Oct4 may act as regulator to the naïve state, ensuring that cells are capable of exiting 
pluripotency, as they must do so in vivo in order to progress in development. However, this is at odds 
with reports that Oct4 upregulates expression of naïve pluripotency genes (Ben-Shushan et al., 1998; 
Chew et al., 2005; Rodda et al., 2005). In this thesis I hope to address the impact of loss of Oct4 from 
naïve cells and of maintenance of Oct4 in somatic cells. In doing so, I hope to demonstrate that more 
than a naïve factor, Oct4 is a fate transition factor. 
It is well established that Oct4 behaves in a manner highly dependent on the level of expression 
(Karwacki-Neisius et al., 2013; Niwa et al., 2000; Radzisheuskaya et al., 2013). In chapters 3 and 4, I 
seek to control Oct4 levels more tightly than has been performed in past work. With this in mind, I 
will investigate the impact of sustaining an ESC level of Oct4 on differentiation in vivo and on somatic 
cell reprogramming (chapter 3). Additionally, starting from a naïve identity, I will investigate the 
consequences of losing Oct4 without passing through a protracted Oct4-low state (chapter 4). In 
chapter 5, I will compare the differentiation induced by loss of Oct4 to alternative methods 
extraembryonic differentiation, particularly with regards to the (mis)regulation of Xist. 
Conventionally, reprogramming to naïve pluripotency is achieved with very high levels of Oct4, 
potentially leading to neomorphic effects. Additionally, Oct4 is typically introduced via retroviral 
transfection, resulting in variable expression between cells. In this work, I will investigate the capacity 
of Oct4 to reprogram cells at a defined level, that of mouse ESCs. 
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Oct4 knockout experiments have been performed in the past, and result in differentiation of ESCs to 
a trophoblast-like identity (Niwa et al., 2000). However, it has recently been shown that cells 
expressing a low level of Oct4 become trapped in the naïve state (Karwacki-Neisius et al., 2013; 
Radzisheuskaya et al., 2013), and even overexpress pluripotency factors in some cases. Previous 
experiments have relied upon gradual degradation of Oct4 protein following ablation of the Oct4 gene 
or transcriptional repression (Nichols et al., 1998; Niwa et al., 2000). As a result, these cells will have 
transiently passed through an Oct4-low state, and it is unclear what effect this has on their progression. 
I will develop and utilize a rapid inducible system to achieve degradation of Oct4 at the protein level 
and investigate the order of events as these cells exit naïve pluripotency. 
Additionally, I will use this system to investigate the impact of loss of Oct4 on the genomic binding of 
other transcription factors prior to transcriptional changes; rapid depletion of Oct4 makes it possible 
examine changes in transcription factor binding prior to identity changes. As a result, it is possible to 
directly ascribe changes to the removal of Oct4 using this novel system, whereas following gradual 
depletion of Oct4 differences in transcription factor localization could be caused by the onset of 
differentiation rather than due to loss of Oct4 specifically.  
I will also investigate the impact of loss of Oct4 on Xist expression. First, following the observation 
that exit from pluripotency induces Xist expression (Sousa et al., 2018), I will examine the effect of 
differentiation of ESCs by depletion of Oct4 on the initiation of XCI. I will then investigate whether 
Xist expression is misregulated during extraembryonic differentiation induced by alternative means 
(chapter 5), and discuss the implications of this for the current models of XCI. 
Together, this body of work primarily focuses on the activity of Oct4; the mechanism by which this 
factor contributes to the naïve pluripotent identity is unclear, and the contradictory phenotypes 
associated with different expression levels of Oct4 have led to significant confusion. I hope to draw 
together several strands of work, both current and historical, to establish a coherent model for the role 
of Oct4 within the naïve state. More generally, I will investigate the impact of Oct4 on cell fate 
transitions, as this protein has a much broader role than simply maintaining a pluripotent identity. 
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Chapter 2: Materials and Methods 
2.1. Cell Culture 
2.1.1. Culture conditions 
All cell types were manipulated in a sterile BioMAT Class II Microbiological Safety Cabinet (Thermo 
Scientific) and maintained in a humidified Sanyo incubator (MCO-18M) at 37°C and 7% CO2, unless 
specified otherwise. 
ESCs were cultured in N2B27 supplemented with CHIR99021 (Chiron), PD0325901 (PD03) and LIF 
(N2B27-2iL) or serum-based medium supplemented with LIF (SL) as specified, on tissue culture plastic 
(Falcon) coated with 0.15% gelatin (Sigma Aldrich) in DPBS (Sigma Aldrich). iPSCs were cultured in 
N2B27-2iL, SL, or GMEM supplemented with Knockout serum replacement (KSR), Chiron, PD03 
and LIF (KSR-2iL) as specified, on gelatin-coated tissue culture plastic. NSCs were cultured in NSC 
medium on tissue culture plastic coated with 10 μg/ml fibronectin (Millipore) in DPBS. MEFs were 
cultured in SL on gelatin-coated tissue culture plastic. PLAT-E cells were cultured in SL on tissue 
culture plastic with no additional coating.  
N2B27 was made as follows: 
1 : 1 Neurobasal (Gibco) : DMEM/F12 (Gibco), 0.5% N2 (homemade: Tissue Culture facility, W-MRC 
CSCI, University of Cambridge), 1% B27 (Gibco), 2 mM l-glutamine (Gibco), 0.1 mM 2-
mercaptoethanol (Gibco). 
N2B27-2iL was made by supplementing N2B27 with 3 μM CHIR99021 (Stewart lab, Dresden), 1 μM 
PD0325901 (Stewart lab, Dresden) and 20 ng/ml mLIF (homemade: Department of Biochemistry, 
University of Cambridge). 
TSC medium was made by supplementing N2B27 with 12.5 ng/ml FGF2 (homemade: Department of 
Biochemistry, University of Cambridge), 20 ng/ml Activin A (homemade: Department of 
Biochemistry, University of Cambridge), 10 μΜ XAV939 (Tocris), 5 μM Y27632 (Tocris). 
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SL was made as follows: 
GMEM without l-glutamine (Sigma Aldrich), 10% FCS (Labtech), 2mM l-glutamine, 0.1mM 2-
mercaptoethanol, 1X MEM non-essential amino acids (Sigma Aldrich), 1mM Sodium Pyruvate (Sigma 
Aldrich), 20 ng/ml mLIF. 
KSR-2iL was made as follows: 
GMEM without l-glutamine, 10% KOSR (Gibco), 1% FCS (Labtech), 2mM l-glutamine, 0.1mM 2-
mercaptoethanol, 1X MEM non-essential amino acids, 1mM Sodium Pyruvate, 20 ng/ml mLIF, 3 μM 
CHIR99021, 1 μM PD0325901. 
NSC medium was made as follows: 
DMEM/F12, 0.5% N2, 1% B27, 29mM glucose (Sigma Aldrich), 4.5mM HEPES (Gibco), 1X MEM 
non-essential amino acids, 120 μg/ml BSA (Gibco), 0.1 mM 2-mercaptoethanol, 10 ng/ml Egf 
(Peprotech), 20 ng/ml FGF2. 
Media were supplemented with 1X penicillin-streptomycin (Sigma Aldrich), 500 nM 
4-hydroxytamoxifen (Sigma Aldrich), 1 μg/ml doxycycline (MP Biomedicals), 500 μM IAA (Cayman 
Chemical), 100 μg/ml cycloheximide (Sigma Aldrich), 0.5 μM 5-azacytidine (Sigma Aldrich), 400 
μg/ml G418 (Life Technologies), 200 μg/ml hygromycin B (Life Technologies), 20 μg/ml blasticidin 
(Life Technologies), 1μg/ml puromycin (Sigma Aldrich) as required. 
2.1.2. Passaging and freezing 
ESCs were passaged every 2-4 days according to density and colony size. Briefly they were dissociated 
with pre-warmed TrypLE Express (Gibco), diluted 1:10 in DMEM/F12, pelleted at 300g for 3 minutes, 
supernatant was removed and cells were resuspended in growth medium and plated. Typically cells 
were split 1:6 each passage. 
NSCs were passaged every 3-5 days according to density. Briefly, they were dissociated with pre-
warmed accutase (Millipore), diluted 1:10 in DMEM/F12, pelleted at 300g for 3 minutes, supernatent 
was removed and cells were resuspended in growth medium and plated. Typically cells were split 1:4 
each passage. 
iPSCs were passaged every 2-4 days according to density and colony size. iPSCs were passaged as NSCs. 
Typically cells were split 1:6 each passage. 
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MEFs were passaged every 4-8 days according to density. MEFs were passaged as ESCs. Typically cells 
were split 1:6 each passage. 
All cells were frozen in 9 : 9 : 2 DMEM/F12 : FCS : DMSO in a -80°C freezer before transfer to a liquid 
nitrogen tank for long-term storage.  
2.1.3. Cell lines 
Oct4F/- Rosa26:CreERt2 ESCs (from male and female littermates) and NSCs (male) were previously 
derived from embryos. Briefly, Oct4+/- mice were bred with Oct4F/F Rosa26:CreERt2 mice. NSCs were 
treated with 4-OHT to give Oct4-/- NSCs. These were transduced with retroviral Klf4 and cMyc, and 
transfected with PB-CAG-Oct4 to generate Oct4-/- fixed-Oct4 iPSCs (Radzisheuskaya et al., 2013). 
Oct4-/- NSCs were alternately transfected with pPB-CAG-NLS-m.OsTir1-IRES-bsd and either pPB-
CAG-Oct4-PGK-hyg or pPB-CAG-O4AID-PGK-hph, and transduced with retroviral Oct4, Klf4 and 
cMyc to generate Oct4-/- Oct4 or Oct4-AID iPSCs (See 2.1.5 NSC Reprogramming). 
Oct4F/- ESCs (Line A and Line B) were a generous gift from Aliaksandra Radzisheuskaya. They were 
transfected with linearized pCAG-CreERT2-NLS-IRES-bsd 
Inducible Oct4-AID ESCs were generated by transfecting wild-type E14Tg2a cells (a generous gift 
from Aliaksandra Radzisheuskaya) with pPB-CAG-rtTA-IRES-pac, pPB-CAG-NLS-m.OsTir1-IRES-
bsd and pPB-TRE-O4AID-PGK-hph. 
iOct4 cells were a generous gift from Aliaksandra Radzisheuskaya. Briefly, wild-type E14Tg2a cells 
were transfected with PB-TRE-Oct4 and PB-CAG-rtTA. After selection, a clonal line was derived. 
Oct4-/- TetOFF-Oct4 ESCs were a generous gift from the Smith lab (ZHBTc4 cells, (Niwa et al., 2000)). 
Oct4-/- Oct4-AID ESCs were generated by transfecting these cells with pPB-CAG-NLS-m.OsTir1-
IRES-bsd and pPB-CAG-O4AID-PGK-hph and maintaining cells in the presence of dox. 
Rex1-GFP ESCs were a generous gift from the Smith lab (Wray et al., 2010). iCdx2 and iGata6 cells 
were generated by transfecting this cells with pPB-CAG-rtTA-IRES-pac and either pPB-TRE-Cdx2-
PGK-hyg or pPB-TRE-Gata6-PGK-hyg. 
2.1.4. Cell transfection 
NSCs were transfected using Amaxa Nucleofection Technology (Lonza AG). 2 x 106 cells were used 
per nucleofection, using program T-020. ESCs and iPSCs were transfected using Lipofectamine 2000 
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(Life Technologies). In this case, 350000 cells were plated the day prior to transfection, and on the day 
of transfection a mixture of Lipofectamine 2000, plasmid DNA and DMEM/F12 was added to fresh 
culture medium for 24 hours. Typically, piggyBac transposon (pPB) plasmids were co-transfected with 
piggyBac transposase expression vector pBase in a 1:1 ratio to generate stable cell lines. pCAG-
CreERT2-NLS-IRES-bsd was linearized using ScaI prior to transfection. PLAT-E cells were transfected 
using FuGENE6 (Promega). 
2.1.5. NSC Reprogramming 
Retroviruses were produced in PLAT-E cells; briefly, cells were transfected with pMXs-Oct3/4, 
pMXs-Klf4 or pMXs-cMyc using FuGENE 6 reagent (Promega). Medium was changed the following 
day, and 48 hours virus-containing supernatants were collected. The media were filtered through 
0.22 μm filters and mixed in equal ratio, then polybrene (Sigma-Aldrich) was added to a final 
concentration of 4 μg/ml. The polybrene/virus mixture was applied to NSCs. 24 hours later NSCs 
were nucleofected with a 1:5 ratio of pBase and either pPB-CAG-O4AID-PGK-hph or pPB-CAG-
Oct4-PGK-hyg using Amaxa Nucleofection Technology and plated in NSC medium for 2 days then 
switched to SL medium. Medium was switched to KSR-2iL, and selection was added for expression of 
the endogenous Oct4 locus on the ninth day in KSR-2iL. Once colonies had expanded they were 
passaged into N2B27-2iL. 
2.1.6. Reprogramming somatic cells from E8.5 embryos 
Chimeras were generated by blastocyst injection of fixed-Oct4 iPSCs by William Mansfield using 
standard methodology and C57BL/6 host embryos. All animal work was performed in accordance with 
Home Office guidelines and regulations at the University of Cambridge, UK. The posterior portion of 
E8.5 embryos was dissected away and discarded, and the anterior portion was manually dissociated in 
a small volume of PBS and cultured with or without addition of 5-aza in N2B27 supplemented with 
LIF or KSR medium with LIF but lacking 2i in wells coated in gelatin. After 7 days, 5-aza was removed 
where present and 2i was applied to all conditions. After 5 days G418 was added. 
2.1.7. NSC and MEF derivation 
Chimeras were generated as above. Embryos were harvested at E12.5 and visceral organs were 
removed and genital ridges were identified and carefully dissected away. The brain was dissected out 
from the skull and manually dissociated in a small volume of PBS. Material was then plated in NSC 
medium on laminin-coated wells. The remaining carcass was dissociated in prewarmed trypsin-EDTA 
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(Life Technologies) and manually dissociated. Trypsin was inactivated by addition of FCS and material 
was plated in SL medium on gelatin-coated wells. 
2.2. Molecular Biology 
2.2.1. Plasmids and cloning 
Plasmid name Source 
pCAG-CreERT2-NLS-IRES-bsd Kindly provided by Dr Joerg Betschinger 
pMXs-Oct3/4 Addgene plasmid #13366 
pMXs-Klf4 Addgene plasmid #13370 
pMXs-cMyc Addgene plasmid #13375 
pBase (CMV-PBase) Kindly provided by Aliaksandra Radzisheuskaya 
pPB-CAG-rtTA-IRES-pac Kindly provided by Keisuke Kaji 
pPB-CAG-rtTA-IRES-bsd Kindly provided by Tim Lohoff 
pCAGGS-NLS-m.OsTir1-IRES-pac Kindly provided by Dr Oliver Baker 
pPB-CAG-Dest-PGK-hph Kindly provided by Dr Joerg Betschinger 
pPB-TRE-Dest-PGK-hph Kindly provided by Aliaksandra Radzisheuskaya 
pDONR211 Obtained from Life Technologies 
* pEntr Oct4-AID Synthesized by Life Technologies 
* pEntr NLS-m.OsTir1  
* pEntr Cdx2 Synthesized by Life Technologies 
* pEntr Gata6 Synthesized by Life Technologies 
* pPB-CAG-O4AID-PGK-hph  
* pPB-TRE-O4AID-PGK-hph  
* pPB-CAG-NLS-m.OsTir1-IRES-bsd  
pPB-CAG-Oct4-PGK-hyg Kindly provided by Aliaksandra Radzisheuskaya 
pPB-TRE-Oct4-PGK-hyg Kindly provided by Aliaksandra Radzisheuskaya 
* pPB-TRE-Cdx2-PGK-hyg  
* pPB-TRE-Gata6-PGK-hyg  
* pEntr Oct4-AID, pEntr Cdx2 and pEntr Gata6 were synthesized and cloned into pDONR221 
by Life Technologies. pEntr Oct4-AID was designed by taking the mouse Oct4 coding sequence from 
the Ensembl public database and adding the Arabidopsis thaliana Iaa17 coding sequence to the C-
terminus separated by a short PG linker. pEntr Cdx2 and pEntr Gata6 use the relevant mouse coding 
sequences from the Ensembl public database. pEntr NLS-m.OsTir1 was generated by PCR amplifying 
the mouse-optimised, SV40-NLS tagged Oryza sativa Tir1 coding sequence from pCAGGS-NLS-
m.OsTir1-IRES-puro using primers to introduce attB Gateway cloning arms; the PCR product was 
incubated with pDONR211 and BP Clonase II enzyme mix (Life Technologies) according to the 
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manufacturer’s instructions and transformed into cloning grade chemically competent E.cloni bacteria 
(Lucigen). pPB-CAG-GOI and pPB-TRE-GOI expression vectors were generated incubating the 
relevant pEntr and Dest vectors with LR Clonase II enzyme mix (Life Technologies) according to the 
manufacturer’s instructions; after proteinase K was added to stop the reaction, 2μl of the reaction mix 
was transformed into cloning grade chemically competent E.cloni bacteria. 
2.2.2. RT-qPCR and High Throughput RNA Sequencing 
Total RNA was isolated from cultured cells using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Cells were dissociated then pelleted at 300 g for 3 mins and supernatant 
was removed. Cell pellets were stored at -80 °C until they were processed further. RNA preparation 
included homogenisation of cell lysate with QIAshredder columns (Qiagen) and on-column DNA 
digestion with RNase-free DNase I (Qiagen). RNA quantity and purity were assessed using a Nanodrop 
ND-1000 spectrophotometer. For RT-qPCR, RNA was reverse-transcribed using SuperScript III 
First-Strand Synthesis SuperMix for RT-qPCR (Life Technologies); where possible 1 μg RNA was 
used for all samples, otherwise equal quantities of RNA was used for all samples of an experiment. For 
high throughput RNA sequencing, RNA integrity was assessed on a Qubit Fluorometer 
(ThermoFisher Scientific) and Agilent Bioanalyzer Nano Chips (Agilent Technologies). Depletion of 
ribosomal RNA was performed on 2-5μg of total RNA using the Ribo-Zero rRNA Removal Kit 
(Illumina) and libraries were produced from 10-100ng of ribosomal-depleted RNA using NextFlex 
Rapid Directional RNA-seq Kit (Bioo Scientific) with 12 cycles of PCR amplification. Libraries were 
pooled in equimolar quantities and sequenced on the HiSeq4000 platform (Illumina) at CRUK. Library 
preparation was performed by the W-MRC CSCI genomics facility. 
2.2.3. List of primers and Taqman probes 
Pre-designed taqman probes 
Target ID 












Sox2 Mm03053810_s1  
Xist Mm01232884_m1 
  
Custom Taqman probes 
Target Primer Sequence 















   
RT-qPCR Sybr primers 
Target Primer Sequence 
Elf5 Fw CCCTCCTCCTCTTCAAAACC 
 Rv AAGTTGCCACAAGACCATCC 
Gata6 Fw CCCACTTCTGTGTTCCCAATTG 
 
Rv TTGGTCACGTGGTACAGGCG 
Gapdh Fw CCCACTAACATCAAATGGGG 
 
Rv CCTTCCACAATGCCAAAGTT 
   
ChIP qPCR primers 
Target Primer Sequence 











Chr6 negative locus Fw ACTACCCAAACTATTGCTCCTGA 
 
Rv GCTTAACCTGCTCTCCCAGG 
Klf4 enhancer Fw TGTCCTCTCCACTCCCACAA 
 
Rv AGGAGTGACTGCGTCAAACA 
Nanog enhancer Fw CACCTCTTCGCTCGGATCTT 
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(H3K27ac peak) Rv CTCCGGGTCAAAGGAGTCTG 




2.2.4. Chromatin Immunoprecipitation (ChIP) 
ChIP was performed as followed: 
Cells (5×106 per IP for histone modifications or 10×106 for transcription factors) were fixed for 10 mins 
in Fixing Solution (5 mM HEPES pH 7.5, 10 mM NaCl, 0.1 mM EDTA, 50 μM EGTA, 0.4% 
formaldehyde for histone modifications or 1% formaldehyde for transcription factors, with protease 
inhibitors). Fixation was halted by addition of an excess of glycine. Cells were pelleted at 1400 rcf and 
washed with 1X ice cold PBS. Pellets were frozen at this point and stored at -80 °C. 
Nuclei were isolated: Cells were incubation with Lysis Buffer 1 (50 mM HEPES pH 7.5, 140 mM NaCl, 
1 mM EDTA, 10% Glycerol, 0.5% NP40, 0.25% Tx100) at 4 °C for 10 mins, pelleted, then incubated 
with Lysis Buffer 2 (10 mM Tris pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA) at 4 °C for 10 
mins. 
Nuclei were pelleted then resuspended in Shearing Buffer (50 mM Tris pH 8.0, 1% SDS, 10 mM 
EDTA) and sonicated to obtain an average DNA fragment size of 300-600 bp depending on the protein 
of interest. Debris was removed by centrifugation at 14000 rcf at 4 °C, and a sample was taken to 
determine fragment size. Sonicated chromatin was diluted 1:10 in Dilution Buffer (50 mM Tris pH 8.0, 
167 mM NaCl, 1.1% Tx100, 0.11% Sodium deoxycholate). Dynabeads Protein G (Invitrogen) were 
prepared by pre-incubating with isotypic IgG antibody. Diluted chromatin was pre-cleared by 
incubating with the beads for 2 hr at 4 °C. Supernatent was collected, a 10% input sample was taken 
for relative quantitation, and the chromatin was the incubated overnight at 4 °C with 1-5 μg of 
antibody or 2 μg of isotypic IgG (see Table 2.6). Beads were blocked overnight with BSA. The 
chromatin-antibody mix was incubated for 1 hr with BSA-blocked beads at 4 °C to allow chromatin-
conjugated antibody to bind to the beads. Beads were then washed twice in Wash Buffer 1 (50 mM 
Tris pH 8.0, 0.1% SDS, 0.1% Sodium deoxycholate, 1% Tx100, 150 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA), once in Wash Buffer 2 (50 mM Tris pH 8.0, 0.1% SDS, 0.1% Sodium deoxycholate, 1% Tx100, 
500 mM NaCl, 1 mM EDTA, 0.5 mM EGTA), once in Wash Buffer 3 (50 mM Tris pH 8.0, 250 mM 
LiCl, 0.5% Sodium deoxycholate, 0.5% NP40, 1 mM EDTA, 0.5 mM EGTA), and twice in Wash Buffer 
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4 (50 mM Tris pH 8.0, 10 mM EDTA, 5 mM EGTA). Chromatin was eluted twice for a total of 
30 mins at 65°C with shaking in Elution Buffer (1% SDS, 0.1 M NaHCO3) and eluates were pooled. 
NaCl was added to samples and inputs to a final concentration of 200 mM, before incubating overnight 
at 65°C to reverse cross-links. DNA was purifying using the QIAquick PCR Purification Kit (Qiagen). 
 
Target Species Antibody Supplier 
H3K27ac Rabbit ab4729 Abcam 
Nanog Rabbit A300-397A Bethyl Laboratories 
Sox2 Rat 14-9811 Ebioscience 
Normal rat IgG Rat sc-2026 Santa Cruz 
Normal rabbit IgG Rabbit sc-2027 Santa Cruz 
2.2.5. Protein extraction and Western blotting 
Cells were lysed in RIPA buffer (50 mM Tris-Cl pH8.0, 150 mM NaCl, 1% Tx100, 0.1% SDS, 1mM 
EDTA) containing Complete-ULTRA protease and PhoStop phosphatase inhibitor cocktails (Roche), 
and sonicated for 3 cycles, 30 seconds ON 30 seconds OFF in a Bioruptor200 (Diagenode) at high 
intensity. Debris was removed by pelleting, and aliquots of supernatant were frozen and stored at -80°C 
or mixed with 4X Bolt LDS Sample Buffer and 10X Bolt Sample Reducing Agent (ThermoFisher). 
Samples were boiled at 95°C for 5 minutes. SDS-PAGE electrophoresis was performed using Bolt 10% 
Bis-Tris Plus gels (ThermoFisher) in a Mini Gel Tank (ThermoFisher). Protein transfer was 
performed using the iBlot2 dry blotting system (ThermoFisher) and iBlot2 nitrocellulose Transfer 
Stacks (ThermoFisher). Membranes were incubated with primary antibodies (see below). Detection 
was achieved using HRP-conjugated secondary antibodies against the appropriate species (GE 
Healthcare) and ECL Plus Western Blotting Detection System (GE Healthcare). 
Target ID Supplier 
Oct4 (used in 4.2.1 and 4.2.2) sc8628 Santa Cruz Biotechnology 
Oct4 (used in 4.2.3) 83932 Cell Signaling Technology 
Nanog A300-397A Bethyl Laboratories 
Sox2 14-9811 ThermoFisher 
α-tubulin ab7291 Abcam 
2.2.6. Histology 
E8.5 embryos were fixed for 4 hours at 4°C with 4% paraformaldehyde (Sigma) in PBS, gradually 
adjusted to 20% sucrose over 2 days, then mounted in OCT and snap frozen on liquid nitrogen. 8 µm 
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cryosections were taken and stored at -80°C. Following rehydration in PBS, sections were 
permeabilised in 0.25% Triton X-100 (Sigma) in PBS, then blocked in 5% donkey serum (Sigma) and 
0.1% Triton X-100 in PBS. Sections were incubated overnight at 4°C in blocking buffer with the 
following primary antibodies: Nanog (1:300, rat mAb, eBioscience); Oct4 (1:300, rabbit mAb, Cell 
Signaling); Oct4 (1:300, goat pAb, Santa Cruz); Sox1 (1:300, rabbit pAb, Cell Signaling); Sox2 (1:300, 
rat mAb, eBioscience). The following day, washes were performed with 0.1% Triton X-100 in TBS, 
and samples incubated with DAPI and AlexaFluor secondary antibodies against the appropriate species 
at 1:1000 (Life Technologies).  
Sections were imaged using a Zeiss ApoTome microscope at 20x then tiled. After imaging, H&E 
histological staining was performed on the same sections according to standard methodologies. These 
sections were then re-imaged in the same pipeline. Cyrosectioning and H&E staining were performed 
by the W-MRC CSCI histology facility, immunochemistry and imaging was performed by Hannah 
Stuart, as noted in the text. 
2.3. Bioinformatic analysis 
2.3.1. ChIP-seq and RNA-seq alignment and visualization 
RNA-seq reads were adaptor-trimmed with cutadapt v1.10 (Martin, 2011) via TrimGalore v0.4.1 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore) and mapped to the mouse 
reference genome (GRCm38/mm10) with TopHat2 v2.1.0 (https://ccb.jhu.edu/software/tophat) 
using default parameters for paired end reads. Transcript counts were normalized by library size or by 
the normalization factor calculated by DESeq2 v1.14.1 (Love et al., 2014) as indicated. ChIP-seq reads 
were adaptor-trimmed with cutadapt v1.10 via TrimGalore v0.4.1 and mapped to the mouse reference 
genome (GRCm38/mm10) with BWA v0.7.12-r1039 using the BWA-backtrack algorithm (Li and 
Durbin, 2009) by calling aln and samse using default parameters for single-end reads. ChIP-seq counts 
were normalized by library size and extended to match the fragment size. Files were converted to 
bedgraph format and uploaded to the UCSC Genome Browser for visual inspection. Strand specific 
RNA-seq files were generated by Michael Barber and Sabine Dietmann using featureCounts (Liao et 
al., 2014). Gene-wise counts were generated using featureCounts (Liao et al., 2014) to annotate the 
genes from Ensembl GRCm38.86 release. 
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2.3.2. RNA-seq statistical analysis 
Normalization and statistical analyses were performed using DESeq2 v1.14.1 (Love et al., 2014) 
For Oct4F/- ESC dataset, two biological replicates of each timepoint were sequenced on two lanes. 
Technical replicates were collapsed after validating that correlation between technical replicates was 
greater than correlation across samples. Size factor and dispersal estimation, and model fitting and 
testing were performed by calling DESeq (DESeq2 v1.14.1) with default parameters. MA plots and 
PCA analysis were performed using DESeq2. 
2.3.3. ChIP-seq analysis 
Nanog ChIP-seq was performed on duplicate IPs for two hour IAA induced and uninduced samples. 
Nanog peaks were obtained using MACS2 v2.1.1.20160309 on merged reads of induced samples. Oct4 
peaks were obtained using MACS2 on publically available Oct4 ChIP-seq data (GEO accession 
GSM307140) against whole cell extract control (GEO accession GSM307155) (Marson et al., 2008). 
Remaining false-positive peaks located in repetitive regions were blacklisted. Differential binding 
analysis was performed using DiffBind v2.2.12 (Rory and Brown, 2011; Ross-Innes et al., 2012). 
Normalization factors were calculated using DESeq2. Heatmap and summary plots were generated 
using DeepTools3 Galaxy Version 3.1.2.0.0 (Ramírez et al., 2016). 
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Chapter 3: Establishing the 
reprogramming capacity of fixed-Oct4 
cells after in vivo differentiation 
3.1. Introduction 
It is well established that Oct4 plays a vital role in the establishment and maintenance of naïve 
pluripotency in vivo (Le Bin et al., 2014; Nichols et al., 1998), but in recent years it has become 
increasingly clear that a specific level of Oct4 is critical both for entry into and exit from pluripotency 
in vitro. Radzisheuskaya et al. demonstrated that cells successfully completing somatic cell 
reprogramming to form iPSCs converge to a wild-type level of Oct4 even if it is exogenously expressed 
(Radzisheuskaya et al., 2013), indicating that a precise level of Oct4 is required at some point in the 
reprogramming process. Meanwhile, reducing the level of Oct4 in naïve cells while maintaining a 
basal level of expression (~1/5 to 1/2 a wild-type level) compromises the ability of cells to exit 
pluripotency (Karwacki-Neisius et al., 2013; Radzisheuskaya et al., 2013). With this in mind, I was 
interested to see how constitutive expression of an ESC level of Oct4 would affect differentiation in 
vivo and subsequent somatic cell reprogramming. 
Specifically, I wanted to examine the capacity of cells maintaining an ESC level of Oct4 to exit 
pluripotency in vivo. Typically, a transient increase in Oct4 expression is observed in differentiation 
from ESCs (Kalkan et al., 2017), and it is unclear whether this is required for normal differentiation. 
In the absence of an endogenous allele cells cannot regulate Oct4 in this manner, allowing us to test 
whether cells can differentiate normally while sustaining an ESC level of expression. Furthermore, 
given that an ESC level of Oct4 appears to be required at some stage in the reprogramming, I wanted 
to test whether somatic cells expressing Oct4 at this level throughout the process would demonstrate 
efficient reprogramming. 
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3.1.1. Generating cells with a fixed ESC level of Oct4 
An iPSC line has previously been generated in our group wherein the endogenous Oct4 gene is 
knocked out from both alleles and Oct4 is expressed entirely from randomly integrated, constitutively 
expressed Oct4-2a-Cherry transgenes (fixed-Oct4 iPSCs) (Radzisheuskaya et al., 2013, Figure 3.1a). 
Radzisheuskaya et al. demonstrated that during reprogramming cells select for an ESC level of Oct4; 
consequently this line expresses a wild-type level of Oct4, and this level is roughly maintained during 
somatic differentiation (Radzisheuskaya et al., 2013). 
3.1.2. Cells with an ESC level of Oct4 differentiate and reprogram efficiently in vitro 
Recent work in our lab has shown that cells maintaining an ESC level of Oct4 can be differentiated to 
EpiSCs in vitro (Stuart et al., in preparation). This demonstrates that they retain the capacity to exit 
the naïve state; however, it does not resolve whether they are able to make more advanced cell fate 
decisions, exit pluripotency or whether they differentiate in response to normal cues in vivo. 
Nonetheless, it has been exciting to observe that these fixed-Oct4 EpiSCs are able to revert to naïve 
pluripotency solely by switching to naïve growth conditions (Figure 3.1b) with remarkable speed and 
efficiency, and without requiring induction of naïve-specific transcription factors or application of 
chromatin-modifying factors. It is therefore interesting to investigate the capacity of fixed-Oct4 iPSCs 
for more advanced differentiation, and to test the limits of their reprogramming potential. 
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3.2. Results 
3.2.1. Fixed-Oct4 cells are able to differentiate in vivo and integrate well into E8.5 
chimeras 
In order to produce appropriately differentiated cells, we generated chimeric embryos through 
blastocyst injection of fixed-Oct4 iPSCs into wild-type blastocysts (Figure 3.2a). By late E8.5, most 
embryos had completed turning. At this stage, no clear abnormalities were observed from a visual 
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analysis (Figure 3.2b). Chimeric embryos could not be distinguished from non-chimeric littermates 
other than by fluorescent analysis of Cherry signal derived from the constitutive Oct4-2a-Cherry 
transgene. Most embryos showed a high level of chimerism with contribution from fixed-Oct4 cells 
throughout the embryo (Figure 3.2b and Table 3.1). 
 
In order to examine the degree of chimeric contribution more thoroughly, and to check that fixed-
Oct4 cells had integrated into differentiated tissues, we performed cryosectioning and 
immunofluorescence staining. Figure 3.3, adapted from the graduate thesis of Hannah Stuart, shows 
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extensive contribution of Cherry positive cells throughout the E8.5 embryo. Oct4 staining corresponds 
well with Cherry signal, indicating that Cherry is a good proxy for the presence of Oct4. It should be 
noted that Nanog is specifically localised to the nucleus in PGCs and pluripotent ESCs and EpiSCs 
(Chambers et al., 2007; Gillich et al., 2012; Yamaguchi et al., 2005); specific (nuclear) Nanog signal is 
entirely absent indicating that all cells have successfully exited pluripotency (Figure 3.3a), but also that 
this section does not contain any germ cells from either parent. Sections of another embryo 
demonstrated even higher levels of chimerism (Figure 3.3b). In this embryo, it is clear that Oct4 is well 
integrated into various tissues, with extensive contribution to the myocardium and somites. 
Anteriorly, there is significant overlap in staining for Sox1 and Sox2 with Oct4, showing that fixed-
Oct4 cells are differentiating efficiently into neural lineages, while distal overlap is indicative of gut 
endoderm differentiation. 
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3.2.2. In vivo-differentiated fixed-Oct4 cells reprogram efficiently 
Given that these embryos did not show any obvious defects or tumours, we concluded that early 
differentiation events had occurred relatively normally in these embryos. In order to examine the 
40 Mechanisms of Oct4 in the entry to, maintenance of, and exit from pluripotency 
reprogramming potential of the differentiated fixed-Oct4 cells, we removed the posterior half of the 
embryos in order to prevent contamination with any remnants of the primitive streak and associated 
pluripotent cells, though none should remain (Osorno et al., 2012), and any primordial germ cells or 
their precursors (Molyneaux et al., 2001; Tam and Snow, 1981). We manually dissociated the anterior 
section of the embryos to small clumps of cells and plated these in a range of media conditions (Figure 
3.2a), reserving some material for RT-qPCR analysis. 
Dissociated cells were plated in stringent and permissive reprogramming conditions. There is evidence 
that immediate application of naïve-specific 2iL conditions to differentiated cells inhibits 
reprogramming (Silva et al., 2008), an effect that is likely due to inhibition of key survival signalling 
before reprogramming occurs. Indeed, in preliminary experiments, dissociated anterior cells plated 
directly in 2iL failed to reprogram, while germ-cell-containing allantois readily generated EGCs. To 
avoid this inhibition, cells were grown for one week in reprogramming media lacking 2i before 
switching to 2iL conditions. In permissive conditions cells were maintained for one week in basal 
media plus LIF in the presence of 5-azacitidine, a DNA methyltransferase inhibitor (Stresemann and 
Lyko, 2008), and/or ascorbic acid (in the form of KSR-based media (Blaschke et al., 2013)), a Tet 
enzyme and JmjC-domain histone demethylase agonist (Blaschke et al., 2013; Klose et al., 2006; Yin et 
al., 2013), both of which lead to a global reduction in DNA methylation (Blaschke et al., 2013; 
Mikkelsen et al., 2008; Yin et al., 2013) and have been shown to improve both the rate and efficiency 
of somatic cell reprogramming (Esteban et al., 2010; Mikkelsen et al., 2008; Tsuji-Takayama et al., 
2004; Wang et al., 2011). After this, media was changed to N2B27 2iL or KSR 2iL, and after a further 
5 days selection for endogenous Oct4 promoter activity was applied. Meanwhile, in stringent 
conditions cells were maintained in N2B27 LIF prior to media switch to N2B27-2iL and subsequent 
selection. Medium change to ESC maintenance conditions is reportedly sufficient to revert a fraction 
of some EpiSC lines to the naïve state (Bao et al., 2009); however, generally reprogramming to naïve 
pluripotency requires the addition of transgenes, altered signalling environments or epigenetic 
modifiers (Gillich et al., 2012; Guo et al., 2009; Guo and Smith, 2010; Hanna et al., 2009; Murayama et 
al., 2015; Silva et al., 2009; Zhang et al., 2016). In this study, cells should be more advanced in their 
differentiation than EpiSCs, having already undergone the events of gastrulation and lineage 
segregation, and so we would not anticipate that any wild-type cells would reprogram under these 
stringent conditions. 
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Of the 11 embryos collected, 10 were chimeric by visual inspection of Cherry contribution, with one 
non-chimeric embryo which we used as a negative control (Table 3.1). Additionally, we plated material 
from the posterior end of the embryos together with allantois tissue; these regions should contain 
migrating primordial germ cells (Molyneaux et al., 2001; Tam and Snow, 1981), which should readily 
convert to embryonic germ cells (EGCs) in our reprogramming conditions (Leitch et al., 2010), and 
thus act as a positive control. 
  Embryo number 
1 2 3 4 5 6 7 8 9 10 11 
Chimeric? Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes 
Reprogrammed in 
stringent conditions? 
Yes No Yes Yes Yes Yes Yes No No No Yes 
Reprogrammed in 
permissive conditions? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes 
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 
As detailed in Table 3.1, all of the chimeric embryos were able to generate iPS lines in the permissive 
conditions, typically with very high efficiencies (Figure 3.4, top left), while the non-chimeric control 
did not (Figure 3.4, middle left). This implies that constitutive expression of Oct4 at an ESC level instils 
competency to post-implantation somatic cells to reprogram to the naïve state. More remarkably, we 
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established iPS lines from 7 of the 10 chimeric embryos (70%) under our stringent reprogramming 
conditions (Figure 3.4, top right), relying solely upon exogenous Oct4 expression and a change in the 
signalling environment to revert their identity to naïve pluripotency. This is particularly noteworthy 
given the small amount of starting material; cell numbers were limited since the posterior end of the 
embryo was removed, a portion was retained for expression analysis and the remainder was split into 
four reprogramming conditions. Consequently each reprogramming well contained approximately 
10% of a single embryo, equating to perhaps 5x105 cells (Cho et al., 2011). 
 
The fixed-Oct4 iPSCs were generated using retroviruses which are stably silenced during the 
reprogramming process. In order to validate that Oct4 was the sole reprogramming factor present, I 
performed RT-qPCR using probes specific for the retroviral Klf4 and cMyc transgenes. The 
transgenes were not reactivated in the embryonic tissue (Figure 3.5). 
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It should be noted that the cells that we plated do appear to have fully exited pluripotency in vivo, as 
expression of the naïve-specific marker Rex1 and the general pluripotency marker Nanog were 
extinguished in the chimeric embryos as well as in the non-chimeric control (Figure 3.6). Both markers 
are expressed robustly in the successfully reprogrammed iPSCs at levels comparable to the parental 
iPSCs and the positive control EGCs (Figure 3.6). 
3.2.3. Constitutive Oct4 expression causes several severe malformations in E12.5 
chimeras 
Given that cells with an ESC level of Oct4 appear to undergo normal early embryogenesis, we decided 
to examine their capacity to contribute to more advanced embryos (Figure 3.7a). Extensive chimerism 
was observed in E12.5 embryos, with contribution to organs and somites, and throughout the body 
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(Figure 3.7b and c). However, this was accompanied by several developmental defects with varying 
levels of severity between chimeras (Table 3.2). 
 
An immediately obvious phenotype was an extreme expansion of the mesencephalon. In over one 
third of chimeras (Table 3.2) the midbrain shows sufficient growth in the confined space that it buckles 
and pushes outwards (Figure 3.7b). It is impossible to ignore that the midbrain shows a large number 
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of Oct4 Sox1 double positive cells in our E8.5 staining (Figure 3.3b). Sox1 is a neurepithelial 
determinant which maintains neuronal precursors in a primitive state, with low expression of glial 
markers BLBP and β3-tubulin (Suter et al., 2009). Cells lose Sox1 expression as they differentiate 
(Pevny et al., 1998), and overexpression of Sox1 during differentiation leads to expansion of the self-
renewing neurepithelial population (Suter et al., 2009). It is therefore tempting to speculate that an 
ESC level of Oct4 disrupts the normal loss of Sox1 expression in the midbrain, causing an increase in 
proliferation leading to this phenotype. However, this would require more investigation to confirm. 
Despite this, we were able to derive NSCs from such chimeric embryos with no obvious phenotype at 
early passage numbers, though these have not been extensively characterized. Additionally, a small 
number of embryos displayed exencephaly (Figure 3.8a and Table 3.2), in which the brain did not 
appear to be fully covered by surface ectoderm. Exencephaly normally results from an earlier failure 
to fully close the neural tube (Macdonald et al., 1989; Wallace et al., 1978). Interestingly, exencephaly 
commonly displays partial penetrance, and often co-occurs with blebs in the epidermis (Wallace et al., 
1978) which we observed in over half of the chimeras (Table 3.2). Alternatively, it has been previously 
noted that overexpansion of the midbrain can lead to exencephaly-like abnormalities; embryos in 
which RhoA is knocked out in the mesencephalon demonstrate midbrain expansion similar to our 
embryos and subsequently the brain protrudes, without any sign of failure to close the neural tube 
(Katayama et al., 2011).  
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1st round Embryo 
Summary 1 2 3 4 5 6 7 8 
Skin blebs Y Y N Y N N Y Y 5 
Vascular buds Y N Y N Y Y N Y 5 
Malformed 
forelimbs 










N N Y N Y Y N N 3 
Exencephaly N N N N Y N N N 1 
 
2nd round Embryo 
Summary 1 2 3 4 5 6 7† 8 9 10 
Skin blebs Y N N Y Y Y Y Y Y Y 8 
Vascular buds Y Y N Y N Y N N Y N 5 
Malformed 
forelimbs 










N Y Y Y Y N N N N N 4 















1st round 8 5 5 1 3 1 0 
2nd round 10 8 5 6 4 2 1 
Total 18 11 (61%) 10 (56%) 7 (39%) 7 (39%) 3 (17%) 1 (6%) 
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Roughly one third of chimeras demonstrated dramatic limb malformations with various levels of 
penetrance (Figure 3.8b), though only one or two limbs were ever affected (Table 3.2). Some of these 
malformations (Figure 3.8b ii. and iii.) resemble the phenotype observed in classical transplantation 
experiments involving engraftment of an additional zone of polarizing activity (ZPA) to the anterior 
side of the limb bud. This results in an anterior-posterior (A-P) mirroring of limb formation 
(Saunders, J. W., 1968; Tickle et al., 1975) as the limb A-P axis is established by a gradient of SHH 
secreted by the ZPA (Riddle et al., 1993). This is a striking phenotype, normally only seen on ZPA 
transplantation or exogenous application of SHH or retinoic acid (López-Martínez et al., 1995; 
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Summerbell, 1983; Tickle et al., 1982). It would be interesting to investigate the mechanism behind 
this phenotype further; in particular future work could elucidate whether constitutive Oct4 expression 
results in aberrant formation of a second ZPA at the anterior side of the limb bud or if it affects the 
way cells interpret the normal SHH gradient. Unfortunately, this is beyond the scope of this thesis, but 
such work could uncover interesting details relating to the combinatorial manner in which local 
signalling environments interact with transcriptional networks to make cell fate and patterning 
decisions in development. 
The final phenotype we observed was the generation of small, vascularized buds of tissue on the 
exterior surface of roughly half of the chimeric embryos (Table 3.2). These structure typically 
contained blood within a complex structure of branched vessels (Figure 3.8c). It is not clear what these 
structures represent, nor whether they are connected to the embryonic vasculature or if they are a site 
of haematopoiesis. They were most often found growing in around the mouth. 
3.3. Discussion 
By working with cells constitutively expressing Oct4 at roughly an ESC level, we have demonstrated 
that Oct4, in combination with naïve-specifying environmental conditions, is sufficient to efficiently 
reprogram somatic cells to an iPSC identity. The property of reprogramming iPSCs to self-select for 
an ESC level of Oct4 (Radzisheuskaya et al., 2013) makes it trivial to generate a naïve cell line 
constitutively expressing Oct4 at this level from a transgene. Using this reagent we have confirmed 
the results of Radzisheuskaya et al. (Radzisheuskaya et al., 2013) that continued expression of Oct4 is 
compatible with exit from pluripotency (Figure 3.3 and Figure 3.6). Oct4 overexpression is sufficient 
to induce differentiation of naïve pluripotent stem cells in vitro (Niwa et al., 2000), so it is not entirely 
surprising that maintenance of Oct4 expression is compatible with differentiation in vivo; however, 
given the level-specific phenotypes that Oct4 demonstrates, with reduced Oct4 expression 
compromising differentiation both in vitro (Karwacki-Neisius et al., 2013; Radzisheuskaya et al., 2013) 
and in vivo (Radzisheuskaya et al., 2013), it is valuable to validate this finding. Notably, differentiation 
of pluripotent cells constitutively expressing Oct4 has been demonstrated in other systems in vitro and 
in vivo, but in these cases the transgene level was known to be significantly lower (Niwa et al., 2000; 
Ramos-Mejía et al., 2005) or far greater (Niwa et al., 2000) than that seen in ESCs. Additionally, it was 
introduced into cells already expressing endogenous Oct4, likely resulting in selection for greatly 
reduced transgene levels. 
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However, Radzisheuskaya et al. did not investigate the reprogramming capacity of differentiated fixed-
Oct4 cells. It has previously been shown that overexpression of Oct4 can lead to reprogramming of 
somatic cells, especially under permissive conditions, though this typically takes 3-6 weeks (Kim et al., 
2009; Li et al., 2011; Tsai et al., 2011; Yuan et al., 2011). In our permissive reprogramming 
experiments, cells were maintained in basal media containing ascorbic acid, 5-azacitidine and LIF for 
one week before switching to naïve growth conditions (supplementing the basal media with 2i); after 
five days we selected for activation of the endogenous Oct4 locus, and colonies emerged from all 
chimeric embryos. This compares favourably with Oct4-induced reprogramming in the presence of 
multiple chemical reprogramming factors (Li et al., 2011; Yuan et al., 2011). 
However, it is remarkable that we observed the generation of iPSCs in the same short timespan in our 
restrictive reprogramming conditions; we cultured cells for one week in basal media with LIF, lacking 
any naïve specifiers or epigenetic modifiers, and again when we switched to naïve culture media we 
obtained lines with activation of the endogenous Oct4 locus within five days from 70% of our embryos 
(Table 3.1). In earlier experiments (not shown), we had assumed that addition of small molecules such 
as ascorbic acid and 5-azacitidine would be necessary to overcome the epigenetic barriers established 
during differentiation, and that Oct4 alone would only be able to reprogram a small fraction of cells 
over a protracted period in the absence of these factors, as has previously been observed (Kim et al., 
2009; Tsai et al., 2011). Instead, it appears that when Oct4 is present at an ESC level it is capable of 
rapidly reverting cells to naïve pluripotency, requiring less than two weeks as opposed to the 4-5 weeks 
reported following retroviral transduction of Oct4 (Kim et al., 2009). 
It is important to note, however, that the constitutive expression of Oct4 could have affected the 
transcriptional and epigenetic state of these cells. This might have generated a state in which cells were 
more prone to reprogram. This is difficult to test, as it is not straightforward to allow cells to 
differentiate normally with endogenous gene expression, then remove the endogenous allele and 
transgenically express the gene at that specific level. An additional factor is that we are utilizing a 
secondary system, reprogramming cells that have already been reprogrammed once before. Typically, 
secondary systems have far greater reprogramming efficiencies than primary systems (Nagy, 2013). 
Ideally, to gauge the relative efficiency of reprogramming of fixed-Oct4 cells they should be directly 
compared to iPSCs that are wild-type with respect to Oct4 to control for this. This sort of experiment 
would also require accurate counts of starting cells, ideally isolated through FACS sorting to remove 
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wild-type host cells, and counts of generated colonies. In this way we could conclusively determine 
whether the fixed-Oct4 cells have an advantage in reprogramming. 
It should be noted that cells required a period in media lacking 2i. While PGCs from the allantois 
reprogrammed efficiently to EGCs on direct application of N2B27-2iL, similar treatment did not result 
in the generation of any iPSC colonies from the anterior segment of our chimeras. This is indicative 
that they did not contain a small population of cells retaining pluripotency or any teratocarcinomas, 
which would be capable of outgrowth in 2iL conditions. 
Interestingly, it has previously been reported that cells of the post-implantation epiblast lose the 
capacity to form primed pluripotent EpiSC cultures between E7.5 and E8.25, but exogenous Oct4 
expression extends this window to E14.5, albeit with significantly reduced efficiency at later times 
(Osorno et al., 2012). In the work presented in this chapter, we dramatically expand on this, 
demonstrating that maintaining an ESC level of Oct4 with simple naïve-specifying culture conditions 
is sufficient to reprogram in vivo differentiated cells to naïve pluripotency. 
We observed a range of interesting phenotypes in E12.5 chimeras (Table 3.2). In normal development, 
Oct4 is downregulated in most somatic cells during and soon after gastrulation (Osorno et al., 2012). 
However, some expression is observed broadly in the gastrulating embryo, particularly in the 
mesoderm until the 8 somite stage, at which point it becomes restricted to the germ lineage (Downs, 
2008). Constitutive ubiquitous Oct4 expression in embryogenesis has been studied before (Ramos-
Mejía et al., 2005), using a CAG promoter to drive Oct4 expression in all cells of the embryo. There 
are similarities and differences in the developmental abnormalities we observe, which may relate to 
differences in Oct4 expression level, or non-cell-autonomous interactions with the wild-type cells 
present in our chimeras. 
At E9.5, Ramos-Mejía et al. identified a reduction in the size of the forebrain and midbrain due to 
increased cell death in Oct4-expressing embryos, with recovery to normal brain morphology by E12.5. 
The effect of Oct4 on the brain is dramatically different in our chimeric embryos. Although we have 
not quantitated brain sizes, in part due to the difficulty in identifying identically staged embryos, there 
was no obvious difference in the scale of the forebrain or midbrain between wild-type embryos and 
fixed-Oct4 chimeras at E8.5. However, at E12.5 many of our chimeric embryos showed gross 
expansion of the midbrain (Figure 3.8b and Table 3.2). It is interesting to note that deletion of Oct4 in 
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the post-implantation embryo at around E7.5 results in a diminished midbrain and greatly reduces 
cranial mesenchyme density (DeVeale et al., 2013); however, it was suggested that this was due to 
reduced proliferation in the primitive streak, where Oct4 expression normally persists at this time. 
This suggests that either expansion of the primitive streak continues for a longer time in our chimeric 
embryos, or that the expansion of the midbrain that we observe is due to a different mechanism. 
Furthermore, we observed a small number of exencephalic embryos at E12.5 (Table 3.2). While the 
exact cause here is unclear, exencephaly is typically the result of failure in anterior neural tube closure 
(Harris and Juriloff, 2007; Macdonald et al., 1989; Wallace et al., 1978); this could be related to the 
defective closure of the posterior neural tube observed by Ramos-Mejía et al. (Ramos-Mejía et al., 
2005). 
Ramos-Mejía et al. also found that E12.5 embryos were smaller overall, with failed development of 
digits and zeugopod elements in the limbs, a kinked tail, and a clear reduction in the mandibular arch 
resulting in a small lower jaw. The fixed-Oct4 chimeric embryos did not appear any smaller than their 
non-chimeric littermates. We did observe a dramatic phenotype in the limbs, similar to that seen 
previously. However, we noted highly variable penetrance, with many embryos displaying three 
normal limbs and a single defective limb, and a particular prevalence in forelimbs (Table 3.2). The 
defect also appeared to be variable, with some embryos appearing to duplicate the limb axis and others 
generating secondary limb outgrowths. We did not examine the tail in detail, but there was no obvious 
sign of posterior failure to close the neural tube, and no gross increase in the number of somites (Aires 
et al., 2016). Similarly, the structure of the jaw was not examined thoroughly, but was clearly greatly 
reduced in a single chimera (Table 3.2). 
It is also interesting to compare our findings to the effects of ectopic Oct4 expression in adult mice. 
Previously, ES-derived and chimeric mice carrying a doxycycline-inducible Oct4 transgene have been 
studied (Hochedlinger et al., 2005). On application of doxycycline, Oct4 is expressed to varying levels 
in tissues throughout these animals, though not in the brain or testes. On induction of Oct4, mice 
rapidly developed dysplasia in the stomach, intestines and skin. Notably these tumours appears to 
derive primarily as a result of inhibition of the differentiation of adult stem cells in these tissues. 
Remarkably, on withdrawal of doxycycline these tissues rapidly returned to normal, with appropriate 
differentiation and no sign of teratomas. This suggests that in this context, Oct4 was incapable of 
reverting these cells to pluripotency. Nonetheless, it would be interesting to investigate whether a 
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similar block in terminal differentiation and exit from the cell cycle is responsible for the embryonic 
phenotypes we and Ramos-Mejía et al. observed. 
It should be noted that in ongoing work I have derived NSC and MEF cell lines from our E12.5 fixed-
Oct4 chimeras. This allows us to examine the gene expression profile of these somatic cells and 
compare them to lines derived from non-chimeric littermates, to generate a greater number of cells to 
test alternative reprogramming strategies, and to generate a useful resource for future work. In 
collaboration with Hannah Stuart, I have been working with these cells, and preliminary data suggest 
that under appropriate conditions it is possible to revert these MEFs to naïve pluripotency solely 
through manipulating their environment. This builds on our finding that somatic cells from E8.5 
chimeras can reprogram. It demonstrates that cells in advanced stages of differentiation can be 
converted to naïve pluripotency in the presence of an appropriate level of Oct4, and it goes further 
towards demonstrating that there is not a small, undetected population of pluripotent cells maintained 
in these embryos as we are able to obtain iPSC lines from a relatively well defined somatic population. 
The high contribution of fixed-Oct4 cells to chimeras demonstrates that an ESC level of Oct4 is not 
incompatible with advanced cellular differentiation, although clearly it interferes with signalling in 
some contexts. It is interesting to note that in the early embryo, Oct4 is present during each of the 
major differentiation / cell fate decision events. Maternally contributed Oct4 is present in the zygote, 
and zygotic Oct4 expression is initiated at around the 4-cell stage. Oct4 can be detected in all cells 
during the initial segregation of trophectoderm and ICM, though it has been shown that maternal 
zygotic Oct4-/- embryos successful establish this compartmentalization (Le Bin et al., 2014). Oct4 is 
then present in all cells of the ICM, and is required for maturation and segregation of the ICM into 
the naïve epiblast and primitive endoderm. Subsequently, Oct4 is present during the transition and 
differentiation from the apolar, naïve epiblast to polarized epithelium of the post-implantation 
epiblast. Studies have shown that Oct4 is required for the equivalent process in vitro, where knockout 
or knockdown of Oct4 prevents this forward progression (Niwa et al., 2000; Radzisheuskaya et al., 
2013). Oct4 is still present during the initial stages of gastrulation as cells establish their prospective 
somatic fate, although the precise role of Oct4 at this point has not been established. Embryos in which 
Oct4 is deleted around the time of implantation suffer from disorganisation of the epiblast, with poor 
axis establishment (Mulas et al., 2018), however. Together with the reprogramming data, this suggests 
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Oct4 plays an important role in facilitating transitions between different cellular identities rather than 




Chapter 4: Loss of Oct4 reveals that it 
is both antagonistic to and necessary 
for expression of the naïve 
transcription factor network 
4.1. Introduction 
Oct4 is known to be necessary for the maintenance of pluripotency in vivo and in vitro. In both cases, 
loss of Oct4 ultimately leads to exit from pluripotency and eventually cells take on characteristics of 
the trophoblast lineage, including expression of marker genes Cdx2, Pl-1 and Eomes, and adoption of 
trophectoderm-like morphology (Nichols et al., 1998; Niwa et al., 2000; Velkey and O’Shea, 2003). 
Despite this, it is not clear precisely why Oct4 is essential to the naïve state; Oct4 is a highly 
promiscuous transcription factor, binding to thousands of sites in the genome (King and Klose, 2017; 
Simandi et al., 2016), and many of its target genes are known not to be essential for the maintenance 
of ESCs (Hall et al., 2009; Matoba et al., 2006; Zwaka, 2012). At the same time, no target has been 
identified that can rescue Oct4-loss driven differentiation through overexpression or knockout (Hall 
et al., 2009; Matoba et al., 2006). It therefore seems likely that differentiation upon loss of Oct4 is the 
result of misregulation of a number of genes rather than of any single critical target. 
Nonetheless, existing models of the action of Oct4 suggest that Oct4 may act on a relatively defined set 
of targets. The limiting cofactor model suggests that a factor or complex that interacts with Oct4 is 
present in limiting quantities such that key pluripotency regulatory elements are active normally, but 
on Oct4 overexpression the cofactor is distributed more broadly resulting in inefficient activation of 
these important pluripotency genes. Meanwhile the see-saw model proposes that Oct4 is essential for 
the repression of ectodermal specifiers, counteracting the pro-neural differentiation influence of Sox2. 
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With this in mind, I set out to investigate early responses to loss of Oct4 in ESCs in order to determine 
the proximal cause of differentiation. I reasoned that later events would be the cumulative result of a 
large number of expression changes, while the direct targets of Oct4 responsible for initiating this 
cascade should be some of the most immediately affected by removing Oct4. 
4.2. Results 
4.2.1. Studying Oct4 depletion using a Lox-Cre system 
Initially I decided to utilize a conventional conditional Lox-Cre system to study the effect of loss of 
Oct4 in ESCs. This system uses cell lines containing one floxed Oct4 allele (Oct4F) and one knocked 
out by targeted deletion (Oct4-) (Nichols et al., 1998) (Figure 4.1a), which I transfected with a construct 
for expression of CreERT2. In the absence of induction, the oestrogen receptor subunit maintains 
cytoplasmic localisation of the Cre recombinase, preventing it from interacting with the floxed Oct4 
allele in the nucleus. When 4-hydroxytamoxifen (4-OHT) is added and binds to the oestrogen receptor 
subunit, CreERT2 translocates to the nucleus and recombines LoxP sites, resulting in excision of the 
remaining Oct4 allele (Oct4F → Oct4-). 
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After briefly characterizing cell lines from two genetic backgrounds, I found that one line (Line A, 
Figure 4.1b) typically only led to Oct4 excision in roughly 50% of cells. Since the second line (Line B, 
referred to as Oct4F/- ESCs hereafter) gave complete Oct4 depletion, I used this for all further work. 
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Loss of Oct4 protein in these cells is gradual, and is completed within ~36 hours of addition of 4-OHT. 
Four days after induction, cells began to show morphological changes, resembling trophoblasts then 
more differentiated trophectodermal cells (Figure 4.1d). I carried out a timecourse over early 
timepoints after loss of Oct4 in an attempt to identify important direct targets of Oct4. I decided to 
analyse this data using high throughput RNA-seq methods in order to see global changes in gene 
expression levels with greater reliability and coverage than traditional microarray approached. Note, 
principal component analysis of the normalized data prior to collapsing technical replicates shows little 
variance between technical replicates indicating that there were no problems with the libraries, and 
little variance between biological replicates indicating the robustness of these changes (Figure 4.2b). 
Additionally, the principal component of variance maps well with progression in time. As Figure 4.2a 
shows, in the earliest stages the expression of very few genes changes; within 12 hours of addition of 
4-OHT, 55 genes show a statistically significant change in expression. However, few of these are 
obvious candidates for factors essential to naïve pluripotency. One fifth are general metabolic enzymes 
with no specific link to pluripotency, which could be responses to the treatment rather than changes 
in Oct4. A small number of receptors, ligands and transcription factors show expression changes which 
may imply their regulation by Oct4 in pluripotency. For instance Lefty1 and Lefty2 are upregulated 
and Fgf4 and Lifr are downregulated on loss of Oct4; direct regulation of the Lefty1 and Fgf4 loci by 
Oct4 binding have been described before (Dailey et al., 1994; Nakatake et al., 2006; Niwa et al., 2002; 
Yuan et al., 1995), though Oct4 has previously been reported been reported to promote Lefty1 
expression. However, none of these are essential in ESCs. One essential factor downregulated in these 
cells is G2e3, an E3-ubiquitin ligase. Knockout embryos fail at the blastocyst stage, though this is due 
to extensive apoptosis rather than trophectodermal differentiation (Brooks et al., 2008). 
18 hours after induction, other 1000 genes are differentially expressed. By this point it is impossible to 
identify any likely key targets over all of the other factors that are changing. That said, it is noteworthy 
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that several important trophectoderm-associated transcripts are significantly upregulated, including 
Gcm1, Hand1 and Eomes, while expression of several key pluripotency genes like Nanog remain 
unchanged (Figure 4.2a). This could suggest that dismantling of the naïve network is a consequence 
of de-repression of the extraembryonic transcriptional network. By 36 hours, when the majority of 
Oct4 is finally lost at the protein level (Figure 4.1c), over 5000 genes are differentially expressed. At 
this time, Lefty1 and Lefty2 are downregulated, as the literature suggests they should be in the absence 
of Oct4 (Nakatake et al., 2006; Niwa et al., 2002). Surprisingly, however, Nanog expression is increased 
in these cells (Figure 4.2a), even as they begin to exit pluripotency. This was validated by RT-qPCR, 
where Nanog expression could be seen to increase as Oct4 protein levels were decreasing (Figure 4.2c). 
Direct comparison to the work of Hall et al. (Hall et al., 2009), in which transcriptional repression of 
Oct4 was used to studying downstream changes, shows similar overall trends. A large amount of 
variance between the two datasets can be seen in a principal component analysis (Figure 4.3a), likely 
due to multiple factors such as the use of different cell lines, different growth conditions, RNA 
treatment and measurement of expression. Despite this, the two systems show very similar trends 
across the second principal component of variance (Figure 4.3a). Notably, however, progression along 
the second principal component is more continuous in the Oct4 deletion dataset presented here, 
whereas the Hall et al. dataset shows a shows less robust separation of earlier timepoints and a large 
jump to the final timepoint. 
As expected, examining the contributions of differentially expressed genes to the principal component 
analysis shows that timepoints are separated by expression of pluripotency- vs differentiation-
associated genes (Figure 4.3b). Comparing the differentially expressed genes in each system, there is a 
lot of overlap; around a half of the genes that show statistically significant variation in the gene deletion 
system are also differentially expressed in the transcriptional inhibition system (Figure 4.3c). Oddly, a 
very large number of genes are differentially expressed even at the earliest timepoint in the Hall et al. 
dataset, despite there being only a minor change in Oct4 protein level at this time; this agrees with the 
analysis performed in Hall et al. On the other hand, in the Oct4 deletion dataset there is a gradual 
accumulation of differentially expressed genes. It is unclear why this is the case, and this is not 
explained by Hall et al. It may be that there are a number of changes early in the timecourse relating to 
the induction procedure rather that the downregulation of Oct4, but picking this apart would require 
a greater amount of data to be generated from control lines by both Hall et al. and myself. 
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Despite the similarities between my results and those of Hall et al., these results were somewhat 
counterintuitive. Some gene expression changes were contrary to published data, and they did not 
provide any clear clues as to the essential targets of Oct4. However, I noticed that sustained, and even 
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upregulated, Nanog expression is a feature of Oct4-low cells (Karwacki-Neisius et al., 2013; 
Radzisheuskaya et al., 2013). It therefore seemed plausible that the unexpected transcriptional changes 
could be a result of cells transiently passing through an Oct4-low state rather than transitioning 
directly from a wild-type to a null identity. This is also suggested by the protracted period over which 
Oct4 protein is lost (Figure 4.1c). The half-life of OCT4 is variously stated at 2-12 hours (Buckley et 
al., 2012; Lin et al., 2012; Saxe et al., 2009; Wei et al., 2007; Yao et al., 2014), with post-translational 
modification such as ubiquitilation and sumoylation having a significant impact on the stability of the 
protein (Wei et al., 2007; Yao et al., 2014). As a result, it is not trivial to study the immediate impact 
of loss of Oct4 on target genes. 
4.2.2.  Establishing a novel system to study the immediate effects of loss of Oct4 
In order to avoid issues with gradual protein decay, I decided to establish a system for depleting Oct4 
via conditional proteasomal degradation. The auxin-inducible degron (AID) is a domain found in some 
auxin-responsive plant proteins (Abel and Theologis, 1996) which, on co-binding the small molecule 
auxin (IAA), binds the SCF ubiquitin ligase complex (Dharmasiri et al., 2005; Kepinski and Leyser, 
2005; Tan et al., 2007). On polyubiquitilation, the AID-containing protein is destroyed by the 
proteasome. The SCF complex is functionally conserved across eukaryotes (Deshaies, 1999), with 
expression of different F-box proteins providing spatio-temporal specificity through direct 
interactions with targets (Skowyra et al., 1997). IAA-bound AID is recognised by the plant-specific F-
box protein Tir1 (Gray et al., 1999; Ruegger et al., 1998). Exogenous expression of this protein in 
mammalian cells allows targeted degradation of any fusion protein containing the AID domain by 
adding auxin to the culture medium (Holland et al., 2012; Nishimura et al., 2009). 
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I designed a construct for the expression of an Oct4-AID C-terminal fusion protein. When co-
expressed with Tir1, this should result in rapid depletion on addition of IAA (Figure 4.4a). To test that 
the AID domain was functional in the fusion protein, I cloned the construct into a Piggybac 
tetracycline response plasmid to achieve efficient random genomic integration and inducible 
expression (Figure 4.4b). I transfected this, alongside constitutively expressed Tir1 and rtTA (a 
transcription factor that activates transcription downstream of a tetracycline response element (TRE) 
in the presence of doxycycline (dox)) Piggybac vectors, into wild-type mouse ESCs, generating 
inducible Oct4-AID ESCs (iO4AID ESCs). After selecting for transgene integration, I treated cells with 
dox to induce expression of Oct4-AID, then added IAA to induce its degradation. As a fusion protein, 
Oct4-AID has a higher molecular weight than wild-type Oct4, so the two proteins can be readily 
separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE). Western blot analysis using 
antibodies specific to the N-terminus of Oct4 shows that the fusion protein is expressed on addition 
of dox, and largely depleted in the presence of IAA (Figure 4.4c). 
Since I had confirmed the degron to be functional, I needed to test that Oct4 was not compromised 
within the fusion protein. Since Oct4 is essential for the maintenance of pluripotency I decided to 
confirm this by expressing Oct4-AID in ESCs lacking wild-type Oct4. A TetOFF-Oct4 cell line 
(ZHBTc4, Oct4-/- TetOFF-Oct4 hereafter) has previously been established through multi-stage 
genetic manipulation of CGR8 mouse ESCs (Niwa et al., 2000). Both endogenous Oct4 alleles are 
knocked out in this line. They constitutively express tTA and contain TetOFF controlled Oct4 
expression driven from a TRE; on addition of dox, tTA dissociates from the promoter and 
transcription stops. Functional Oct4 is required for the maintenance of ESCs, and non-functional 
transgenes cannot rescue self-renewal on dox-induced inhibition of wild-type Oct4 in these cells (Niwa 
et al., 2002), allowing them to be used in a complementation assay. I transfected these cells with a 
constitutively expressed Piggybac Oct4-AID and Tir1 constructs to generate Oct4-/- TetOFF-Oct4 
Oct4-AID ESCs (Oct4-AID ESCs hereafter) and maintained cells in the presence of dox to inhibit 
expression of wild-type Oct4 (Figure 4.5a). Cells continued to proliferate and showed normal 
morphology (Figure 4.5b). Cells expressed the fusion protein with no detectable wild-type Oct4 
present (not shown), and did not show substantially altered expression of key pluripotency genes 
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(Figure 4.5c). This demonstrates that the Oct4 fusion protein retains its original capacity to maintain 
naïve pluripotency and is not substantially altered in its function by the addition of the AID domain. 
Finally, I tested that the degron was functional in the context. Where the parental Oct4-/- TetOFF-
Oct4 cells downregulated Oct4 after around 3 hours, losing expression 4 hours after induction, OCT4-
AID protein was almost undetectable within one hour of addition of IAA (Figure 4.5d). 
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To further validate the function of Oct4 within the fusion protein, I decided to generate iPSCs, null 
for endogenous Oct4 and therefore wholly reliant on the Oct4-AID transgene for their maintenance. 
As a starting point, I took the Oct4-/- NSCs used by Aliaksandra Radzisheuskaya to generate fixed-
Oct4 cells used in Chapter 3, which had been made by Cre treatment of Oct4F/- NSCs (with the same 
knockout strategy shown in Figure 4.1a). I transfected these cells with constitutively expressed 
Piggybac Oct4 or Oct4-AID and transduced them with retroviral Oct4, Klf4 and cMyc. After a period 
of outgrowth, cells initiated reprogramming and generated intermediate pre-iPSCs (Silva et al., 2008; 
T. W. Theunissen et al., 2011). I replated these highly proliferative cells in naïve-specific conditions. 
One of the null Oct4 alleles has a β-geo cassette knocked in which is driven by the endogenous Oct4 
regulatory elements. I used this geneticin resistance to select for cells that had activated transcription 
from this locus in order to ablate non-reprogramming cells. As Figure 4.6b shows, colonies with a 
domed, iPS-like morphology were readily obtained using either wild-type or Oct4-AID constructs. 
Pre-iPS reprogramming intermediates showed strong expression of retroviral transgenes, but the 
pluripotency gene Nanog was not present (Figure 4.6c). In the fully reprogrammed iPSCs, Nanog was 
robustly expressed while retroviral transgenes were efficiently silenced (Figure 4.6c). The ability of the 
Oct4-AID transgene to maintain pluripotency in this clean Oct4 knockout background demonstrates 
that the essential function of Oct4 is maintained. It should also be possible to reprogram cells with 
Oct4-AID in the absence of any wild-type Oct4 if the fusion construct fully maintains the functionality 
of the untagged protein; unfortunately this has not been tested thoroughly. In a preliminary 
experiment in which Oct4-/- NSCs were transfected with wild-type Oct4 or Oct4-AID and transduced 
with retroviral Klf4 and cMyc, neither were able to generate fully reprogrammed iPS lines. All cells 
collapsed in 2iL under selection with either form of Oct4. This could indicate that the level of Oct4 
used was not appropriate for complete somatic cell reprogramming or that retroviral transduction was 
inefficient. Since the positive control failed to reprogram in this early work, further experimentation 
will be required to determine the capacity of Oct4-AID to perform in this role. The generated Oct4-
AID iPSCs did not display detectable endogenous Oct4 (Figure 4.6d), while the Oct4-AID fusion 
protein was robustly expressed as in the Oct4-AID ESCs. Again, I checked that the AID domain was 
functional, and indeed Oct4 was almost undetectable within 2 hours of IAA treatment. 
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4.2.3. Using rapid depletion to probe the essential function of Oct4 in ESCs 
With this system that allows rapid depletion of Oct4 at the protein level, I planned to identify the 
essential role of Oct4 in ESCs. While existing systems did not show full depletion of Oct4 until long 
after transcriptional changes were already evident, the Oct4-AID system achieves complete loss of 
Oct4 in such a short space of time that I expected cells to avoid passing through the confounding Oct4-
low state. I therefore hoped that this system would allow me to identify early transcriptional changes 
caused by Oct4 deletion that correspond to essential targets of Oct4 in the maintenance of naïve 
pluripotency. 
I performed qRT-PCR analysis of expression of several pluripotency genes in a timecourse following 
acute depletion of Oct4 in these ES and iPSCs. Many naïve-associated factors were rapidly 
downregulated on loss of Oct4 (Figure 4.7a-b). While some of these downregulated genes, such as 
Nr0b1, were repressed relatively rapidly in Oct4F/- ESCs on genomic ablation of Oct4, others such as 
Nanog appeared to be actively maintained in the slower system. This shows that there are important 
differences between reducing Oct4 levels and removing Oct4 entirely in terms of transcriptional 
responses. Examining several trophoblast-associated genes confirmed that these cells exit pluripotency 
following loss of Oct4 and differentiate towards trophectodermal lineages (Figure 4.7a-b), in keeping 
with conventional Oct4 depletion systems. 
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Global transcriptional changes were examined by RNA-sequencing, though only a single sample for 
each timepoint was analysed. Consequently, statistical and advanced bioinformatics analysis is 
impossible. A conservative analysis suggests that cells do not undergo conventional exit from 
pluripotency on loss of Oct4. In typical differentiation from naïve pluripotency cells begin to lose 
naïve-specific gene expression, but maintain expression of general pluripotency genes such as Sox2 
and Tdgf1 (Brons et al., 2007; Kalkan et al., 2017; Tesar et al., 2007). Coincident with this is 
upregulation of early post-implantation genes, which are upregulated in primed pluripotent EpiSCs 
relative to naïve ESCs (Brons et al., 2007; Hayashi et al., 2011; Kalkan et al., 2017; Tesar et al., 2007). 
Subsequently, lineage markers are upregulated (Han et al., 2010; Joo et al., 2014; Kojima et al., 2014), 
prior to loss of pluripotency gene expression and lineage commitment. However, in the case of 
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differentiation induced by loss of Oct4, we observe concurrent loss of both naïve-specific and general 
pluripotency gene expression (Figure 4.8a). There is no notable increase in expression of markers of 
primed pluripotency or of the early post-implantation epiblast. Less surprisingly, subsequent 
upregulation of embryonic lineage markers never occurs either. Instead, we observe upregulation of 
extraembryonic genes, particularly trophoblast-associated transcripts (Figure 4.8a), though the earliest 
changes remain the rapid downregulation of specific naïve transcription factors. Comparing global 
transcriptional changes between the genetic ablation system and induced protein degradation system, 
it is clear that cells follow the same trajectory of transcriptional change, indicating that the overall 
pattern of differentiation is comparable (Figure 4.8b). However, the AID system yields far more rapid 
changes. 
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4.2.4. Studying the role of Oct4 in the binding of other transcription factors to DNA 
Many pluripotency-associated transcription factors bind to a large number of enhancer elements 
throughout the genome (Kim et al., 2008; Loh et al., 2006), including many genes that are not actively 
transcribed in ESCs. To explain this phenomenon, it has been suggested that binding of several 
transcription factors may be required for the activation of genes in naïve cells. This is supported by 
the fact that many active loci in ESCs display binding of multiple pluripotency factors at their enhancer 
elements (Chen et al., 2008; Göke et al., 2011). With this in mind, it has been hypothesised that a key 
role of Oct4 may be to recruit other transcription factors to pluripotency genes (King and Klose, 2017), 
either through direct interactions or by creating a less restrictive chromatin environment through 
epigenetic modifications. 
It has been found that Oct4 and Sox2 form a complex on DNA (Fong et al., 2011; Kuroda et al., 2005; 
Lam et al., 2012; Merino et al., 2014), and bind to their respective motifs in a cooperative manner 
(Ambrosetti et al., 2000, 1997; Reményi et al., 2003; Tokuzawa et al., 2003). Oct4 has also been shown 
to form complexes with Nanog (Liang et al., 2008; Pardo et al., 2010; Wang et al., 2006), and they co-
bind to many loci throughout the genome (Chen et al., 2008; Göke et al., 2011; Kim et al., 2008; Loh 
et al., 2006). I was therefore interested to see how the binding of these pluripotency transcription 
factors to the genome would be affected immediately following loss of Oct4. 
Western blot analysis confirmed that 90 minutes after addition of IAA, Oct4 was efficiently depleted 
while the level of Sox2 and Nanog proteins were yet to be strongly affected in Oct4-AID ESCs (Figure 
4.9a). Pulling down regions associated with Sox2 by chromatin immunoprecipitation (ChIP) and 
analysing enrichment by qPCR revealed a small decrease in Sox2 binding to the Oct4 distal enhancer 
(Figure 4.9b). This did not achieve statistical significance due to the small number of replicates, so it 
should be interpreted cautiously, but is in agreement with previous studies (Ambrosetti et al., 2000, 
1997; King and Klose, 2017; Reményi et al., 2003; Tokuzawa et al., 2003). On the other hand, the 
immediate response of Nanog to loss of Oct4 was an increase in binding to the Oct4 regulatory region, 
though again this data requires replication to give confidence to these findings (Figure 4.9c). A 
previous study using TetOFF-Oct4 ESCs suggested that Nanog binding decreased in the absence of 
Oct4 (King and Klose, 2017); however, in that work ChIP was performed 24 hours after induction of 
72 Mechanisms of Oct4 in the entry to, maintenance of, and exit from pluripotency 
Oct4 depletion, leaving ample time for secondary effects to alter the Nanog binding profile. 
Interestingly, other work has suggested that in the Oct4-low state Nanog has increased genomic 
occupancy, though it is unclear whether this is associated with increased or decreased Oct4 at the same 
sites (Karwacki-Neisius et al., 2013; Radzisheuskaya et al., 2013). In the data presented here, we 
actively avoid the Oct4-low state; this common finding suggests that Oct4 may indeed actively reduce 
the ability of Nanog to bind to enhancer elements. 
 
To further validate this, I repeated the experiment in Oct4-AID iPSCs. Again, addition of IAA rapidly 
and efficiently depleted Oct4 from cells with minimal impact of Nanog protein levels (Figure 4.10a). 
In this experiment there was little change in Nanog binding to the Oct4 distal regulatory element, but 
there was a significant increase in the pulldown efficiency of the Nanog enhancer (Figure 4.10b). This 
confirmation of increased Nanog bound to DNA in an independent cell line lends further strength to 
this dataset. 
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4.2.5. Global analysis of Nanog distribution following loss of Oct4 
To test the impact of loss of Oct4 on Nanog localisation globally, I submitted Nanog 
immunoprecipitated chromatin for high thoughput sequencing. After aligning the reads to the mouse 
genome, I examined the Nanog binding profile at the regulatory regions of several key pluripotency 
genes using the UCSC Genome Browser (Kent et al., 2002). There was a clear increase in the read 
density, represented by a greater peak area, following depletion of Oct4 (Figure 4.11). This confirms 
that Nanog binding increases at key pluripotency loci in the absence of Oct4. 
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I decided to look globally at all Nanog peaks, generated from the Oct4-depleted samples since they 
appeared to show increased Nanog binding. By plotting the change in read counts at all 12622 loci, it 
is clear that Nanog binding increases at the majority of binding sites, though it does decrease at a small 
number of loci (Figure 4.12a). I also looked more specifically at the complementary subsets of peaks 
that either overlap with an Oct4 peak (1812 sites) or do not co-bind with Oct4 (10810 sites) (Figure 
4.12a-b). At Oct4-Nanog co-binding sites there was a detectable increase in overall Nanog binding; 
globally this was statistically significant (Mann-Whitney test, P <10-10), and many individual peaks did 
show greater binding (52 increased and 6 decreased with an FDR <0.05 out of a total of 1810 peaks). 
However, Nanog peaks that do not overlap with Oct4 displayed a more dramatic increase in Nanog 
binding (Mann-Whitney test, P <10-10), with more than 10% of peaks showing greater Nanog 
occupancy in the absence of Oct4 (1650 increased and 2 decreased with an FDR <0.05 out of a total of 
10753 peaks). Examining heatmaps of Nanog enrichment (Figure 4.12bi. and ii.), it appears that Nanog 
is enriched at all of the binding sites identified in Oct4-depleted samples prior to removal of Oct4. This 
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suggests that Nanog is not binding to new loci in the absence of Oct4, even if the overall level of 
binding is increasing. 
While counterintuitive, this implies that Oct4 may be able to regulate the ability of Nanog to interact 
with chromatin indirectly, perhaps through sequestering a binding partner or Nanog itself in the 
nucleoplasm. Alternatively, it may be that Nanog is recruited to sites that it only weakly binds to, and 
are therefore undetected, by Oct4, and thus in the absence of Oct4 this pool of Nanog would be free to 
associate with stronger binding sites; however, it seems unlikely that this is sufficient to account for 
the level of increased binding observed. It would be interesting to more precisely quantitate the 
amount of Nanog bound to chromatin, either by relative quantitation in chromatin-enriched samples 
by mass spectrometry or through single-molecule imaging of Nanog and determination of the 
chromatin-bound fraction by their residence time, in order to clarify whether there is a broad increase 
in genomic occupancy by Nanog, or whether the changes observed represent a redistribution across 
Nanog binding sites. 
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I additionally examined the effect of chromatin context on the change in Nanog binding following loss 
of Oct4. Using publically available data for the binding of histone marks associated with active 
enhancer or promoters or repressed loci, as well as the highly abundant transcription factor p300 and 
RNA PolII, I assigned Nanog binding sites as associated with one or more of these loci. As expected, 
the largest group was enhancer associated Nanog binding sites (Figure 4.12d). Looking at the change 
in Nanog binding following loss of Oct4, there is an increase in binding at many enhancer- and 
promoter-associated sites (Figure 4.12c). However, at repressed loci there appears to be a bimodal 
distribution of changes in Nanog binding; a small number of sites show very large increases in Nanog 
binding, but loci in which Nanog binding decreases appear to be enriched in this group (Figure 4.12c).  
One possible explanation for an increase in enhancer-bound Nanog would be if the protein is more 
stable in the absence of Oct4. To test whether this is the case I performed a cycloheximide chase assay 
(Figure 4.13a). Cycloheximide inhibits protein synthesis by binding within ribosomes and preventing 
translocation by blocking the passage of tRNAs out of the complex (Schneider-Poetsch et al., 2010). 
As a result, no new proteins are synthesized, and by monitoring the levels of proteins over time their 
rate of decay can be determined. I quantitated Nanog levels following addition of cycloheximide, with 
or without addition of IAA, by Western Blot, using a standard curve to adjust for the non-linear 
relation between protein quantity and band intensity (Figure 4.13b). As expected, Nanog degradation 
followed exponential decay kinetics and as a result can be described by Equation 1. Plotting the natural 
log of the protein quantity yields the linear equation in Equation 2, so the decay constant, λ, can be 
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calculated as the gradient of the line. Doing this gives the decay constants shown in Figure 4.13b-iii. 
Finally, using Equation 3, we can calculate the half-life of Nanog; in the presence of Oct4 this is 2.3 
hours, and this is reduced to 1.4 hours in the absence of Oct4. This fits with previous findings that 
Nanog displays increased stability in the presence of Oct4 (Muñoz Descalzo et al., 2013). Again, 
however, this previous study investigated Nanog stability 24 hours after the initiation of Oct4 
depletion, whereas the work presented here examines the immediate impact of loss of Oct4. 
Regardless, this suggests that stability is not the cause of the increased genomic occupancy of Nanog 
that we observed in Figures 4.9-4.12. 
 
 
 Loss of Oct4 reveals that it is both antagonistic to and necessary for expression of the naïve transcription factor network 79 
𝑥(𝑡) = 𝑥0𝑒
𝜆𝑡  







4.2.6. Studying the epigenetic impact of loss of Oct4 
Given this increase in Nanog binding to pluripotency genes, including at enhancer elements where it 
acts as a transcriptional activator (Festuccia et al., 2012; Shi et al., 2006; Stuart et al., 2014), I was 
interested to see if there were epigenetic changes associated with increased enhancer usage in cells 
following loss of Oct4. 
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Acetylation of histone H3 at lysine 27 (H3K27ac) is a marker of active enhancer elements; surprisingly, 
despite the increase in Nanog binding, H3K27ac enrichment did not increase at the regulatory 
elements of several pluripotency genes short after depletion of Oct4, instead decreasing at several loci 
(Figure 4.14). 
Given this apparent decrease in enhancer usage, despite increased Nanog occupancy, I examined the 
expression of enhancer RNAs in cells shortly after removal of Oct4. Again, despite the increase in 
Nanog binding at the regulatory elements of pluripotency genes, and in line with the reduced level of 
H3K27ac at some loci, there was also a rapid decrease in the level of some enhancer RNA transcripts 
(Figure 4.15). 
4.3. Discussion 
The phenomenon of pluripotency has been of great interest for many years, perhaps since it was first 
shown that cells taken from a donor blastocyst could integrate into a recipient blastocyst and 
contribute to normal embryonic development (Gardner, 1968). Since then, we have learned how to 
capture pluripotency in vitro (Evans and Kaufman, 1981; Martin, 1981), and how to maintain cells in 
a state equivalent to the preimplantation epiblast (Boroviak et al., 2015, 2014; Ying et al., 2008). Oct4 
was perhaps the first factor described as essential for the establishment of the naïve epiblast (Nichols 
et al., 1998). Since then it has been shown that Oct4 is dispensable for initial generation of the 
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blastocyst structure, but required for segregation of the inner cell mass into naïve epiblast and 
primitive endoderm (Le Bin et al., 2014). We have also learned that Oct4 is essential for maintaining 
naïve pluripotency in vitro (Niwa et al., 2000). Despite this, the manner in which Oct4 is required for 
these processes is unclear; no downstream target, exogenous expression or knockout of which can 
rescue the Oct4 knockout phenotype, has been identified (Hall et al., 2009; Matoba et al., 2006; Niwa 
et al., 2000). 
4.3.1. Conventional systems for depletion of Oct4 pass through an Oct4-low state 
In order to identify essential targets of Oct4, I wanted to examine initial transcriptional changes in 
response to Oct4 depletion. It is notable that similar experiments have been performed before (Hall et 
al., 2009; Matoba et al., 2006) and have failed to yield an essential role for Oct4, but I anticipated that 
studying a larger number of timepoints would reveal more specific targets that could be further 
characterized. This system did reveal some interesting results, such as the rapid upregulation of several 
key trophectodermal transcription factors prior to downregulation of many pluripotency genes 
(Figure 4.2). It is tempting to interpret this as evidence that Oct4 is primarily required for the 
repression of trophectodermal genes, and following their depression these lead to loss of pluripotency 
and adoption of an extraembryonic fate. However, I wanted to rule out the possibility that my results 
were skewed as a result of cells passing through an Oct4-low state. It is known that cells exhibiting a 
low level of Oct4 can sustain expression of pluripotency markers under mild differentiation conditions 
(Karwacki-Neisius et al., 2013; Radzisheuskaya et al., 2013), and I wondered if transcription of such 
factors was being artificially maintained by the low levels of Oct4 that remain until all Oct4 protein 
eventually gets degraded. The half-life of Oct4 is sometimes reported to be very long (Lin et al., 2012; 
Wei et al., 2007); it took about a day for Oct4 to be fully removed from the cells used in this work 
(Figure 4.1c), and published work shows more than 10 hours for complete Oct4 depletion using a 
TetOFF system (Hall et al., 2009; Niwa et al., 2000). This is a significant amount of time, especially 
when one is trying to study direct and immediate responses to loss of Oct4. No timescale has been 
reported for cells to start showing responses to the Oct4-low state, and it is unclear what represents 
direct changes caused by lower Oct4 levels and what are compensatory changes induced by feedback 
loops or downstream responses to altered transcriptional networks. 
Utilizing advances in imaging and counting mRNA molecules in single cells, it has recently been 
described that transcription occurs in bursts in prokaryotes (Cai et al., 2006; Golding et al., 2005) and 
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eukaryotes (Chubb et al., 2006), including in mammals (Raj et al., 2006). These bursts are characterized 
by pulses of polymerase activity interspersed with inactive periods. The length of these intervals 
between transcription are highly variable between genes, but are typically in excess of an hour and up 
to several hours (Suter et al., 2011). Reports suggest that the ‘off’ time for Nanog is between 1 and 4.5 
hours (Muñoz Descalzo et al., 2013; Skinner et al., 2016), which would allow ample time for low Oct4 
levels to affect Nanog burst frequency or size using conventional Oct4 depletion systems. 
In order to avoid this confounding effect, I chose to establish new cell lines which utilise rapid 
depletion of Oct4 at the protein level (Figure 4.4a). It has previously been reported that the auxin 
inducible degron can reduce the half-life of tagged proteins to ~20 minutes in mammalian systems 
(Holland et al., 2012; Nishimura et al., 2009), and indeed I found that tagged Oct4 protein was greatly 
reduced within half an hour and almost undetectable within an hour of addition of IAA (Figure 4.5d 
and Figure 4.6d). 
4.3.2. DNA binding of pluripotency factors is affected immediately following loss of Oct4 
After ensuring that both the AID domain and Oct4 were unaltered in their function in this fusion 
protein (Figure 4.5 and Figure 4.6), I proceeded to re-examine the immediate effects of loss of Oct4. 
Since depletion of Oct4 was so rapid, I was able to examine the effect of loss of Oct4 prior to changes 
in the protein level of other pluripotency transcription factors. The interaction between Oct4 and Sox2 
has been relatively well described; a model of the Oct4-Sox2-DNA complex has been generated via 
homology to an Oct1-Sox2-DNA crystal structure (Reményi et al., 2003; Yesudhas et al., 2016), and 
the cooperative binding of these proteins on DNA has been studied extensively in vitro (Ambrosetti et 
al., 2000, 1997; Reményi et al., 2003; Tokuzawa et al., 2003). These previous findings suggest that in 
the absence of Oct4, Sox2 should not interact as strongly at their co-binding sites. That said, single-
molecule studies into the kinetics of Oct4 and Sox2 binding to DNA have suggested that Oct4 only 
slightly increases the residence time of Sox2 at specific binding sites (Chen et al., 2014). Despite this, I 
observed a decrease in Sox2 binding at the Sox2 regulatory element following loss of Oct4 (Figure 
4.9b). As Biddle et al. suggest, there may be significant diversity in the cooperativity of Oct4 and Sox2 
across the genome (Biddle et al., 2019). Further studies into genome-wide changes in Sox2 binding 
following acute loss of Oct4 could be helpful in further understanding the interactions of these two 
factors. It should be noted that these results are not very robust, due to sub-optimal ChIP conditions 
and lack of biological replicates. Nonetheless, to the best of my knowledge, this represents the first 
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time it has been shown that Oct4 is required for efficient binding of Sox2 to DNA ex vivo in mouse 
ESCs. 
ChIP-qPCR and ChIP-seq against Nanog protein yielded an interesting and surprising result; in the 
absence of Oct4, greater levels of Nanog were found bound to the genome (Figure 4.9c, Figure 4.10b, 
Figure 4.11 and Figure 4.12). Remarkably, this extended beyond Oct4 co-bound sites, with a significant 
increase in Nanog levels observed at many binding sites lacking Oct4 (Figure 4.12a and b). While it 
seems plausible that Oct4 may physically occlude Nanog binding sites where they colocalise, resulting 
in competitive binding, this is somewhat contradicted by previous reports of simultaneous binding of 
Oct4 and Nanog to regulatory regions as detected by sequential ChIP (Medeiros et al., 2009). It is 
noteworthy, however, that while there is significant overlap between Oct4 and Nanog binding sites, 
the two proteins are typically separated by several nucleotides and may not physically interact on the 
DNA (Ferraris et al., 2011). To the best of my knowledge, it has not been shown whether Oct4 and 
Nanog interact cooperatively or competitively on DNA through in vitro assays, rather assumed from 
indirect evidence such as overlap in binding sites as described above. 
On the other hand, it has been demonstrated that Nanog and Sox2 strongly interact, even in the 
absence of DNA (Gagliardi et al., 2013). Despite the fact that Oct4 and Sox2 are commonly presented 
as important co-binding factors, Sox2 actually co-localises more frequently with Nanog than Oct4 in 
genome-wide studies (Chen et al., 2008; Göke et al., 2011). It would be very interesting to look globally 
at changes in Sox2 binding in the immediate aftermath of Oct4 withdrawal; it may be that Sox2 is 
liberated from Oct4 co-binding sites, and recruits other transcription factors including Nanog to non-
Oct4 bound sites. A previous study examined the localisation of Nanog and Sox2 24 hours after 
transcriptional depletion of Oct4 (King and Klose, 2017). In this work, they found that Sox2 and Nanog 
binding was reduced at many Oct4 co-bound sites correlating with reduced chromatin accessibility in 
the absence of Oct4. However, a subset of co-bound sites retained chromatin accessibility after Oct4 
depletion, and at these sites binding of both Nanog and Sox2 was increased. Of course, this carries the 
caveat that such changes may be due to subsequent transcriptional and epigenetic changes downstream 
of loss of Oct4 rather than direct effects, but this could represent a similar redistribution of Sox2 and 
Nanog to sites where Oct4 binding is of less functional relevance. 
It is currently unclear how the global chromatin state changes following acute depletion of Oct4. 
Previous work has suggested that Oct4 may act as a pioneer factor, opening chromatin that would 
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otherwise be highly compacted (King and Klose, 2017; Soufi et al., 2015).  As a result, removal of Oct4 
might result in the eviction of other transcription factors and repression of gene expression. 
Additionally, there could be significant changes in the chromatin architecture due to altered 
topological domains in the absence of Oct4. Decommissioning of super enhancers, many of which are 
bound by Oct4 in ESCs (Whyte et al., 2013), could lead to a reorganisation of the nuclear structure as 
these elements can interact with multiple promoter regions, even over large distances (Novo et al., 
2018). It would be interesting to examine the chromatin state of cells before and after depletion of 
Oct4 to test these hypotheses. DNA FISH approaches could be used to examine the interactions of 
individual loci, while techniques such as Hi-C and Promoter-Capture Hi-C could be used to build a 
global picture of chromatin interactions and particularly promoter-superenhancer interactions (Novo 
et al., 2018). Other approaches such as MNase-seq and ATAC-seq could provide information about 
chromatin accessibility to determine whether chromatin is more highly compacted overall, and 
specifically in the region of Oct4 binding sites. 
In agreement with existing literature, it appears that the half-life of Nanog is increased in the presence 
of Oct4 (Muñoz Descalzo et al., 2013). As a result, increased Nanog stability is not likely to be 
responsible for the increased genomic occupancy I observed. However, it would be interesting to see 
what other attributes of Nanog protein are altered in the absence of Oct4. It has been suggested that 
phosphorylation of Nanog by Erk1 results in ubiquitylation and subsequent degradation (Kim et al., 
2014), a process antagonised by the de-ubiquitylase USP21 (Jin et al., 2016; Kwon et al., 2017; Liu et 
al., 2016). Nanog phosphorylation at partially overlapping sites has also been associated with an 
increase in stability via interaction with the prolyl isomerase Pin1 (Moretto-Zita et al., 2010). It would 
therefore be interesting to examine whether post-translational modification of Nanog is affected by 
the presence/absence of Oct4, to see whether Oct4 plays a role in recruiting these factors or protecting 
Nanog from their binding. It would also be interesting to see if the residence time of Nanog on DNA 
is altered in the absence of Oct4. It is becoming increasingly common to use single molecule tracking 
techniques to calculate the kinetics of the interactions between transcription factors and chromatin 
(Hemmerich et al., 2011; Loffreda et al., 2017; Mazza et al., 2012; Morisaki et al., 2014). This could 
indicate whether Nanog interacts more strongly with DNA in the absence of Oct4, possible explaining 
the increase in occupancy we observe. It could also reveal whether the increased binding we observe 
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via ChIP-seq is caused by an increase across all cells, or a reduction in the heterogeneity of Nanog 
binding between cells (Mueller et al., 2013). 
4.3.3. Oct4 is required for transcription of key pluripotency factors 
As previously established, conventional systems used to study loss of Oct4 are characterized by transit 
through an Oct4-low state. It has previously been shown that this can result in altered responses to 
signalling molecules and differential expression of several key pluripotency associated genes 
(Karwacki-Neisius et al., 2013; Radzisheuskaya et al., 2013). Therefore, while thousands of 
differentially expressed genes have been identified following depletion of Oct4 (Hall et al., 2009; 
Matoba et al., 2006), it is unclear what are genuine responses to removal of Oct4 rather than responses 
to reduced levels of Oct4. Consequently, the rapid Oct4 depletion system is well suited to examining 
the immediate impacts in a way that existing systems cannot. 
As I have described, expression of several key pluripotency factors drops rapidly as a result of loss of 
Oct4 (Figure 4.15a-c). Some of these factors show contrasting responses to acute versus prolonged 
depletion of Oct4; for instance, in my LoxCre system Klf4 responds slowly to removal of Oct4, whereas 
upon rapid loss of Oct4 it is quickly downregulated. Similarly, by microarray analysis Nanog was not 
differentially expressed on transcriptional inhibition of Oct4 (Hall et al., 2009), while transcript levels 
dropped prior to substantial trophoblast gene expression in my system (Figure 4.15a and ). 
Given that Nanog binding is sustained at these loci, these data suggest that Oct4 binding may be 
required for the expression of a subset of pluripotency genes. It would be beneficial to explore this 
more directly by examining changes in nascent transcript levels in the immediate aftermath of acute 
Oct4 depletion. Interestingly, expression of enhancer RNAs at some pluripotency loci is decreased 
rapidly on loss of Oct4 (Figure 4.7). Transcription of enhancer RNAs is strongly correlated with 
enhancer activity (Azofeifa et al., 2018; De Santa et al., 2010; Kim et al., 2010), so this finding implies 
that some Oct4-bound enhancers rapidly lose their functionality when Oct4 is removed. 
These differences go some way to explaining past discrepancies in the perceived role of Oct4 in the 
pluripotency network. As Hall et al. note, Nanog has been described as an Oct4 target gene, and there 
is significant biochemical data validating that Oct4 binds to the Nanog enhancer region and is required 
for its expression (Kuroda et al., 2005; Rodda et al., 2005), yet Oct4 depletion appeared to have a 
limited, even positive impact on Nanog mRNA. I propose that the reason for this is that while Oct4 
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may be essential for Nanog expression, above a minimal level Oct4 negatively regulates the binding of 
other transcriptional activators. Thus, as Oct4 levels drop and cells pass through an Oct4-low state, 
binding of Oct4 to the Nanog enhancer is reduced and other transcription factors can be recruited, 
buffering Nanog expression levels. Once Oct4 is entirely depleted, very rapidly in the case of induced 
degradation, Nanog expression falls as the locus is no longer transcribed. Clearly this is highly 
speculative, and requires a significant amount of work to validate. However, this would reproduce the 
phenotypes observed with varying Oct4 levels (Figure 4.16): a minimal level would be required for 
expression of key pluripotency factors, and below this cells would not be able to maintain pluripotency; 
above this, a low level of Oct4 would be optimal for self-renewal, with strong expression of many 
pluripotency factors; higher, at an ESC level, Oct4 would begin to show a repressive effect on genes 
such as Nanog, generating a state which is permissive for both self-renewal and differentiation; finally, 
on overexpression of Oct4, transcription factors would be excluded from the regulatory regions of key 
pluripotency genes, resulting in collapse of the naïve network and induction of differentiation. 
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Under this model, there would be several key pluripotency factors which require Oct4 for their 
expression. Thus, co-expression of several exogenous genes would be required to rescue the Oct4 
knockout phenotype. Unfortunately, the data generated so far are not statistically rigorous, preventing 
the generation of a full list of candidates, though likely factors include Nanog, Esrrb, Klf4 and Lifr, 
which are rapidly downregulated upon proteolytic Oct4 loss, and in some cases on conventional Oct4 
depletion. 
4.3.4. Exit from pluripotency following loss of Oct4 follows a non-conventional trajectory 
Typically, exit from pluripotency occurs in stages as cells pass through progressively more 
differentiated states, until eventually they undergo fate restriction and lose their potential to form 
other lineages. In vivo, cells of the naïve pre-implantation epiblast undergo polarization as the 
blastocyst implants into the host (Bedzhov and Zernicka-Goetz, 2014). At the same time, these cells 
undergo global chromatin remodelling switching to a much less permissive state (Auclair et al., 2014; 
Smith et al., 2012; Surani et al., 2007), with coincident transcriptional rewiring and exit from the naïve 
state (Boroviak et al., 2015, 2014). The cells of the post-implantation epiblast rely on different external 
signals and internal transcription factors and enhancer usage to promote survival and proliferation. 
As the surrounding extraembryonic tissues mature they polarize the epiblast, which begins to specify 
the fate of cells in a regional manner (Tam and Loebel, 2007). Subsequently, as gastrulation occurs and 
presumptive mesendoderm cells pass through the primitive streak, they differentiate into one of the 
three germ layers (Tam and Loebel, 2007). Within about one day of this, around the time of 
somitogenesis, all cells have lost their capacity for pluripotency (Damjanov et al., 1971; Osorno et al., 
2012). 
These events are recapitulated in vitro through the differentiation of ESCs, where they have been 
examined in molecular detail. ESCs maintained in 2iL culture conditions are equivalent to the E4.5 
naïve epiblast (Boroviak et al., 2015; Silva et al., 2008; Ying et al., 2008). As these cells are subjected to 
differentiation-inducing stimuli, they exit naïve pluripotency via downregulation of naïve-specific 
transcription factors and upregulation of markers of the post-implantation epiblast. Initially, cells 
appear to pass through a pass through a state more advanced than naïve pluripotency yet more 
permissive than primed, with competency for germ cell differentiation (Hayashi et al., 2011; Kalkan et 
al., 2017; Kalkan and Smith, 2014; Mulas et al., 2017). Subsequently, cells progress to the primed state 
of pluripotency (Brons et al., 2007; Buecker et al., 2014; Joo et al., 2014; Tesar et al., 2007; Yang et al., 
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2014), a heterogeneous state with fluctuating expression of lineage markers and similarities to the 
primitive streak in vivo (Kojima et al., 2014; C. Liu et al., 2018; Song et al., 2016; Tsakiridis et al., 2014). 
Further differentiation involves downregulation of general and primed pluripotency factors and 
upregulation of lineage marks as cells become committed (Semrau et al., 2017; Trott and Martinez 
Arias, 2013). 
Coincident with the collapse of the naïve network in Oct4-AID ESCs, expression of general 
pluripotency factors begins to drop. There is no upregulation of primed pluripotency genes in these 
cells, nor are lineage markers expressed. Instead, cells directly start to upregulate silenced 
extraembryonic genes (). However, this makes sense in the context of previous observations that Oct4 
plays an important role in exit from the naïve state (Karwacki-Neisius et al., 2013; Radzisheuskaya et 
al., 2013) and is recruited to different regulatory elements to drive differentiation (Yang et al., 2014). 
Notably, published microarray data from TetOFF Oct4 cells show downregulation of naïve 
pluripotency genes accompanied by extended expression of general pluripotency genes such as Sall4 
and Nanog and upregulation of some post-implantation genes like Otx2 and Sox4, but with a failure 
to upregulate others including Fgf5 and Lef1 (Hall et al., 2009). It is therefore striking that exit from 
pluripotency follows such a radically different trajectory following acute depletion of Oct4. 
4.3.5. Exploring the mechanistic properties of Oct4 
Together, this body of work demonstrates that there is an absolute requirement for a minimal level 
of Oct4 for expression of a subset of factors that help to maintain the naïve state (Figure 4.7). This is 
despite an increase in Nanog binding to the regulatory elements of many such genes (Figure 4.9-12). 
The fact that a threshold level of Oct4 is required for the expression of a set of core pluripotency 
genes, and the observation that binding of the strong pluripotency agonist Nanog to the genome is 
globally lower in cells expressing Oct4 than in cells depleted for Oct4 suggests a coherent mechanistic 
explanation for the various phenotypes associated with different levels of Oct4. In Oct4-low cells, 
Oct4 binds and activates transcription of pluripotency-associated genes, resulting in the 
establishment of a robust network that is relatively insensitive to differentiation cues. As levels of 
Oct4 increase, factors such as Nanog are excluded from the genome, resulting in weaker activation of 
core pluripotency genes, until at sufficiently high Oct4 levels pluripotency can no longer be 
maintained. Meanwhile, in the absence of Oct4 these genes cannot be activated and so the naïve state 
can neither be induced nor maintained (Figure 4.16).  
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Chapter 5: Exit from naïve 
pluripotency induces expression of 
Xist, which is misregulated in 
extraembryonic differentiation 
5.1. Introduction 
X-chromosome inactivation is a key developmentally-regulated process in mice. It is well established 
that female cells exiting naïve pluripotency inactivate one randomly-selected X-chromosome in order 
to balance X-linked gene expression between sexes. The long non-coding RNA Xist is transiently 
expressed from both X-chromosomes prior to being silenced and one chromosome and highly 
upregulated on the other. It coats the chromosome from which it is expressed in cis, recruiting factors 
which silence and inactivate this chromosome. It has previously been established that depletion of 
pluripotency factors induces expression of Xist (Navarro et al., 2008), demonstrating a role of for these 
components in the regulation of this key inactivation factor; however, ablation of the primary 
pluripotency-factor-bound Xist regulatory element does not interfere with either XCI or reactivation 
of the silenced X chromosome in the establishment of naïve pluripotency (Minkovsky et al., 2013). 
Under the conventional model of initiation of XCI, in early differentiation cells undergo a process of 
identifying their X chromosomes through “sensing”, counting their number relative to autosomes, 
then cells with multiple X chromosomes (i.e. females for euploid cells) choose which of these are to 
undergo inactivation, and initiate inactivation through upregulation of Xist which subsequently 
spreads along the X chromosome, coating it and inducing transcriptional silencing (Boumil and Lee, 
2001; Goto and Monk, 1998; Starmer and Magnuson, 2009) (Figure 5.1a). 
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5.1.1. A new model for XCI 
 
Data from our group have suggested that initially Xist expression is induced by the collapse of the 
naïve network, regardless of gender. In studying this effect, Elsa Sousa observed that the upregulation 
of Xist in male and female cells appears to occur after downregulation of pluripotency markers and 
prior to upregulation of differentiation genes, suggesting that a reduction in the level of naïve factors 
could be responsible for de-repression of Xist, leading to its initial upregulation; counting and choice 
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may be later events that lead to silencing of Xist on future active chromosomes rather than activation 
of Xist from presumptive inactive chromosome (Sousa et al., 2018) (Figure 5.1b). This is based on 
observations in vivo and in vitro that Xist is transiently upregulated on exit from pluripotency in males 
and is initially expressed biallelically in females, though it is unclear whether this occurs in all cells or 
a subpopulation. Expression in males initially matches that in females; however, it only reaches a small 
fraction of the level attained in females as they continue to accumulate Xist RNA, whereas 
transcription is rapidly shut down in males (Sousa et al., 2018). 
Notably, upon deletion of Nanog from male or female mouse ESCs, Sousa et al. observed upregulation 
of Xist over a time period in which several other pluripotency markers maintained their expression. 
This suggests a very direct role for some pluripotency factors in the repression of Xist in naïve cells. 
In order to expand our understanding of this phenomenon, I chose to examine the effect of loss of 
Oct4 on expression of Xist. 
5.2. Results 
In order to test whether repression of Xist is a general property of pluripotency factors, I decided to 
examine the response of Xist on loss of Oct4. Unfortunately, the presence of the antisense Tsix lncRNA 
prevents analysis of Xist expression from non-strand specific RNA-seq data; I therefore repeated the 
Oct4 deletion timecourse using a conventional Lox-Cre system and analysed Xist expression using 
RT-qPCR with a probe that spans the Xist exon 1-2 boundary to achieve specificity. This also had the 
advantage of allowing me to examine the response in both male and female cell lines derived from 
littermates; ESCs were previously derived from male and female Oct4F/- blastocysts that constitutively 
express CreER from a Rosa26 knock-in allele. Surprisingly, regardless of whether male or female ESCs 
were used, Xist was upregulated to levels seen in female somatic cells, rather than the limited level of 
upregulation observed in normal differentiating male ESCs or on loss of Nanog (Figure 5.2) (Sousa et 
al., 2018); in normal differentiation, expression of Xist is only transiently upregulated to very low 
levels in male cells (Sousa et al., 2018). Even more interestingly, expression of Xist was sustained for 
at least 7 days on removal of Oct4, whereas Xist is only expressed for ~24-48 hours on conventional 
differentiation of male ESCs. In male trophoblasts Xist is entirely silenced by imprints (Goto and 
Takagi, 2000; Latham, 1996; Lee, 2000), so it is somewhat surprising that it is so strongly upregulated 
on deletion of Oct4. Examination of two long non-coding RNA regulators of Xist, Tsx and Tsix, 
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showed that these were both rapidly downregulated on removal of Oct4 (Figure 5.2), unlike regular 
differentiation in which both of these factors are transiently upregulated (Sousa et al., 2018) 
 
Trophoblast stem cells (TSCs) can be maintained in vitro by plating trophectoderm tissue in chemically 
defined media. In order to test whether cells could self-renew with such high levels of Xist, I 
differentiated male Oct4F/- ESCs by transferring them to TSC maintenance conditions at the same 
time as inducing deletion of Oct4 with 4-OHT. I was able to generate a TSC line (Figure 5.3a); 
however, every passage was accompanied with extreme cell death, and cells had to be transferred into 
a fresh well without removing any material in order to maintain the line. These cells exhibit a TSC-
like morphology (Figure 5.3a) and express the marker Elf5, and to a lower level Cdx2 (Figure 5.3b). 
They have fully downregulated the ESC marker Rex1. However, they proliferated slowly, only 
requiring passaging every 8-9 days. Xist appears to have been strongly downregulated in these cells 
(Figure 5.3b), perhaps suggesting that cells that continued to express Xist were outcompeted or died. 
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
5.2.1. Generating cell lines to study XCI in extraembryonic differentiation from ESCs 
In order to test whether this observation that Xist is strongly upregulated in male cells on depletion of 
Oct4 is a result of this unconventional exit from the naïve state or a peculiarity of this non-
physiological disruption to the transcription factor network, it would be useful to examine the 
response of ESCs to alternative methods of induced extraembryonic differentiation. I therefore sought 
to establish systems to achieve extraembryonic differentiation in this manner, and examine the 
trajectory of differentiation and the impact that this has on the regulation of Xist. 
It has previously been demonstrated that overexpression of certain transcription factors is sufficient 
to cause differentiation of mouse ESCs to extraembryonic fates (Blij et al., 2015; Fujikura et al., 2002; 
Kinoshita et al., 2015; Niwa et al., 2005; Shimosato et al., 2007). I designed dox-responsive constructs 
for inducible expression of Cdx2 and Gata6 in order to promote differentiation towards 
trophectoderm and extraembryonic endoderm respectively (Fujikura et al., 2002; Niwa et al., 2005). I 
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generated Piggybac plasmids harbouring these constructs and randomly integrated either Cdx2 or 
Gata6, as well as constitutively expressed rtTA3, into male mouse ESCs carrying a GFP reporter at the 
Rex1 locus (Figure 5.4). I validated the gender of the cell lines by profiling expression of X- and Y-
linked gene expression; genes from both sex chromosomes where robustly expressed, demonstrating 
that the cells were indeed male (Figure 5.5a). 
 
After selection, once the constructs had stably integrated, I tested that the transgenes induced 
appropriately and the cells differentiated to their appropriate lineages as expected. Inducible Cdx2 cells 
downregulated the naïve gene Nanog and upregulated the trophoblast marker Elf5 (Figure 5.5b, left), 
and flattened on addition of dox. After four days in culture, trophoblast giant cells also began to appear 
(not shown). Inducible Gata6 cells immediately adopted a characteristic cobblestone morphology, 
which became more pronounced as induction continued (not shown). They also lost Nanog expression 
and expressed the extraembryonic gene Gata4 (Figure 5.5b, right). 
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5.2.2. Extraembryonic differentiation from male mouse ESCs results in Xist upregulation 
Once I had confirmed that the cell lines responded as anticipated to dox induction, i.e. they exited 
pluripotency and differentiated towards extraembryonic lineages, I performed a timecourse and sent 
samples for strand-specific high throughput RNA sequencing. Analysis of these data shows that exit 
from pluripotency differs across different routes to extraembryonic lineages. iCdx2 cells continue to 
express naïve-specific and general pluripotency genes longer than iGata6 (Figure 5.6a and Figure 5.7a), 
although they are strongly downregulated. Both iGata6 and iCdx2 lines still show little activation of 
markers of primed pluripotency, however. Instead they directly activate the appropriate 
extraembryonic gene network following downregulation of naïve factors (Figure 5.6a, Figure 5.7a), 
with iCdx2 cells upregulating TSC markers such as Hand1, Elf5 and Cdh3, and iGata6 cells expressing 
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high levels of Gata4, Sox7 and Foxa2. Interestingly, induction of either Cdx2 or Gata6 results in a rapid 
diversion from the path of normal embryonic differentiation (Figure 5.6b). 
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As with Oct4 knockout induced trophectoderm differentiation, overexpression of Cdx2 resulted in 
prolonged expression of Xist to a high level (Figure 5.6a, Figure 5.7a), validating this finding and 
demonstrating that it is not an artefact specifically caused by non-physiological Oct4 manipulation. 
Remarkably, Gata6-induced extraembryonic endoderm differentiation also caused significant 
transcription of Xist over the period of a week. This indicates that protracted Xist expression may be 
a general property of male cells differentiating to extraembryonic lineages. 
I validated the induction of Xist following extraembryonic differentiation by RT-qPCR, using female 
neural stem cells to gauge the level of expression (Figure 5.7b). In the case of Cdx2 induction, Xist 
RNA was detected at approximately the same level as female somatic cells, while overexpression of 
Gata6 induced Xist around one fifth of this; this level of Xist expression without manipulation of the 
X inactivation centre in male differentiation is only paralleled in my previous Oct4 deletion 
experiments to the best of my knowledge. 
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It is possible to probe expression across the XIC using strand-specific RNA-sequencing. Elsa Sousa 
performed a timecourse of embryoid body differentiation from male ESCs and generated strand-
specific RNA-seq data in order to demonstrate transient upregulation of Xist. In reviewing this data, 
we can see that embryoid body differentiation is associated with rapid upregulation of Tsix and Tsx, 
negative regulators of Xist (Figure 5.8). Interestingly, on induction of Gata6, Tsx and Tsix are only 
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gradually induced (Figure 5.8), which might restrain the upregulation of Xist without robustly 
extinguishing its expression as seen in embryoid differentiation. Meanwhile, neither Tsx nor Tsix are 
strongly upregulated on overexpression of Cdx2 (Figure 5.8). It appears that in the absence of sufficient 
induction of inhibitors, expression of Xist continues unimpeded. 
 
Oct4 binds in the region of Tsx and Tsix in ESCs, while other pluripotency factors such as Nanog only 
bind within intron 1 of Xist (Figure 5.9a). This is particularly relevant as Oct4 is far more rapidly 
downregulated following Cdx2 induction than following Gata6 induction or in normal embryonic 
differentiation (Figure 5.9b). It is plausible that the lack of Oct4 prevents induction of Tsx and Tsix, 
resulting in cells achieving high and sustained levels of Xist expression following Cdx2 overexpression 
or Oct4 depletion. Meanwhile, the sustained expression of Xist seen after Gata6 induction could relate 
to the absence of factors involved in the normal silencing of Xist in somatic differentiation, or changes 
in the Oct4 binding profile resulting in weaker induction of Tsx and Tsix. 
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5.2.3. Oct4 plays a direct role in repression of Xist 
It is notable that in all of the experiments so far I have demonstrated strong and persistent upregulation 
of Xist in exit from pluripotency. ESCs differentiate when subjected to increased Oct4 levels (Niwa et 
al., 2000), unlike some pluripotency factors such as Nanog or Esrrb, which strengthen the naïve state 
when overexpressed (Chambers et al., 2003; Festuccia et al., 2012). Initial reports suggested that 
overexpression of Oct4 in ESCs primarily induces mesendodermal differentiation (Niwa et al., 2000; 
Thomson et al., 2011). However, it appears that this is highly dependent on the culture environment, 
with Oct4 overexpression leading to efficient neurectodermal (Shimozaki et al., 2003) and cardiac 
differentiation (Zeineddine et al., 2006) in appropriate conditions, and markers from all three germ 
layers are upregulated following induction of Oct4 in permissive conditions (Radzisheuskaya et al., 
2013; Thorold W. Theunissen et al., 2011). 
Given that I have demonstrated such strong induction of Xist on loss of Oct4, it seems plausible that 
overexpression of Oct4 could have an antagonistic effect. Additionally, male ESCs display persistent 
expression of Xist, albeit at a very low level, in differentiation permissive SL conditions. Oct4 
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overexpression is therefore an ideal system to test both whether Xist upregulation is a common feature 
of differentiation induced by transcription factor overexpression, and more excitingly, whether Oct4 
is able to inhibit induction of Xist. 
With this in mind, I took advantage of a previously established clonal TetON Oct4 cell line (iOct4 
ESCs), generated by former colleague Aliaksandra Radzisheuskaya (Figure 5.10a). She transfected wild 
type male mouse ESCs in the same manner that I established iCdx2 and iGata6 lines, then picked a 
clonal line that strongly induces Oct4 on addition of dox. 
I set up parallel timecourses of induced and uninduced samples, transferring them to SL media with or 
without dox. Cells exposed to dox rapidly upregulated Oct4, while Oct4 levels remained consistent in 
the uninduced samples (Figure 5.10b).  Uninduced cells showed partial downregulation of Nanog, 
consistent with previously described heterogeneity and reduced expression of Nanog in SL conditions 
compared to 2iL (Chambers et al., 2007; Sousa et al., 2018; Ying et al., 2008). On the other hand, Oct4 
overexpressing cells showed more rapid and complete repression of Nanog (Figure 5.10b). 
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Uninduced cells transferred to these conditions showed a degree of differentiation, with upregulation 
of the lineage markers Pax6 (ectoderm) and Gata6 (mesoderm) (Figure 5.10b). Concurrently they 
showed mild upregulation of Xist; note that this also serves to demonstrate that while Xist is 
upregulated on transition of ESCs to SL, the scale is incomparable to that seen on overexpression of 
Cdx2 or Gata6 where levels are 100-500 fold greater. Overexpression of Oct4 resulted in faster 
induction of lineage markers. Despite this, and the far greater percentage of the cells undergoing 
differentiation, upregulation of Xist was greatly reduced in Oct4-overexpressing cells compared to 
uninduced cells simply transiting to SL. Not only does this demonstrate that Xist upregulation is not 
caused by our dox-inducible transgene expression system, it also indicates that Oct4 plays an active 
role in the repression of Xist even as the rest of the naïve transcription network collapses. 
5.3. Discussion 
Random X chromosome inactivation is a common mechanism by which eutherians achieve dosage 
compensation of X linked genes. Female cells of the preimplantation epiblast, and ESCs in vitro, have 
two active X chromosomes, and one of these undergoes inactivation at the onset of differentiation. 
Xist is a master regulator of this process, coating the prospective inactive X chromosome and 
recruiting chromatin modifiers to inhibit expression. Meanwhile, differentiating male cells show very 
transient Xist upregulation and rapidly reverse any associated gene inactivation that may occur. As 
described in the previous chapter, the long-standing model of XCI suggests that a process of counting 
X chromosomes and choice of the presumptive inactive X follows the decision to initiate 
differentiation, followed by upregulation of Xist on the chosen chromosome. Work in our group 
suggests that events unfold differently, with Xist upregulated as a direct consequence of the collapse 
of the naïve network. Under this new model, counting and choice occur subsequently and result in 
downregulation of Xist on chromosomes that will not be inactivated. 
5.3.1. Xist is misregulated in male cells following depletion of Oct4 
The observation that male cells upregulate Xist, the principal factor in the control of X chromosome 
inactivation (XCI), following depletion of Oct4 is somewhat unexpected. Literature suggests that 
during differentiation female cells specifically upregulate Xist from the prospective inactive X 
chromosome (Panning et al., 1997; Sheardown et al., 1997), while male cells entirely silence Xist from 
the low levels observed in ESCs maintained in SL (Panning et al., 1997; Sheardown et al., 1997). Since 
male cells have a single X chromosome, it is expected that they should not upregulate Xist as counting 
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precedes the onset of inactivation. However, recent data suggest that upregulation of Xist is connected 
to the dissolution of the naïve pluripotency network (Sousa et al., 2018). Since this happens rapidly on 
removal of Oct4, it is not entirely surprising that Xist is upregulated. 
However, following genetic ablation of Oct4 I observe a far greater expression of Xist in male cells 
than is observed in normal differentiation of male ESCs or on loss of Nanog (Sousa et al., 2018), with 
Xist levels continuing to rise almost in line with female cells (Figure 5.2b). Initially, it is somewhat 
surprising that Xist is upregulated so highly and persistently in male ESCs on loss of Oct4, since Xist 
is not expressed at all in male trophoblast cells. However, it is important to note that during 
development in vivo, Xist expression in the extraembryonic lineages is regulated in a different manner 
than later in embryonic lineages. The maternal Xist allele is silenced through epigenetic imprinting 
during oogenesis (Fukuda et al., 2014; Inoue et al., 2017). It is reactivated only in the naïve epiblast 
(Silva et al., 2009), and therefore remains inactive in extraembryonic tissues in males, while paternal 
Xist expression maintains silencing of the paternal X chromosome in the extraembryonic 
compartment in females. It has been shown that removal of these imprints in early embryogenesis 
results in Xist expression from both X chromosomes in female trophectoderm, leading to initiation of 
XCI on both chromosomes (Inoue et al., 2017). Furthermore, it has been suggested that inheritance of 
two maternal X chromosomes in parthenogenotes, which results in failure to inactivate either 
chromosome due to the lack of Xist expression, may be responsible for the very low survival rate 
shortly after implantation (~25% survive to E9.5) (Tada and Takagi, 1992). While reports vary 
(Kaufman et al., 1978; Rastan et al., 1980), it appears this could particularly affect extraembryonic 
tissues, with many implanted parthenogenotes lacking a discernible ectoplacental cone or 
extraembryonic endoderm (Tada and Takagi, 1992). However, a proportion of cells eventually escape 
the imprinted inactivation of Xist and successfully inactivate a single X chromosome (Nesterova et al., 
2001). It seems plausible that the machinery for counting and inactivating Xist may be absent in less 
potent cells undergoing transdifferentiation to a trophectoderm-like fate since this differentiation 
normally occurs within the very early embryo. It may be that following induction of Xist on exit from 
pluripotency, silencing of the lncRNA cannot occur unless cells are progressing normally towards an 
epiblast-like identity. 
This would explain the continued accumulation of Xist RNA in male cells following depletion of Oct4; 
since Xist is not imprinted in ESCs, the induced trophoblast-like cells would naturally express all Xist 
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alleles. It would also predict that the trophoblast-like cells generated by removing Oct4 should be 
defective in proliferation and survival. I attempted to generate a trophoblast stem cell line following 
Oct4 depletion in male ESCs; while I was able to serially passage a line that expressed trophectoderm 
markers Elf5 and Cdx2 (Figure 5.3a and b), cells were very slow growing and a large percentage of the 
population was lost every passage. After three passages Xist was not detectable (Figure 5.3b), perhaps 
suggesting that a small percentage of cells are able to recover their normal X status as in 
parthenogenotes, and these may have a selective advantage. 
5.3.2. Xist expression is a common feature of extraembryonic differentiation from ESCs 
Depletion of Oct4 results in trophoblast-like differentiation. As described above, this results in strong 
and persistent Xist upregulation in male cells. I considered this to be evidence that collapse of the 
pluripotency network was the proximal cause of Xist induction and hypothesized that extraembryonic 
cells lack the machinery for either counting, choice or Xist repression. 
I therefore sought to confirm that alternative methods of inducing extraembryonic differentiation of 
male ESCs would result in stable upregulation of Xist. To do so, I established cells lines for inducible 
expression of Cdx2 or Gata6, which have previously been demonstrated to stimulate trophoblast and 
extraembryonic endoderm differentiation of ESCs respectively. After demonstrating appropriate 
transgene induction and subsequent expression of relevant extraembryonic markers, I proceeded to 
analyse Xist expression. 
I have found that male cells exiting pluripotency and differentiating towards trophectoderm show 
persistent upregulation of Xist to comparable levels to female somatic cells. This is the case whether 
Oct4 depletion or Cdx2 induction are used to drive the change in cell identity (Figure 5.7b and Figure 
5.8). Notably, I did observe rapid downregulation of Oct4 following overexpression of Cdx2, 
suggesting that the upregulation of Xist in these two systems could occur via a common mechanism. 
However, it is also possible that Cdx2 causes Xist to be expressed independent of Oct4 levels. Ongoing 
work to test this will utilize a fixed-Oct4 ESC background in which Oct4 expression is constitutively 
maintained. Therefore, if upregulation of Xist is blocked on overexpression of Cdx2, this will strongly 
suggest that the downregulation of Oct4 in normal cells is vital for this phenomenon to occur, 
demonstrating that Oct4 is a key negative regulator of Xist. 
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Furthermore, the transition of ESCs to an alternative extraembryonic identity, induction of Gata6 
leading to extraembryonic endoderm differentiation, was also marked by significant upregulation of 
Xist (Figure 5.7b and Figure 5.8). Together with published observations that reduced Nanog 
expression correlates with enhanced Xist expression in naïve ESCs, and that Xist is rapidly upregulated 
in male cells following downregulation of the naïve transcriptional network (Sousa et al., 2018), this 
provides strong evidence that pluripotency-associated factors play a major role in the repression of 
Xist. 
Extraembryonic tissues regulate dosage compensation through the imprinted inactivation of Xist on 
the maternal X chromosome. They are expected to express Xist from any non-imprinted X 
inactivation centre, a hypothesis that is confirmed by experiments studying parthenogenetic embryos. 
Together, these factors explain why Xist upregulation is so dramatic and protracted in my experiments 
inducing extraembryonic differentiation from ESCs. 
What remains unclear, however, is whether these cells continue to express the machinery to enact 
XCI and what the outcome of this would be. This system could be useful for further studies into the 
mechanism of X chromosome counting, choice and Xist inactivation, as they appear to be defective in 
at least one of these stages as these male cells fail to downregulate Xist as in somatic differentiation, 
instead maintaining a high level of expression over at least several days. 
5.3.3. Oct4 overexpression prevents Xist upregulation 
Remarkably, it appears that increased Oct4 expression is sufficient to prevent upregulation of Xist 
during somatic differentiation from male ESCs (Figure 5.10c). It should be noted that the level of Xist 
upregulation in this system in the absence of Oct4 is comparable to very early female differentiation, 
after which female cells rapidly induce Xist to far greater levels whereas Xist subsequently becomes 
silenced in male cells. It would therefore be interesting to repeat the Oct4 overexpression induced 
differentiation experiments in female cells to determine whether Oct4 is capable of repressing Xist 
from far stronger inductive influences. It is also important to keep in mind that Oct4 levels remain 
relatively consistent for some time in normal differentiation; wild-type levels of Oct4 are clearly not 
sufficient to prevent Xist induction. However, it has previously been shown that Oct4 binds to 
regulatory elements of Tsix and Tsx, inhibitors of Xist, and promotes their expression (Donohoe et 
al., 2009). 
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It therefore appears that Xist is upregulated at the onset of both somatic and extraembryonic lineages 
from male ESCs. This appears to be caused by the general dismantling of the naïve transcription factor 
network, but can be prevented through overexpression of Oct4. In somatic differentiation, counting 
and choice result in the silencing of Xist from X chromosomes that are not destined to undergo XCI. 
Meanwhile, during extraembryonic differentiation the process of counting, choice, or Xist silencing 
fails, and Xist continues to be expressed to high levels even in male cells. Together this demonstrates 
novel differences in the machinery associated with XCI between somatic and extraembryonic 
differentiation; this could provide a platform for future work to establish the exact factors and 
mechanisms involved in this process. Additionally, it demonstrates a role for Oct4 in preventing Xist 
induction. Speculatively, this could be related to the mechanism by which Xist expression is silenced 
following counting and choice, and I hope that future work will elucidate whether this is the case.  
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Chapter 6: General Discussion 
6.1.1. Transcriptional regulation by Oct4 
Typically Oct4 is viewed as a core pluripotency factor, and a master regulator of the naïve state. It is 
placed as one of a trifecta of key factors, together with Sox2 and Nanog, which together stabilize naïve 
pluripotency. The three factors were identified as essential for the maintenance of pluripotency, while 
other factors were found to be redundant in their activity. However, over time it has become 
increasingly clear that this is not the case. In the absence of external differentiation stimuli, Nanog is 
not essential for the maintenance of pluripotency in mouse ESCs. Meanwhile, overexpression of Oct4 
is sufficient to render Sox2 dispensable for their self-renewal and differentiation. It appears that this 
leaves Oct4 at the pinnacle of a hierarchy of pluripotency factors. 
In a sense, this may be true; from the work presented here, it appears that the binding of Oct4 may be 
essential for the expression of important pluripotency genes (Figure 4.7). This requirement for Oct4 
likely underscores the importance of this factor in reprogramming, where activation of endogenous 
pluripotency loci is a key step. The rapid reduction in enhancer RNA expression (Figure 4.15) and 
histone modifications associated with active enhancers (Figure 4.14) suggests that Oct4 is required for 
the licensing of these elements. It has also been shown that the presence of a promotor is required for 
expression of enhancer RNAs (Kim et al., 2010); this suggests that a possible essential activity of Oct4 
is to induce enhancer-promoter interactions (Figure 6.1), and that this DNA looping could be lost in 
the absence of Oct4. 
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It is interesting to note that binding of CTCF and the Mediator complex, both of which support long-
range enhancer-promoter interactions (Donohoe et al., 2009; Kagey et al., 2010), is overrepresented 
at Oct4 binding sites (Göke et al., 2011), and Mediator strongly co-localizes with Oct4-Nanog-Sox2 
triple bound loci (Göke et al., 2011). Furthermore, it has been demonstrated that Oct4 physically 
interacts with CTCF (Donohoe et al., 2009). Moving forward, it would be interesting to examine how 
chromatin architecture is modified upon loss of Oct4 through chromatin conformation capture 
studies, in order to identify whether promotion of enhancer looping is a key property of Oct4 in 
maintaining expression of key pluripotency factors. 
However, the role of Oct4 is complex, and does not simply involve activation of pluripotency-
associated genes. It has previously been shown that a constitutive trans-activating Oct4 fusion protein 
can maintain ESC self-renewal; however, these cells are defective in differentiation, demonstrating 
that a repressive role of Oct4 is essential for its normal function in ESCs (Hammachi et al., 2012). This 
is in keeping with the fact that overexpression of wild-type Oct4 induces differentiation of ESCs, while 
a reduced level of Oct4 enhances self-renewal while blocking differentiation. Mechanistically, this may 
be linked to the enhanced binding of Nanog to the genome following reduction of Oct4 levels that I 
have observed (Figure 4.9c, Figure 4.10b, Figure 4.11, Figure 4.12). It may be that overexpression of 
Oct4 leads to sequestration of pluripotency factors at non-essential enhancer elements, depleting them 
from key loci, or even the formation of complexes in the nucleoplasm without binding to chromatin 
at all (Figure 6.2). Alternatively, it may be that at higher concentrations enhancer elements spend a 
greater proportion of time with Oct4 bound, resulting in physical occlusion of binding sites for other 
factors or allowing sufficient time for the many inhibitory chromatin modifiers that interact with Oct4 
to decommission active enhancers (Figure 6.2). 
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In order to investigate the mechanism by which overexpression of Oct4 leads to collapse of the naïve 
network in more detail, there are several routes that could be pursued. Exploring the genome-wide 
binding of various transcription factors in wild-type and Oct4-overexpressing ESCs would give an 
indication of whether Oct4 is recruiting pluripotency factors away from key loci and spreading them 
across the genome, while quantitative mass spectrometry of non-chromatin-bound Oct4 binding 
partners would indicate whether Oct4 is sequestering proteins within the nucleoplasm. 
It would also be interesting to investigate the recruitment of chromatin modifying complexes by Oct4. 
While protein interactions have been routinely observed between Oct4 and members of various 
repressive complexes, it is unclear how positive regulators are recruited to some enhancer elements 
and negative regulators to others. It is unknown whether Oct4 residence time has a role in this 
decision; this could be examined through single-molecule tracking of Oct4 combined with labelling of 
activatory loci such as the FGF4 enhancer and repressive loci such as Cdx2. If there appears to be a 
significant difference between such loci, this could be further tested by introducing point mutations to 
create stronger or weaker Oct4 binding sites, and therefore alter the residence time of Oct4. 
However, it may be that the chromatin context of the locus or co-occupancy by other transcription 
factors that effects this difference in function. This is harder to test since, by their nature, repressive 
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loci will be bound by repressive factors and positive regulatory elements will be bound by trans-
activating factors. It is possible to test whether transiently altering the chromatin environment at 
repressed loci, through recruitment of P300 by a dCas9 (catalytically inactive Cas9, an RNA-mediated 
DNA binding protein) fusion protein for instance, alters the composition of bound factors, and 
whether a repressive chromatin environment is reinstated or if this permanently alters the function of 
the regulatory element. More thorough profiling of the factors bound at positive and negative 
regulatory elements could also be informative. This could be examined through enChIP (engineered 
DNA-binding-molecule-mediated ChIP), which utilizes custom DNA-binding factors such as dCas9 
to precipitate specific loci of interest, after which the bound proteins can be identified though sensitive 
mass spectrometry. However, this technique is still being developed and therefore costly and 
inefficient, and it is unclear whether it provides sufficient sensitivity for identifying novel factors 
bound at complex regulatory elements, particularly in a repressive chromatin context. 
6.1.2. Oct4 as a reprogramming factor 
Oct4 is known to be an important factor in the process of somatic cell reprogramming, as well as in 
transdifferentiation. However, it is common for Oct4 to be used at levels never normally seen in a 
biological context. This leads to questions as to whether the expression of Oct4 seen in the early 
embryo is sufficient to induce cell fate transitions or if this is a neomorphic effect of extreme 
overexpression of Oct4. It is well known that the precise level of Oct4 has a profound impact on its 
ability to influence cell fate decisions. Previous work has indicated that low levels of Oct4 restrict the 
ability of naïve cells to exit pluripotency (Karwacki-Neisius et al., 2013; Radzisheuskaya et al., 2013). 
Here we observe that an ESC level of Oct4 is permissive for the fate transition from somatic cells back 
to the naïve state (Figure 3.4, Figure 3.5, Figure 3.6). This is supported by the recent finding that 
activation of the endogenous Oct4 locus using an artificial transcription factor is sufficient to induce 
somatic cell reprogramming (P. Liu et al., 2018); however, in that work the level of Oct4 expressed 
during reprogramming in single cells that successfully generate iPSCs remains unclear. Additionally, 
preliminary work being performed in our group suggest that this level of Oct4 may facilitate the 
transdifferentiation of somatic cells, as well as reprogramming of E12.5-derived MEFs to pluripotency. 
Looking to the future, it would be interesting to explore whether different levels of Oct4 facilitate 
different stages of the reprogramming process. It is interesting that in the course of reprogramming 
Oct4-/- cells with transgenic Oct4 there is some form of restriction such that all successful 
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reprogramming events occur in cells with an ESC level of Oct4 (Radzisheuskaya et al., 2013). It may 
be that higher levels are deleterious to the expression of pluripotency factors as seen in stable naïve 
cells. With this in mind, it would be informative to examine the reprogramming efficiency of somatic 
cells with different defined levels of Oct4. This could perhaps be achieved by targeted knock-in of Oct4 
with enhancer elements of differing strengths to the Rosa26 locus in an Oct4-/- background. 
Alternatively, the kinetics of Oct4 expression over the course of reprogramming could be tracked in 
single cells alongside a series of markers indicative of a productive reprogramming trajectory (Schwarz 
et al., 2018; Zunder et al., 2015). Tagging Oct4 with the short fragment of a split fluorescent protein 
(Cabantous et al., 2005; Feng et al., 2017) could permit accurate tracking of Oct4 levels in real time in 
live cells. In this system, a large fragment of GFP that is not significantly fluorescent is expressed 
constitutively, while a short, complementary fragment is tagged to the protein of interest. This tag can 
be as short as 17 amino acids. When co-expressed, the fragments self-associate and form a functional 
fluorophore, without requiring lengthy fluorophore folding times or causing significant disruption to 
the activity of the tagged protein. This would make it possible to track the level of Oct4 expressed over 
time within cells, and retrospectively identify those that successfully reprogram, in order to find out 
the level of Oct4 that is most beneficial at different stages in the reprogramming context. 
6.1.3. Oct4 in pluripotency and differentiation 
Nevertheless, the fact that a wild-type level of Oct4 is permissive both for differentiation and 
reprogramming implies that rather than being a specifier of the naïve state, Oct4 may act primarily as 
an architect of pluripotency in a broader sense, holding the key to cell fate transitions when present in 
an appropriate quantity. It may be that the secret to maintaining the naïve state lies less in the specifics 
of the transcription factor network and more in the signalling conditions of the preimplantation 
epiblast, with Oct4 allowing cells to progress forward as soon as the embryo implants and the 
environment shifts. It remains unclear what signals within the embryo maintain and dissolve the naïve 
state. In vitro, autocrine FGF4 signalling is a major driver of differentiation; cells of the naïve epiblast 
robustly express FGFR1 and secrete FGF4, so it is unclear how they retain their pluripotent identity 
(Kang et al., 2017; Molotkov et al., 2017). Additionally, LIF signalling is not required to sustain the 
naïve epiblast (Stewart et al., 1992; Ware et al., 1995; Yoshida et al., 1996) unless embryos enter into 
diapause (Nichols et al., 2001). It seems likely then that BMP, WNT and Activin/Nodal signalling may 
play a more important role in the maintenance of naïve pluripotency in vivo, but the precise 
 General Discussion 113 
requirement of each of these remains unclear (Menchero et al., 2017). The shift in identity from naïve 
to primed, and the concurrent changes in morphology and cell-cell interactions, are presumably driven 
by signals from the trophectoderm, but this too is poorly understood. It is interesting to note that Oct4 
continues to be expressed in PGCs, and could therefore play a key role in their capacity to convert to 
EGCs in appropriate conditions. The role of Oct4 in these other contexts is poorly understood, and 
future work in new systems for studying early embryonic differentiation in vitro, such as gastruloids 
(van den Brink et al., 2014) and ETX embryo structures (Sozen et al., 2018), may play a key role in 
uncovering the function of Oct4 as cells continue forwards in development. 
Recent work has uncovered conditions for maintaining human pluripotent cells in a naïve-like state 
(Takashima et al., 2014; Theunissen et al., 2014). While it remains unclear precisely how these relate 
to the naïve epiblast of human embryos (Bates and Silva, 2017), they provide the best model system to 
date for studying the earliest fate transitions following epiblast specification in humans. 
Interestingly, differentiation of these cells is a slow and drawn-out process, requiring a stage of priming 
prior to efficient exit from pluripotency (Guo et al., 2016; Takashima et al., 2014), mirroring the far 
longer process of implantation, polarization and priming observed in non-human primate embryos in 
vivo (Nakamura et al., 2016). This work has led to the suggestion that cells may pass through a separate 
identity, perhaps equivalent to mouse EpiLCs, during their transition to the primed state (Smith, 
2017). Using this knowledge, work is ongoing to establish conditions to maintain this state in vitro 
(Kinoshita and Smith, 2018; Mulas et al., 2017), particularly using mouse cells. This has been labelled 
the formative state, as it has been suggested that it is during this transient phase that cells acquire the 
capacity for somatic differentiation (Smith, 2017). This is based on the observations that immediately 
following exit from naïve-specific growth conditions cells are unresponsive to differentiation stimuli 
(Mulas et al., 2017) and that the dissolution of the naïve transcription network precedes induction of 
lineage markers (Kalkan et al., 2017; Kalkan and Smith, 2014). 
It is particularly interesting to consider the phenotype of Oct4 knockout in naïve ESCs in this context. 
We have seen that depletion of Oct4 results in the dismantling of the naïve transcriptional network 
in the absence of forward differentiation (Figure 4.8). This is eventually followed by upregulation of 
trophectoderm-associated gene expression, as readily observed following rapid ablation of Oct4 at the 
protein level. It is therefore tempting to speculate that Oct4 may be required for entry to the formative 
state or for gaining the capacity to undergo somatic differentiation and that consequently Oct4-null 
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cells must pass to an identity that does not require transit through the formative state. Research into 
the role of Oct4 in the formative state may well bring rapid advances to our understanding of how 
pluripotent cells gain the capability to undergo multi-lineage differentiation and form all the cell types 
of the embryo proper. Evidently this fits well with the role of Oct4 established throughout this body 
of work as primarily a facilitator of cell fate transitions and identity changes rather than specifically 
acting to maintain pluripotency as previously assumed. 
6.1.4. Control of Xist repression by Oct4 and in extraembryonic differentiation 
Recent work from our group has suggested that Xist is not expressed in ground state naïve cells 
maintained in 2iL conditions, but it upregulated from all alleles as cells exit pluripotency (Sousa et al., 
2018). Following counting and choice, Xist expression is subsequently restricted to the chromosomes 
that will undergo complete XCI. Data presented in this work supports this hypothesis; the fact that 
Xist upregulation is observed on depletion of Oct4 (Figure 5.2), despite the fact that these cells do not 
upregulate markers of primed pluripotency (Figure 4.8), suggests that it is loss of naïve-specific factors 
that triggers this event rather than progression to a more advanced stage of pluripotency. However, 
this leads to the question of what causes the subsequent downregulation of Xist on chromosomes that 
are not destined to undergo XCI. 
Mutation of Tsix in males results in initiation of XCI in a small proportion of cells (Luikenhuis et al., 
2001; Sado et al., 2002; Vigneau et al., 2006), while females always choose to silence the mutant 
chromosome (Lee and Lu, 1999; Luikenhuis et al., 2001). Recent work suggests that a small proportion 
of female Tsix mutants actually undergo XCI from either the mutant allele or both alleles and the 
apparent non-random inactivation is due to the senescence and death of cells that inactivate both 
chromosomes (Gayen et al., 2015). Additionally, following introduction of a constitutively active 
promoter to one Tsix allele in females, either the wild-type chromosome is selected and undergoes 
normal XCI or else both Xist alleles become silenced and XCI does not occur (Stavropoulos et al., 
2001). Altogether, this suggests that Tsix plays a role in the silencing of Xist following its initial 
upregulation at the onset of differentiation. 
I propose that Oct4 promotes expression of Tsx; Tsx and Oct4 bound to Xite both co-activate Tsix 
transcription (Figure 6.3). In the naïve state, binding of Oct4 and other pluripotency factors to intron 
1 of Xist, together with this Tsix transcription act to silence Xist. On differentiation, pluripotency 
factors, perhaps including Oct4, are removed from Xist intron 1 leading to depression and initial 
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upregulation of Xist. However, Oct4 remains bound at the Tsix and Tsx regulatory elements and their 
expression increases, leading to silencing of Xist (Figure 6.3). Thus, male cells initially upregulate Xist, 
but subsequently repress it and do not complete XCI. 
 
In the case of Oct4 deletion, expression of Tsx and Tsix would drop, while collapse of the naïve 
network would initiate upregulation of Xist. In the absence of negative regulators, Xist expression 
would continue to rise to somatic levels. Rapid repression of Oct4 may be the primary factor that 
induces prolonged Xist expression in Cdx2- and Gata6-induced extraembryonic differentiation. 
Alternatively, it could be that other components that promote the silencing of Xist are not present due 
to the unconventional trajectory of differentiation in these cells. 
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Regulation in female cells is more complicated, as one chromosome needs to be selected for continued 
expression of Xist while the other allele is silenced; as this work focused mainly in male cells, more 
speculation is required to consider how Oct4 may fit in to this process. Introduction of multiple copies 
of small transgenes containing Xist is required to induce XCI in males, while single copies fail to do so 
(Herzing et al., 1997). However, heterozygous disruption of Xist in females does not prevent XCI, 
which still occurs on the chromosome carrying a wild type Xist allele (Marahrens et al., 1998; Penny 
et al., 1996). This implies that Xist is weakly able to induce counting once it is upregulated, but is not 
necessary for the process. Other factors must permit the continued expression of Xist in heterozygous 
females. A recent theory on the mechanism of counting relies on the observation that the both X 
chromosomes physically pair around the region of the XIC prior to XCI (Augui et al., 2007; Bacher et 
al., 2006; Xu et al., 2006). The region around the Tsix transcriptional start site and the Xite region 
(Bacher et al., 2006; Xu et al., 2006), and a region containing the Slc16a2 gene (Augui et al., 2007) all 
appear to play key roles in this pairing process. It has also been suggested that the reason why multi-
copy XIC transgenes can induce XCI in males but single-copy insertions do not relates to the fact that 
they lack the Slc16a2 locus and therefore display weaker pairing, requiring multiple Tsix/Xite regions 
to efficiently bring the two chromosomes together (Augui et al., 2007; Xu et al., 2006). Oct4 plays a 
key role in this process; it has been observed that X-chromosome pairing does not occur following 
knockdown of Oct4 in female cells (Donohoe et al., 2009). I hypothesize that in the absence of pairing 
between two functional XIC regions Xist is silenced in cis by Tsix, the expression of which is dependent 
on Oct4. If pairing does occur, one Xist allele is protected from inactivation. This could be through 
the establishment of an unknown protective mark that prevents silencing of Xist on that chromosome, 
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or it could simply be through inactivation of Tsix on one chromosome. Once this is established the 
chromosomes can separate. The unmarked chromosome can undergo silencing as occurs in the 
absence of pairing. Meanwhile the prospective inactive X upregulates Xist, which coats the 
chromosome in cis and leads to widespread silencing. 
 
Several factors fall in favour of this hypothesis. Introduction of transgenic pairing regions into 
autosomes in females reduces the rate of pairing between X chromosomes, and this is associated with 
failure to induce XCI (Augui et al., 2007; Lee, 2005). In this case, since neither X chromosome is paired 
to a functional XIC, they would each undergo the Oct4/Tsix-induced Xist silencing as seen in wild-
type male cells. Heterozygous deletion of the Tsix start site leads to non-random XCI in the majority 
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of cells; this would be a combined effect of poor chromosome pairing leading to silencing of Xist on 
the wild-type allele, and unrestricted Xist upregulation of the mutant allele. Interestingly, homozygous 
Tsix mutants do undergo random XCI at a greatly reduced efficiency (Lee, 2002); the large proportion 
of cells display two Xist clouds, but many cells only have one (Lee, 2005). This implies that weaker 
pairing may still occur and additional elements may contribute to a lesser effect to the silencing of Xist. 
This could also contribute to the variable penetrance of XCI induction in male cells carrying Tsix 
mutations.  
More work will be required in order to test some of these models. In the simpler case of male 
differentiation and repression of Xist, it will be important to confirm that Xist upregulation is a 
prevalent event. This model suggests that removing the Xist intron 1 pluripotency factor binding site 
and the Tsx/Tsix Oct4 binding sites together should lead to Xist upregulation even within naïve 
conditions, and should cause unrestricted Xist expression on differentiation in male cells. It may be 
technically difficult to test this without disrupting the locus, however, though. Another prediction is 
that restoring Oct4 to Oct4-depleted cells prior to the later stages of XCI might be sufficient to restore 
Tsx/Tsix expression and silence Xist. 
If downregulation of Oct4 is the primary factor causing protracted Xist expression on extraembryonic 
differentiation, then one would predict that overexpression of Cdx2 in a constitutive Oct4 expression 
cell line, such as fixed-Oct4 iPSCs, would downregulate Xist as in male somatic differentiation. If this 
is not the case, then this would be a good model system for investigating other key repressors of Xist. 
A hypothesis that might be easier to test is that insertion of a constitutive promoter driving Tsix 
expression could be sufficient to prevent Xist accumulation in male cells on knockout of Oct4 or 
overexpression of Cdx2. 
Testing the model of female XCI remains very difficult. One would expect that homozygous knockout 
of Tsix would induce sustained Xist expression from both chromosomes, but instead expression 
appears to be chaotic (Lee, 2002). However, it is unclear whether chromosome pairing is interrupted 
in this system. It is possible to inhibit transcription with dCas9 which binds to the DNA and blocks 
the passage of RNA polymerase. This should act without affecting pairing, and could provide a 
different result, leading to a more complete picture of the role of Tsix in Xist silencing. If an activatory 
mark is deposited during X chromosome pairing, it is possible that Xist might not be competent to 
coat the chromosome and induce silencing if chromosome pairing fails to occur; this would result in 
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continued X-linked expression in male cells expressing Xist. Interestingly, this is what we observe 
following overexpression of Cdx2 or Gata6. 
6.1.5. In summary 
Altogether, this work demonstrates that Oct4 is a very important and perhaps unique transcription 
factor. It appears that Oct4 is essential for the expression of several key pluripotency factors in naïve 
cells, and helps to maintain active epigenetic marks to facilitate this. Despite this, even at physiological 
levels Oct4 impedes the binding of the pluripotency factor Nanog, a negative impact on the otherwise 
highly self-sustaining naïve network. This may be a key activity to maintain the vitally important 
capacity for differentiation in these cells. Interestingly, ablation of Oct4 from these cells seems to 
entirely prevent forward differentiation, with cells exiting pluripotency entirely and then upregulating 
extraembryonic genes. 
Oct4 also facilitates fate transitions in the opposite direction, from somatic cells back to a naïve 
identity. It is capable of achieving this at an ESC level, and does not require overexpression to induce 
reprogramming of in vivo differentiated cells.  
This work also provides more evidence that differentiation is accompanied by upregulation of Xist 
from all X chromosomes, and that key steps in the regulation of XCI actually relate to the silencing of 
Xist from chromosomes that do not require inactivation. Oct4 appears to have a key function in this 
process as well, contributing to the expression of key regulators that silence Xist when required, and 
also in establishing inter-chromosomal interactions that lead to the demarcation of one chromosome 
to be silenced. 
6.1.6. On the role of Oct4 
A great deal of emphasis has been placed on identifying the essential role of Oct4 in the context of 
naïve pluripotency. From the body of work presented, I hope it is clear that this question is overly 
simplistic. Oct4 does not play one role, and thus cannot be simply substituted with another gene as is 
the case for so many naïve factors. Oct4 lies at the heart of many crucial events, including the 
establishment of the naïve state, maintenance of pluripotency gene expression and competency for 
differentiation, and control of X chromosome inactivation. In each of these, Oct4 likely acts through 
many key targets simultaneously, making attempts to rescue knockouts futile. Furthermore, rather 
than behaving like many other factors and actively enforcing the maintenance of self-renewal and the 
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naïve identity, Oct4 acts as an arbiter, required for pluripotency while preserving the capacity for 
differentiation. Rather than a naïve pluripotency factor, I see Oct4 more as a fate transition factor 
which plays a wider role in development and differentiation in vivo, as well as in reprogramming to 
pluripotency and transdifferentiation in vitro. Returning to the metaphor of Waddington’s landscape, 
rather than having a preformed hill, with predefined hills and furrows, it is better to imagine a 
constantly evolving scene. Stable states are represented by depressions in a plane. Oct4 helps to carve 
out the indentation representing naïve pluripotency. However, as Oct4 levels increase it reduces the 
barriers to nearby states and thus encourages identity changes. Other factors such as Nanog or Esrrb 
simply deepen the recess in which ESCs sit, an effect which is lessened when increasing amounts of 
Oct4 displace them. While some of the precise mechanistic details of the activity of Oct4 remain to be 
uncovered, I hope this work ties together many disparate threads of work of many years to form a 
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Unbiased list of expression changes in iCdx2 ESCs from Day 0 to Day 4 of induction. Genes with an 





from D0 to D4) 
Adjusted 
P-value 
Iigp1 86.62 10.49 2.62E-17 
Vtcn1 111.64 10.07 2.55E-16 
Serpinb9g 122.46 9.90 7.62E-15 
Oasl2 68.67 9.75 6.94E-15 
1810065E05Rik 39.41 9.58 9.94E-14 
Olr1 343.67 9.57 1.07E-18 
C1ql2 60.21 9.36 3.84E-11 
Dppa1 739.76 9.24 1.67E-68 
1700071M16Rik 31.70 9.24 1.67E-11 
Timd2 149.02 9.22 8.70E-14 
Serpinb9c 100.65 9.05 5.89E-13 
Sqor 57.06 9.05 8.00E-11 
Reg3b 51.58 9.02 9.52E-13 
Pparg 337.77 9.01 2.21E-38 
Wfdc17 17.09 8.99 1.24E-10 
Acta2 152.19 8.94 2.68128E-22 
1600025M17Rik 59.62 8.90 8.37E-11 
BC051665 1518.17 8.86 2.49E-88 
Postn 44.45 8.82 8.63173E-12 
Tmprss4 29.60 8.81 8.42E-12 
Slc16a2 75.04 8.81 2.75E-12 
Pla2g7 1376.90 8.80 9.31E-126 
Fthl17a 137.97 8.75 3.66E-16 
Gucy2c 77.86 8.75 8.93E-16 
H19 47988.60 8.70 3.99E-63 
Tmem54 60.96 8.65 1.13E-11 
Gm4926 269.91 8.59 4.33E-29 
1700086L19Rik 25.33 8.57 9.94E-11 
Gata3 352.57 8.56 9.74E-51 
Tlx2 246.65 -8.54 2.23E-13 
Myo7b 159.37 8.53 1.06E-28 
Cartpt 18.24 8.50 1.57E-08 
Noxa1 17.80 8.48 1.29E-10 
Sod3 17.03 8.47 5.88E-10 
Ctsll3 128.51 8.46 9.25E-11 
Scnn1g 34.67 8.45 2.34E-09 
Igf2 6683.27 8.43 1.86E-41 
Add2 412.09 8.41 5.62553E-56 
Fnd3c2 92.94 8.40 2.90E-10 
Mid2 83.75 8.38 9.87E-14 
Fgd3 340.64 8.38 3.91E-39 
Mcub 16.80 8.33 3.30E-10 
Ifit1 28.84 8.31 7.11E-09 
BC053393 698.18 8.28 9.54E-96 
Flt3 40.89 8.23 2.47E-08 
Pde6h 14.67 8.18 1.84E-08 
Entpd1 1317.85 8.15 2.73E-101 
Enpp1 706.96 8.13 4.13E-106 
Hand1 931.51 8.13 3.16E-136 
Ccbe1 41.01 -8.11 3.00E-10 
Wdr72 59.99 8.10 9.73E-11 
Cdh5 1553.08 8.07 1.19E-92 
Duoxa2 52.15 8.06 2.11E-10 
Rhox12 39.77 8.02 7.51E-10 
Tmprss2 1813.23 7.97 4.24E-23 
Epn3 554.62 7.97 4.42E-47 
Tmem171 72.82 7.95 1.89E-23 
Exoc3l4 626.68 7.92 4.32E-74 
Clic5 745.68 7.91 8.05E-41 
Enpp2 75.82 7.88 3.45E-17 
Mettl7b 14.61 7.84 1.94E-08 
Tifa 203.99 7.83 9.07E-44 
Ccrl2 30.03 7.82 1.50E-09 
Osm 156.71 -7.82 1.86E-27 
Mgam 114.36 7.82 6.46E-39 
Pcdh12 570.34 7.81 8.70E-78 
Trpv5 226.27 7.80 5.16E-40 
Mlkl 14.49 7.80 2.46E-07 
Gad2 17.64 -7.80 2.17E-06 
Slc1a2 9.30 7.79 6.00E-08 
Pnliprp2 11.51 7.79 4.31E-07 
Tmigd1 10.22 7.77 1.36E-07 
Dmkn 397.10 7.76 1.89E-50 
Pkp1 40.81 7.76 1.03E-11 
Lgals3bp 623.28 7.75 1.43E-81 
Serpinb9d 22.75 7.73 1.40E-08 
Atp8b1 257.29 7.72 2.88E-59 
Tgm7 7.58 7.71 9.33E-06 
Serpinb9f 90.65 7.70 1.46E-12 
Slc6a14 435.85 7.67 1.05E-56 
Tspan8 544.83 7.67 6.13E-87 
Tmem132e 182.70 7.65 2.25E-10 
Krt18 14620.81 7.64 0.00E+00 
Cd200r2 7.88 7.64 5.43E-05 
Akr1c19 21.27 7.63 2.90E-07 
Wnt5a 172.38 7.62 2.93E-58 
Ptprb 106.42 7.61 2.17E-23 
Psg29 83.41 7.61 1.77E-08 
Jakmip2 7.23 7.56 1.37E-05 
Plac1 513.80 7.52 2.28943E-17 
Igf2os 501.33 7.52 3.55E-99 
Havcr1 171.92 7.52 3.72E-22 
Phox2b 25.60 7.51 6.44E-11 
Slc9a3 12.52 7.50 1.08E-07 
P4ha3 32.18 7.48 1.20E-08 
Metrnl 557.08 7.48 4.84E-74 
Prl2c5 148.85 7.45 7.47E-09 
Alpk1 100.21 7.45 3.12E-26 
Slc16a7 55.56 7.44 3.51E-20 
Kcna6 8.85 7.43 4.38E-06 
Serpinb9e 287.66 7.43 3.96E-42 
Gpr17 21.53 7.41 2.19E-08 
Slc6a2 954.30 7.41 1.39E-28 
Hephl1 12.53 7.41 3.75E-07 
Hemgn 13.19 7.41 3.93E-07 
Tmem252 23.80 7.40 4.97E-10 
Lin7a 6.43 7.40 1.53E-05 
Sp5 328.03 -7.39 4.21E-08 
Chdh 324.99 7.39 1.19E-51 
Pla2g4d 49.99 7.38 7.20E-11 
Mir322 34.63 7.38 7.17E-09 
4930442L01Rik 14.55 7.36 1.85E-07 
Pou4f3 23.30 7.36 2.68E-10 
Chst1 271.64 7.35 5.77E-15 
Vgll1 75.66 7.32 2.96E-22 
Dhrs9 53.14 7.31 2.07E-10 
Gm11190 9.26 -7.31 8.70E-06 
Mfsd6l 18.82 7.31 6.05E-07 
Hcls1 84.50 7.30 2.57E-15 
Thbs1 433.16 7.29 4.45E-57 
Pcdhac2 26.07 7.27 2.71E-10 
Gbp2b 35.28 7.25 2.85E-08 
Prl7d1 119.37 7.24 1.11E-07 
Serpinb1b 10.40 -7.23 1.08E-04 
Hoxb5 7.54 7.21 2.00E-05 
Nxf7 4846.84 7.21 1.69E-30 
Isg15 12.64 7.21 6.94E-06 
Itga2 58.62 7.20 1.05E-07 
Irx4 91.35 7.18 3.10E-32 
Nav3 171.78 7.17 1.60E-34 
1700042O10Rik 19.07 -7.17 1.21E-05 
Krt19 3429.17 7.15 0.00E+00 
Adgra1 7.03 7.15 1.43E-05 
Ccdc184 68.00 7.13 5.96E-16 
Plac8 734.06 7.13 1.70101E-43 
Irf2 74.07 7.13 7.83E-12 
Adh1 385.06 7.12 1.74E-119 
Lyve1 8.32 7.09 1.12E-05 
Kcnj5 9.64 7.09 1.01E-06 
3830417A13Rik 1189.41 7.09 3.12E-92 
Adamtsl3 39.03 7.05 2.21E-14 
Art4 37.56 7.05 3.40E-10 
Plau 253.92 7.04 2.98E-36 
Frmd3 6.00 7.04 4.79E-04 
Hoxa11os 8.35 7.02 2.94E-06 
Klk6 16.82 7.02 4.25E-07 
Sdsl 47.67 7.02 3.39E-07 
Isx 120.35 7.01 7.97E-08 
Hpcal4 68.14 7.00 8.19E-21 
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Oit3 20.29 6.99 7.17E-07 
Nrp1 294.16 6.98 2.62E-83 
Trpc3 43.04 6.96 1.24E-11 
D7Ertd443e 6.17 6.94 1.11E-05 
Hoxb6 32.71 6.94 4.90E-12 
Mir466f-2 10.02 6.93 9.79E-06 
Plppr4 14.35 6.92 2.10E-07 
Mycbpap 110.10 6.90 2.75E-14 
Ifit3 9.93 6.90 6.43E-06 
Gm32591 12.27 6.90 5.05E-07 
Ankrd66 5.75 6.89 4.74E-05 
Ebf3 25.09 6.89 4.67E-09 
Tacstd2 482.67 6.88 3.39E-65 
Chrnd 7.68 -6.88 4.96E-06 
Fbxo32 396.78 6.87 9.50E-95 
Ifit1bl2 5.20 6.86 1.21E-04 
Ptprt 57.57 6.85 2.35E-13 
Ankrd2 16.67 6.84 5.04E-07 
Abca4 425.94 6.83 2.73E-118 
Sct 1334.87 6.82 1.36E-107 
Cryba4 16.59 6.82 2.34E-08 
Jpx 26.94 6.81 2.31E-07 
Slco2b1 28.19 6.80 2.42E-07 
Ifi202b 5.30 6.79 4.01514E-05 
Qrfpr 21.00 6.79 5.56E-07 
Myl4 152.59 6.79 5.84E-18 
Gm10804 9.22 6.78 1.82E-05 
Tnf 8.21 6.78 5.66121E-06 
Zfpm2 6.22 -6.78 9.75E-03 
Scnn1b 192.35 6.76 3.48E-45 
Maf 55.34 6.74 3.21E-11 
Ido1 47.97 6.74 2.79E-12 
Prrx1 4.51 6.74 4.68E-04 
Insm1 8.02 6.73 3.17E-04 
Id2 872.91 6.72 1.43E-101 
Nrk 5505.03 6.72 2.47E-94 
Il2rb 265.16 6.70 1.85E-27 
Dct 4.71 6.69 1.04E-03 
Arhgef6 837.87 6.69 2.4341E-69 
Cd82 1275.04 6.67 2.43E-28 
Cldn11 5.14 6.67 1.22E-04 
Gjb2 729.36 6.66 1.66E-24 
Ccdc194 6.33 6.66 6.47E-06 
Doxl2 12.94 6.65 1.20E-05 
Gsta1 117.38 6.65 4.61E-31 
Nkx2-3 5.58 6.65 5.02E-05 
Fam71f1 8.21 6.65 6.81E-05 
Vnn1 565.60 6.61 6.06E-60 
Ren1 70.99 6.59 9.09E-26 
Tnni1 113.06 -6.59 1.32E-16 
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from D0 to D7) 
Adjusted 
P-value 
Prl2c5 148.85 12.68 1.18E-23 
Ctsll3 128.51 12.39 1.42E-21 
Prl7d1 119.37 12.35 6.16E-20 
Tlx2 246.65 -12.02 1.54E-10 
Serpinb9g 122.46 11.96 6.16E-21 
Fnd3c2 92.94 11.84 6.27E-19 
Psg29 83.41 11.79 1.70E-18 
Prl2a1 71.78 11.61 2.42E-03 
Olr1 343.67 11.54 1.82E-26 
Prl2b1 63.68 11.51 7.98E-19 
Prl7a1 125.62 11.48 7.55E-19 
Ctsr 52.25 11.15 3.45E-03 
Itga2 58.62 11.14 1.16E-16 
BC051665 1518.17 11.11 4.91E-132 
Tmem54 60.96 11.11 1.84E-18 
Tpbpa 49.80 11.06 1.99525E-17 
Pappa2 100.86 11.01 1.97E-18 
Vtcn1 111.64 10.95 3.86E-19 
1600025M17Rik 59.62 10.92 3.25826E-15 
Iigp1 86.62 10.83 2.56E-18 
C1ql2 60.21 10.69 1.47E-13 
Oasl2 68.67 10.63 2.04E-17 
Serpinb9c 100.65 10.59 3.03E-17 
Entpd1 1317.85 10.47 4.74E-159 
Prl3d2 62.03 10.44 8.07E-07 
Flt3 40.89 10.40 5.03E-12 
Cdh5 1553.08 10.35 2.62E-139 
Postn 44.45 10.27 2.06E-15 
Rhox12 39.77 10.27 2.66E-15 
Prl2c2 30.82 10.24 2.32E-11 
Gm4926 269.91 10.22 2.06E-40 
Prl4a1 26.85 10.19 8.66E-03 
Htr5a 80.23 -10.17 2.42E-09 
Scnn1g 34.67 10.01 3.76E-12 
Fthl17a 137.97 9.97 1.51E-20 
Fgd3 340.64 9.95 1.17E-53 
Brinp3 57.99 -9.90 1.49E-09 
Ctsj 696.22 9.86 7.55943E-74 
Prl3d1 150.72 9.84 4.22E-31 
Timd2 149.02 9.80 1.76E-15 
Slc6a2 954.30 9.72 6.94E-47 
Ctsq 21.02 9.72 2.90E-04 
Wdr72 59.99 9.70 6.33E-15 
Serpinb9f 90.65 9.69 3.45E-19 
Pparg 337.77 9.67 3.54E-43 
Ifit1 28.84 9.67 4.20E-11 
Dppa1 739.76 9.59 2.75E-68 
Slc6a14 435.85 9.56 4.08E-85 
Ccrl2 30.03 9.55 1.27E-13 
Prl2c3 67.18 9.54 3.24E-16 
Igf2 6683.27 9.49 1.59E-42 
Serpinb9d 22.75 9.47 4.91E-12 
Clic5 745.68 9.45 8.93E-57 
BC053393 698.18 9.43 7.11E-120 
Prl7b1 15.04 9.42 2.97E-08 
Grem2 61.80 9.41 3.27E-17 
1810065E05Rik 39.41 9.37 5.91E-13 
Epn3 554.62 9.37 1.97E-58 
Exoc3l4 626.68 9.30 1.47E-95 
Plau 253.92 9.24 2.28E-60 
Ceacam15 13.93 9.24 5.77E-03 
Arhgef6 837.87 9.23 3.99E-121 
Il24 13.04 9.19 2.34E-08 
1700086L19Rik 25.33 9.18 7.27E-12 
Cxcr2 110.49 9.16 5.95E-25 
Gpr17 21.53 9.15 4.59E-12 
Serpinb9e 287.66 9.14 7.93E-61 
Tmem132e 182.70 9.14 7.58E-14 
Tacstd2 482.67 9.10 1.23E-107 
Mid2 83.75 9.08 1.26E-15 
Mir322 34.63 9.07 8.37E-13 
Prl5a1 13.55 9.06 1.54E-09 
Acta2 152.19 9.05 2.54E-22 
Procr 381.37 9.05 6.72E-72 
Gbp2b 35.28 9.04 4.03E-12 
Trpv5 226.27 9.04 2.05E-52 
Tmprss4 29.60 9.02 3.81E-12 
Dmkn 397.10 9.02 4.30E-65 
Cts8 11.79 9.01 4.53E-08 
Pcdh12 570.34 9.00 2.77E-96 
Sqor 57.06 8.97 3.29E-10 
Il2rb 265.16 8.96 4.68E-44 
Hcls1 84.50 8.94 5.57E-22 
Gata3 352.57 8.93 3.44E-52 
Metrnl 557.08 8.91 2.23E-98 
Lgals3bp 623.28 8.89 5.26E-99 
Dhrs9 53.14 8.86 1.84E-14 
Mfsd6l 18.82 8.83 3.21E-09 
Hand1 931.51 8.81 1.18E-149 
1700071M16Rik 31.70 8.80 3.82697E-10 
Slc16a2 75.04 8.80 3.57E-12 
Reg3b 51.58 8.78 4.91E-12 
C3ar1 26.05 8.77 8.28E-10 
Doxl2 12.94 8.75 1.40E-08 
Plac1 513.80 8.69 3.20E-19 
Itgb6 46.42 8.67 1.39E-11 
Havcr1 171.92 8.64 1.61E-28 
Plac8 734.06 8.60 2.29E-58 
Dmrtc1a 11.04 8.60 1.41E-06 
Psg22 10.09 8.60 3.89E-08 
Atp2c2 152.57 8.60 1.80E-23 
Gjb2 729.36 8.58 1.92E-33 
Pla2g4d 49.99 8.56 5.13E-14 
Gbp3 22.40 8.54 1.04E-09 
Col3a1 30.39 8.53 1.37E-12 
Adgrf5 1881.06 8.53 1.72E-171 
Csf1r 264.41 8.52 4.06E-60 
Gucy2c 77.86 8.51 7.57E-15 
Mycbpap 110.10 8.50 6.07E-21 
Tnfrsf9 252.02 8.47 6.77E-48 
Chst1 271.64 8.47 4.78E-19 
H19 47988.60 8.45 5.07E-48 
Mmp1a 7.94 8.40 1.82E-06 
Hemgn 13.19 8.40 1.88E-08 
AU021092 10.67 8.36 5.74E-09 
Rsad2 106.21 8.35 4.01E-28 
Mfsd2a 346.99 8.35 1.61E-106 
Qrfpr 21.00 8.35 9.14E-10 
Car4 496.34 8.34 5.27E-52 
Tns4 1966.05 8.33 1.35E-105 
Klk6 16.82 8.32 2.84E-09 
Syna 51.28 8.31 7.93E-19 
Cyp11a1 103.29 8.31 7.95E-06 
Isg15 12.64 8.28 6.01E-07 
Tspan8 544.83 8.27 1.83E-92 
Mettl7b 14.61 8.26 6.66E-09 
Vstm4 86.80 8.26 8.84E-14 
Krt18 14620.81 8.26 2.73E-296 
Hephl1 12.53 8.24 3.32E-08 
Chdh 324.99 8.22 1.75E-60 
Nrk 5505.03 8.22 1.31E-114 
Add2 412.09 8.22 1.67E-48 
Ceacam9 25.53 8.21 2.05E-11 
Enpp1 706.96 8.21 9.81E-106 
Mlkl 14.49 8.20 1.53129E-07 
Duoxa2 52.15 8.19 1.32E-10 
Myo7b 159.37 8.19 2.94E-25 
Cartpt 18.24 8.19 1.63E-07 
Calr4 174.22 -8.16 2.08E-15 
Vgf 157.48 8.13 1.76E-46 
3830417A13Rik 1189.41 8.12 3.22E-103 
Spic 250.50 -8.11 9.73E-29 
Art4 37.56 8.10 5.73E-13 
Tnni1 113.06 -8.10 2.21E-10 
Myl4 152.59 8.07 4.30E-22 
Mcub 16.80 8.07 2.18E-09 
Nxf7 4846.84 8.06 4.10E-31 
Ctla2a 6.84 8.06 1.67E-05 
Irf2 74.07 8.05 4.71E-14 
Dll4 65.00 8.03 5.24E-21 
Tll1 20.09 -8.03 1.79E-06 
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Elf5 245.24 8.02 2.24E-79 
Cd177 28.25 8.01 3.10E-11 
Arhgef37 109.11 7.98 9.11E-26 
Usp18 45.67 7.97 1.71E-16 
Thbd 309.94 7.94 1.10E-97 
Igf2os 501.33 7.93 5.57E-105 
Tmprss2 1813.23 7.92 7.56E-19 
Sod3 17.03 7.92 1.66E-08 
Scnn1b 192.35 7.92 7.50E-59 
Cd82 1275.04 7.92 1.77E-32 
Noxa1 17.80 7.92 3.91E-09 
Jpx 26.94 7.91 1.79E-09 
Entpd8 8.67 7.90 4.10E-07 
Prl6a1 18.06 7.86 2.18E-08 
Pde6h 14.67 7.85 1.81E-07 
Adamts1 73.13 7.82 1.10E-15 
Fasl 38.42 7.82 2.11E-13 
Pla2g7 1376.90 7.78 5.63E-86 
Sbsn 217.13 7.77 2.13E-46 
Mir503 14.56 7.77 3.34E-08 
Krt19 3429.17 7.75 0.00E+00 
Pthlh 21.89 7.75 5.32849E-09 
Slc24a3 47.75 7.74 3.07E-09 
Fam71f1 8.21 7.72 8.11E-06 
Tnf 8.21 7.72 4.35E-07 
Rbbp8nl 12.79 7.71 1.59362E-07 
Tnfaip2 956.90 7.70 4.23E-98 
Atp8b1 257.29 7.69 4.65E-57 
Cd93 7.38 7.69 1.16E-06 
Gm13003 6.81 7.68 1.30E-05 
Chrdl2 14.96 7.67 3.19E-08 
Pkp1 40.81 7.66 3.92E-11 
Gad2 17.64 -7.65 8.57E-05 
Alpk1 100.21 7.64 5.35E-27 
Sct 1334.87 7.64 7.98E-114 
Itga7 1314.14 7.62 1.31E-96 
Ifit3 9.93 7.62 1.30162E-06 
Prom2 44.65 7.61 6.64E-04 
Wnt7a 6.36 7.60 4.32E-06 
Gm10804 9.22 7.55 3.84E-06 
Gm13580 73.47 -7.55 1.12E-11 
Cdk5r2 22.61 -7.52 3.03E-06 
Slc34a2 3213.65 7.52 1.09E-136 
Bgn 93.48 7.52 1.90E-09 
Gsta1 117.38 7.51 3.76E-37 
Krt1 4.56 7.49 2.94E-04 
Irx1 102.52 7.48 5.69E-21 
4930442L01Rik 14.55 7.46 2.56E-07 
Nkx1-2 262.88 -7.40 3.04E-05 
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from D0 to D4) 
Adjusted 
P-value 
Car4 496.34 11.56 6.49E-21 
BC025446 252.14 11.38 2.69E-20 
Gdf6 140.80 11.13 1.79E-18 
Habp2 494.28 11.04 6.43E-37 
Cubn 18054.34 11.00 7.98E-195 
Slc34a2 3213.65 10.92 7.12E-140 
Col6a2 1638.58 10.91 1.62E-61 
Timd2 149.02 10.90 4.00E-19 
Tfec 69.54 10.83 2.60E-16 
Lgals2 126.74 10.61 7.24E-18 
Muc13 518.80 10.56 1.37E-32 
Tlx2 246.65 -10.53 2.83E-11 
Vcam1 120.80 10.46 6.55E-08 
Ttr 55.19 10.12 1.43E-13 
Htr5a 80.23 -10.11 8.08E-13 
Pth1r 3931.10 9.90 0 
Col6a1 3327.32 9.87 1.51E-142 
Slc24a3 47.75 9.81 1.04E-14 
Srgn 5709.38 9.71 0 
Sel1l3 559.43 9.70 9.01E-29 
Serpina3i 56.25 -9.68 2.16E-13 
Ghr 2061.59 9.67 6.51E-130 
Vstm4 86.80 9.63 1.42E-14 
Vsir 4402.44 9.62 3.12E-156 
Il33 818.39 9.60 4.61E-76 
Myl3 408.44 9.54 2.32E-19 
Clic5 745.68 9.53 1.81E-52 
Ihh 365.82 9.48 5.18E-21 
Fcgr2b 53.92 -9.46 7.89E-13 
Brinp3 57.99 -9.43 2.84E-12 
S100g 157.83 9.40 3.76E-27 
Col4a1 230646.30 9.37 1.11E-286 
Enpep 1468.66 9.37 5.74E-125 
1010001N08Rik 169.72 9.34 1.55E-16 
Krt23 62.31 9.29 2.70E-13 
Col4a2 122006.40 9.27 5.02E-262 
Arhgef28 2705.31 9.22 7.09E-187 
Pdgfra 10075.88 9.21 0 
Hkdc1 4455.71 9.21 5.31E-257 
Sp5 328.03 -9.19 5.43E-10 
Foxq1 839.32 9.18 1.75E-16 
Lrrc32 82.24 9.18 3.89E-13 
Atp8a2 585.70 9.15 1.09E-41 
Fgg 32.73 -9.15 1.33E-07 
Nrn1 53.39 9.11 5.81E-13 
Dram1 946.30 9.08 1.27E-91 
Dclk3 74.78 -9.07 5.14E-13 
Wnt9b 52.24 8.99 3.56E-12 
Pik3ap1 377.07 8.96 1.20E-46 
Dab2 3286.32 8.95 8.00E-203 
P3h2 557.02 8.93 1.31E-62 
Zar1 20.22 8.90 1.59E-11 
Aff2 62.05 8.89 2.33E-06 
Dcstamp 31.52 -8.88 5.72E-11 
Crb1 19.29 8.88 2.73E-11 
Ptk6 1847.10 8.87 1.52E-124 
Nxf7 4846.84 8.87 5.40E-46 
Akr1c12 22.57 8.81 3.55E-10 
Mal 420.94 -8.81 7.06E-16 
Adora1 462.51 8.81 1.05E-59 
Plac8 734.06 8.79 1.39E-48 
Bmp2 406.00 8.75 3.26E-46 
Cyp26a1 391.45 8.73 4.79E-67 
Gsc 107.52 -8.70 4.45E-15 
Lgi4 33.08 8.70 1.40E-11 
H19 47988.60 8.63 2.10E-61 
Glipr1 833.88 8.63 4.54E-61 
Frzb 1784.44 8.55 3.09E-128 
Slc39a8 437.11 8.55 3.10E-76 
Ctsh 1061.62 8.54 1.19E-35 
Ugt2b34 846.80 8.52 1.39E-44 
Timp3 3866.32 8.48 1.88E-248 
Hnf1b 488.90 8.43 3.94E-86 
Timp2 14714.37 8.40 1.51E-45 
Gadl1 61.27 8.39 8.24E-10 
Edn3 23.63 8.39 6.42E-11 
Trpm1 509.31 -8.37 8.79E-39 
Slc6a11 17.80 8.34 3.42E-10 
Kctd16 31.99 8.34 1.05E-10 
Lrp2 46455.04 8.34 5.02E-208 
Slc6a2 954.30 8.31 2.17E-31 
Igf2 6683.27 8.30 8.34E-38 
Akr1c19 21.27 8.29 1.60E-08 
Foxa2 761.82 8.29 1.36E-95 
Ccdc33 54.13 8.27 8.58E-11 
Accsl 889.11 -8.27 6.90E-90 
Robo2 67.23 8.23 9.83E-12 
Nkx1-2 262.88 -8.22 3.02E-07 
Hs3st1 1836.68 8.21 4.94E-198 
Plat 4608.26 8.21 0 
Sox17 1603.50 8.20 3.43E-131 
Itgb6 46.42 8.18 1.24E-10 
Gm5535 18.57 8.15 5.98E-09 
Klb 1578.66 8.14 7.22E-154 
BC016579 63.77 8.12 1.45E-10 
Ccdc180 17.85 8.11 1.03E-09 
Arsi 574.81 8.10 2.08E-38 
Aqp1 20.98 8.09 1.57E-09 
Cdh6 200.21 8.05 2.87E-48 
Grrp1 74.45 -8.03 1.48E-12 
Krt42 547.08 -8.02 2.35E-62 
Fthl17a 137.97 8.02 1.37E-10 
Mamdc2 54.33 8.00 2.07E-12 
Bmper 883.55 7.97 1.46E-75 
Enpp2 75.82 7.97 7.11E-09 
2300002M23Rik 18.14 -7.97 2.85E-08 
Nostrin 719.58 7.94 1.75E-143 
Tll1 20.09 -7.92 1.08E-08 
Defb42 17.32 -7.92 6.58E-09 
Sox7 1675.40 7.92 5.19E-168 
Tpbgl 424.59 7.91 1.20E-15 
Myo7a 1362.83 7.91 9.76E-33 
Kcnq5 282.58 7.89 8.58E-31 
Amn 1107.05 7.89 3.32E-149 
Mgat4c 25.27 -7.88 9.75E-09 
Kif12 10.48 7.87 6.91E-07 
Stpg1 35.50 -7.84 1.00E-09 
Tns4 1966.05 7.84 3.80E-112 
Serpinb9e 287.66 7.83 3.66E-10 
Gm805 17.06 -7.82 3.24E-08 
Gm13889 59.68 -7.82 6.56E-10 
Gm5868 9.75 7.81 5.48E-08 
Scn3a 183.65 -7.76 2.12E-28 
Dmkn 397.10 7.76 9.35E-24 
Aqp8 2587.85 7.74 4.14E-27 
Emilin3 6397.03 7.74 1.10E-49 
Fxyd3 95.51 7.73 1.09E-12 
Pramel6 20.28 -7.73 2.57E-08 
St6galnac5 20.18 7.72 1.43E-08 
Klhl34 39.17 -7.72 4.28E-08 
Ramp1 40.05 7.71 6.76E-09 
Chst1 271.64 7.70 4.96E-21 
Kcnk13 12.32 7.70 1.66E-07 
Pcp4l1 36.90 -7.70 2.00E-08 
Lamb1 106034.76 7.69 0 
Pdzd3 268.45 7.68 3.30E-66 
5330411J11Rik 18.86 -7.61 2.01E-08 
Trpm2 222.99 7.60 1.86E-52 
Lypd3 18.02 7.58 1.86E-08 
Bace2 75.86 7.57 8.87E-16 
Lpar3 834.03 7.56 2.06E-102 
Trpc5os 298.83 7.55 8.61E-46 
Kcna2 23.64 -7.55 1.06E-07 
Ifi27l2b 15.74 7.53 2.83E-08 
Olr1 343.67 7.52 6.33E-12 
Pou4f2 13.62 -7.51 2.49E-06 
Ifitm7 13.62 -7.49 1.38E-07 
1600029O15Rik 17.16 7.47 2.63E-07 
T 45.70 -7.46 8.44E-09 
Slc28a2 31.96 7.46 1.82E-08 
Apoa4 33.20 7.45 1.55E-09 
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Slc6a1 213.09 -7.44 5.77E-19 
Acta1 120.10 7.44 1.01E-08 
Ppp1r3d 31.56 7.40 1.13E-08 
Kcng1 372.95 7.39 2.85E-53 
Fgd3 340.64 7.38 3.61E-09 
Nrg2 1029.40 7.38 2.86E-179 
Cpm 1884.99 7.36 1.00E-300 
Igf1 95.27 7.36 2.07E-07 
4921513I03Rik 20.83 7.34 5.85E-08 
Agtr1a 63.24 7.33 1.27E-10 
Pyy 15.81 7.32 9.99E-08 
Prokr2 23.15 7.32 5.53E-08 
Edil3 13.81 -7.32 1.45E-07 
1110002E22Rik 22.51 7.31 2.49E-08 
Pcolce2 307.55 -7.30 2.15E-55 
Cacna1d 482.39 7.28 2.26E-86 
C2cd4a 193.69 7.27 4.54E-56 
Nr2e3 9.74 -7.27 3.13E-05 
Serpinb1b 10.40 -7.27 8.61E-05 
Thsd7b 48.86 7.25 3.51E-09 
Il34 129.21 -7.21 1.99E-18 
Dlx2 14.68 7.20 0.000331798 
Prame 6.26 7.20 2.05E-05 
Ntrk3 181.54 -7.20 2.22E-38 
Plac1 513.80 7.19 8.71E-12 
Mc5r 10.64 -7.18 0.00110486 
Mical2 3292.75 7.16 8.86E-162 
Egflam 354.12 7.16 2.94E-47 
Foxf2 53.48 7.15 1.66E-18 
Frmpd1 1132.18 7.14 1.08E-81 
Rtn1 301.65 7.14 3.75E-51 
Myl9 594.20 7.13 3.13E-38 
Irf4 96.31 7.11 2.33E-13 
4930591A17Rik 26.58 -7.10 3.52E-08 
Hcrtr2 10.01 -7.10 9.68E-06 
Gm3629 15.58 7.07 5.71E-08 
Pcdhb13 5.51 7.06 0.000206034 
Lrrk1 402.38 7.05 1.11E-126 
Cend1 21.72 7.05 3.12E-07 
Arhgap6 828.78 7.04 5.98E-122 
Hsd17b14 244.88 -7.03 2.69E-52 
Creb3l1 863.92 7.02 8.05E-79 
Cwh43 10.95 -7.01 1.31E-05 
Apoa1 40.33 7.00 2.84E-10 
Maml3 832.68 6.99 1.09E-96 
Cdhr2 36.53 6.98 1.50E-12 
Steap4 11.82 6.96 2.63E-07 
Pof1b 27.01 -6.96 1.85E-07 
Cxcl10 8.84 6.96 2.93E-05 
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from D0 to D7) 
Adjusted 
P-value 
BC025446 252.14 12.45 5.54E-24 
Slc15a1 440.42 -12.39 3.18E-15 
Accsl 889.11 -12.15 2.07E-17 
Myl3 408.44 11.71 1.37E-28 
Vcam1 120.80 11.40 3.22E-08 
Slc6a2 954.30 11.38 2.57E-56 
Slc34a2 3213.65 11.26 1.54E-146 
Myom2 174.66 -11.26 2.78E-09 
Sel1l3 559.43 11.24 5.21E-38 
Scn3a 183.65 -11.20 3.14E-13 
Car4 496.34 11.12 2.35E-19 
Col6a2 1638.58 11.11 1.87E-59 
Ugt2b34 846.80 11.07 5.44E-72 
Kbtbd11 160.92 -11.00 9.01E-13 
Gdf6 140.80 10.96 1.16E-17 
Gadl1 61.27 10.91 2.9103E-15 
Etv1 140.26 -10.71 6.06E-11 
Arsi 574.81 10.70 2.19E-65 
Mal 420.94 -10.66 2.3212E-12 
Vsir 4402.44 10.61 4.74E-169 
Atp8a2 585.70 10.61 3.77E-55 
Lemd1 118.57 -10.60 1.46E-11 
Timd2 149.02 10.60 4.03E-18 
Col6a1 3327.32 10.58 1.02E-147 
Ccdc33 54.13 10.57 8.52E-17 
Gsc 107.52 -10.55 6.39E-12 
Col4a1 230646.30 10.51 1.58E-289 
Ghr 2061.59 10.47 1.76E-144 
Krt23 62.31 10.46 2.37E-16 
Frzb 1784.44 10.45 2.10E-184 
Apod 107.56 -10.42 2.16E-11 
Col4a2 122006.40 10.35 1.41E-262 
Gkn1 35.96 10.34 8.36E-13 
Wnt9b 52.24 10.30 2.20E-15 
Muc13 518.80 10.25 2.99E-30 
Padi4 88.36 -10.23 3.19E-11 
Acta1 120.10 10.19 2.69E-15 
Tpbgl 424.59 10.16 6.51396E-22 
Glipr1 833.88 10.15 5.06E-80 
Vstm4 86.80 10.13 7.06E-16 
Arhgef28 2705.31 10.10 4.89E-210 
Stra8 101.56 -10.06 1.41E-07 
Wfdc1 58.20 10.04 2.23E-15 
Srgn 5709.38 10.03 0.00E+00 
Timp2 14714.37 10.01 5.48E-52 
Itgb6 46.42 9.94 4.34E-15 
Hkdc1 4455.71 9.91 8.95E-268 
Ptk6 1847.10 9.91 2.42E-142 
Scn2b 74.79 -9.90 5.59E-09 
Spta1 66.26 -9.85 2.53E-09 
Timm8a2 72.34 -9.80 1.51E-10 
1010001N08Rik 169.72 9.80 1.23E-17 
Ankrd1 183.82 9.77 6.30E-33 
Pth1r 3931.10 9.76 6.33E-305 
Bmp2 406.00 9.71 2.88E-56 
Chst1 271.64 9.71 1.14E-31 
Insyn1 114.21 -9.71 3.62E-10 
Serpina3i 56.25 -9.69 1.30E-09 
Pcsk1 74.63 -9.68 8.11E-10 
Cobl 2006.99 -9.68 1.60E-57 
Enpep 1468.66 9.66 1.02E-126 
Slfn9 317.74 -9.66 7.44E-16 
BC016579 63.77 9.65 2.02E-14 
Myl9 594.20 9.61 1.11E-63 
Fxyd3 95.51 9.52 1.49E-18 
Kctd16 31.99 9.49 2.42E-13 
P3h2 557.02 9.49 1.39E-69 
Lgi4 33.08 9.42 3.36E-13 
Platr17 55.47 -9.40 3.74E-09 
Hs3st1 1836.68 9.39 3.31E-247 
Hsd17b14 244.88 -9.39 3.96E-18 
Cdh2 84.38 -9.38 2.62E-09 
Kcnq5 282.58 9.37 7.71E-41 
Dram1 946.30 9.32 2.16E-92 
Sema6d 861.53 9.31 6.96E-136 
Pdgfra 10075.88 9.29 0.00E+00 
Krt17 41.39 -9.28 3.02E-08 
Slc28a2 31.96 9.28 2.63E-12 
Clic5 745.68 9.28 6.52E-49 
Tnfrsf8 53.51 -9.26 1.43E-09 
Siglecf 42.87 -9.25 5.90E-09 
Smtnl1 44.09 -9.22 9.91E-09 
Plac8 734.06 9.22 1.69E-50 
Lefty2 727.52 -9.22 2.90E-16 
Lpar4 49.76 -9.21 3.96E-07 
Emilin3 6397.03 9.21 6.59E-57 
Lipc 41.74 -9.21 3.02E-08 
Fam19a4 114.53 -9.20 7.51E-10 
Adora1 462.51 9.20 7.94E-64 
4921513I03Rik 20.83 9.20 1.3153E-11 
Nrn1 53.39 9.20 4.75E-13 
Il34 129.21 -9.20 2.67E-09 
Foxa2 761.82 9.14 1.31E-111 
Gm15462 54.49 -9.13 8.67E-09 
Kcnj12 269.34 -9.12 1.68E-16 
Sgo2b 49.15 -9.11 4.33E-08 
Gulp1 156.98 -9.10 4.76E-09 
Aff2 62.05 9.09 5.72E-06 
Zscan5b 46.06 -9.08 5.46E-09 
Tmem169 19.05 9.08 1.30E-11 
Gsg1l 18.52 9.05 8.22E-11 
Adm 83.81 9.05 5.47E-13 
Ttr 55.19 9.04 1.32E-10 
Vtcn1 111.64 9.03 1.69E-13 
Nkx1-2 262.88 -9.02 2.43E-06 
Il33 818.39 8.94 7.28E-62 
Prdm14 718.48 -8.93 1.26E-36 
Lrrc32 82.24 8.93 2.43E-12 
Halr1 50.94 -8.91 9.97E-09 
Irf4 96.31 8.90 1.89E-19 
Dcstamp 31.52 -8.89 5.42E-08 
Acsbg2 37.11 -8.88 1.25E-08 
Habp2 494.28 8.88 5.48E-24 
1700029P11Rik 48.02 -8.87 1.86E-08 
Flt1 738.87 8.86 1.23E-72 
Nxf7 4846.84 8.86 1.20E-37 
Tns4 1966.05 8.84 7.84E-126 
Lpar3 834.03 8.83 1.93E-130 
Nlrp4a 31.37 -8.82 2.85E-07 
Sycp2l 30.93 -8.81 2.96E-07 
Gdf3 1014.14 -8.79 6.34E-69 
Ramp1 40.05 8.78 6.07E-11 
4930502E18Rik 49.11 -8.77 9.38E-08 
Kcng1 372.95 8.75 9.93E-71 
Timp3 3866.32 8.69 2.67E-229 
Rab38 159.80 -8.68 2.20E-12 
Aqp1 20.98 8.68 1.65E-10 
Agtr1a 63.24 8.67 4.14E-14 
St6galnac5 20.18 8.64 3.72E-10 
Tlx2 246.65 -8.63 2.52E-09 
Spic 250.50 -8.63 9.29E-22 
Nanos3 31.93 -8.62 1.60E-07 
Pik3ap1 377.07 8.60 2.97E-42 
Slc27a2 47.18 -8.59 6.42E-08 
Plat 4608.26 8.57 2.7214E-294 
Mical2 3292.75 8.57 9.71E-199 
Jakmip1 785.58 -8.56 1.43E-49 
Mcf2 1734.74 -8.56 3.69E-38 
Cdk14 252.16 8.55 3.29E-39 
Foxn4 35.34 -8.55 3.53E-06 
Stmn3 166.51 -8.54 1.38E-09 
4930519F16Rik 28.73 -8.54 3.99E-08 
Dnajc5g 32.25 -8.53 1.73E-07 
Hdc 261.97 8.52 9.77E-61 
Thbs1 433.16 8.52 2.60E-62 
Tnfaip2 956.90 8.51 7.69E-91 
1600029O15Rik 17.16 8.51 9.65E-09 
Prokr2 23.15 8.50 3.72E-10 
Trpm1 509.31 -8.48 8.39E-29 
Ap3b2 429.44 -8.45 2.44E-27 
1700029M20Rik 24.62 -8.45 1.27E-07 
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Sp5 328.03 -8.44 1.26E-07 
Prmt8 27.38 -8.43 1.73E-06 
Slfn10-ps 28.21 -8.43 7.42E-08 
Hesx1 31.11 -8.43 2.73E-07 
Nanog 12069.85 -8.42 1.18E-102 
Ctgf 4064.78 8.40 0.00E+00 
Bnc2 84.76 -8.39 2.74E-08 
Tmem217 24.68 -8.39 1.74E-06 
Notum 284.36 -8.36 5.17E-19 
Gm10863 26.54 -8.35 1.92E-07 
4930526L06Rik 28.77 -8.35 2.75E-07 
Dmgdh 360.85 -8.34 2.27E-24 
Krt42 547.08 -8.31 4.43E-43 
Sox17 1603.50 8.30 5.09E-117 
Ccnd2 869.75 8.30 1.25E-24 
Tmem132e 182.70 8.28 8.35E-23 
Thsd7b 48.86 8.27 3.96E-11 
Trim54 22.44 -8.25 7.08E-07 
Dlx2 14.68 8.25 1.03E-04 
Creb3l1 863.92 8.25 6.38E-95 
Calr4 174.22 -8.24 5.67E-16 
Gpr88 10.93 8.24 1.19821E-05 
Myh7 78.00 8.24 7.84E-28 
Tmprss2 1813.23 8.23 4.55E-20 
Bche 31.99 -8.22 1.32E-07 
St8sia1 746.13 -8.22 7.7929E-27 
Khdc3 401.58 -8.21 9.52E-37 
Grid2 113.23 -8.20 1.01E-12 
Arhgap6 828.78 8.20 3.52E-152 
Maml3 832.68 8.19 7.26E-129 
Calcoco2 1252.95 -8.18 9.15E-69 
Robo2 67.23 8.16 4.58E-11 
Gm5535 18.57 8.15 1.38E-08 
Trh 2226.84 -8.15 6.51E-11 
Esrrb 10284.46 -8.15 3.63E-133 
Spata31d1a 27.64 -8.11 1.97E-07 
Slc24a3 47.75 8.11 3.31983E-10 
Aqp8 2587.85 8.10 3.58E-24 
1700042O10Rik 19.07 -8.08 2.28E-05 
Osm 156.71 -8.07 1.31E-17 
Lamb1 106034.76 8.07 0.00E+00 
Cacna1d 482.39 8.06 8.12E-100 
Ccdc180 17.85 8.06 2.39E-09 
Cacna1g 71.12 8.06 9.30E-25 
Ihh 365.82 8.06 1.42E-13 
Egfl6 35.75 -8.05 6.74E-07 
Fcgr2b 53.92 -8.03 1.52E-07 
Brinp3 57.99 -8.03 3.10E-07 
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Appendix C 
Reprogramming human cells to naı̈ve pluripotency:
how close are we?
Lawrence E Bates and José CR Silva
Pluripotent stem cells (PSCs) have the potential to revolutionise
biomedical science; however, while it is simple to reproducibly
obtain comparable, stable cell lines in mouse, those produced
from human material typically show significant variability both
within and between cell lines. This is likely due to differences in
the cell identity of conventional mouse and human PSCs. It is
hoped that recently identified conditions to reprogram human
cells to a naı̈ve-like state will produce better PSCs resulting in
reproducible experimental outcomes and more consistent
differentiation protocols. In this review we discuss the latest
literature on the discovery of human naı̈ve-like stem cells and
examine how similar they are to both mouse naı̈ve cells and the
preimplantation human epiblast.
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Introduction
Studies in mouse embryonic stem cells (mESCs) over
many years have led to a detailed understanding of this
cell state. While mouse cells are typically grown in a state
of naı̈ve pluripotency, equivalent to the naı̈ve epiblast of
the preimplantation blastocyst [1], human cells are cul-
tured in primed pluripotency conditions. These are more
similar to the postimplantation epiblast where cells be-
come primed for differentiation [2]. Consequently, there
are significant difficulties in directly applying our knowl-
edge from mouse ESCs to human systems.
There have been several attempts to generate human
naı̈ve pluripotent stem cells (nPSCs) over recent years.
Most often when putative human naı̈ve cells are generat-
ed in vitro they are analysed using criteria that are known
to distinguish mouse naı̈ve cells from primed cells. Such
criteria include responses to extrinsic and intrinsic signal-
ling pathways, the biophysical, biochemical and metabol-
ic status of the cells, and the overall epigenetic and
transcriptomic cell identity. However, recent advances
in our understanding of the human embryo also allow
direct comparisons to the naı̈ve compartment in
vivo. Recently, cells exhibiting human naı̈ve epiblast
molecular features have been described [3,4,5].
Over the course of this review we shall examine how
closely these match the state of both mouse naı̈ve ESCs
and what is known of the human blastocyst.
Transcriptional identity
The transcriptional identity of a cell is often considered to
be a readout of the cell’s state (Figure 1, part 1). However,
it is clear that the transcriptional state of cells is plastic,
and a range of genes fluctuate in response to intracellular
and extracellular conditions. Historically, it has not been
practical to get a large number of high quality human
embryos, necessary to obtain replicates of transcriptomic
data with sufficient depth. Also, such embryos may be
compromised as they have to be cultured in vitro in order
to generate blastocyst-like embryos. Importantly, recent
advances in RNA sequencing, particularly protocols for
small cell numbers and even single cell sequencing, have
made the analysis of these embryos possible.
Using such techniques, Yan et al. [6], and more recently
Blakeley et al. [7], obtained single-cell transcript data from
human embryos including late blastocyst stage embryos.
Yan et al. observed four distinct cell types by unsupervised
clustering which appear to represent two trophectoderm
populations as well as extra-embryonic endoderm and
epiblast cells based on their expression of known marker
genes, as expected in a mature blastocyst. However, both
studies identified only a handful of epiblast cells, giving a
fairly small sample size for further analysis.
Comparing the human naı̈ve induced pluripotent stem
cells (hniPSCs) of Takashima et al., the embryo derived
human naı̈ve ESCs (hnESCs) from Guo et al. [5], the
embryonic naı̈ve epiblast cells from Yan and from Bla-
keley, as well as mouse nESCs and conventional primed
human ESCs, it is clear that the hniPSCs and embryo-
derived hnESCs cluster closely together [5]. This indi-
cates that they share a transcriptional identity. Notably,
the human naı̈ve-like cell lines cluster closer to mouse
ESCs than to human blastocyst cells along a principle
component of variation. It is possible that this separation
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is the result of generic adaptation of cells to in vitro
culture. Interestingly, established human primed lines
are separated from primed epiblast outgrowths along this
same axis.
Theunissen et al. took a different approach to comparing
their datasets to published human embryo data. They
identified genes that are expressed in specific embryonic
stages in the dataset of Yan et al. They then looked for the
proportion of these genes that were differentially
expressed between their hniPSCs and conventional
primed hESCs. While genes specifically expressed in
embryonic epiblast were enriched in the hniPSCs, so
were genes specific to the morula and all other cell types
of the late blastocyst [8]. This is surprising, since unsu-
pervised clustering of all single cells in the study by Yan
et al. [6] indicated that these are well defined states, with
epiblast cells segregating well from other cells of the
blastocyst. As stated by Theunissen et al. [8], this may
indicate that their hniPSCs are in an earlier embryonic
state, perhaps before full segregation of the inner cell
mass. By analysing the expression of transposable ele-
ments, they found striking similarities between their cells
and morula blastomeres. Interestingly, recent work from
Petropoulos et al. [9] suggests that the segregation of
lineages occurs relatively late in human embryos, with
co-expression of lineage-specific genes throughout the
morula. The three lineages only begin to segregate on the
onset of blastocyst formation.
Transcription factor network
At the core of the naı̈ve cell identity in mouse ESCs is a
highly interconnected transcription factor network which
shows remarkable redundancy [10,11] (Figure 1, part 2).
Whereas the complete transcriptome may not be identical
between cell lines and across passages, these factors are
always expressed in naı̈ve cells. They are also functionally
conserved across a range of vertebrates in their ability to
drive induction of naı̈ve pluripotent stem cells [12–14].
Additionally, many of these factors are specific for nPSCs
compared to primed post-implantation epiblast derived
stem cells (EpiSCs) [2] making these a good subset of
genes to use as markers of a naı̈ve state. Takashima, Guo
and Theunissen all investigated a panel of these genes
and found that most were upregulated in their putative
hniPSCs and hnESCs relative to primed cells
[3,4,5]. Neither ESRRB nor KLF2 were upregulated
in any of these naı̈ve lines; however, this may be due to
differences between primate and rodent and the redun-
dant use of paralogue genes such as Klf4 [1,4,7]. It is
interesting, however, that both Takashima and Theunis-
sen were able to efficiently induce a naı̈ve-like state
through exogenous expression of KLF2 alongside
NANOG. Takashima elegantly demonstrated that the
behaviour of the transcription factor network in his
hniPSCs closely corresponded to that of mouse ESCs
with a knockout and rescue strategy. Mouse ESCs can
support the single loss of either Esrrb or Tfcp2l1 due to
redundancies in the network [15,16], but it was expected
that double knockout would lead to network collapse and
subsequent differentiation [4]. Accordingly, shRNA
depletion of TFCP2L1 in hniPSCs resulted in greatly
reduced colony formation, indicating that most cells
had stopped self-renewing. Application of exogenous
ESRRB during this knockdown was able to rescue self-
renewal. Together this provides strong evidence that an
interactive transcription network highly similar to that in
mouse is active in these cells.
Exogenous ligands and intracellular signalling
landscape
A broad array of signalling pathways interact to maintain
or destabilise the naı̈ve state in mouse ESCs (Figure 1,
part 3). These cells are able to self-renew in the absence
of external signals providing that certain pro-differentia-
tion pathways are blocked, namely the MEK/ERK
MAPK signalling axis and the GSK3b pathway which
would otherwise destabilise the network in part through
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(Figure 1 Legend Continued) has a self-sustaining network of transcription factors with many positive feedback loops to promote the
maintenance of pluripotency. Notably, while many of these transcription factors are still expressed in primed cells, the network conformation is
different, with factors binding to different enhancer elements and thus interacting in different ways. By exploring these interconnections, it is
possible to test whether putative human naı̈ve cells share the same connectivity and hence whether the network exists in a naı̈ve configuration.
(3,4) Environmental signals are key to maintaining cell states. In mouse, the naı̈ve state can be maintained in vitro with LIF which activates
downstream JAK/STAT signalling, an inhibitor of MEK/ERK signalling downstream of the FGF receptor, and an inhibitor of b-catenin degradation.
The current human naı̈ve culture conditions extend this with addition of a PKC inhibitor [4], or BRAF, SRC and ROCK inhibitors [3]. In addition
to the response to ligands, cells interact physically with their neighbours and the extracellular matrix. Strong adherens junctions between cells
provide the familiar dome-shaped morphology of naı̈ve ESC colonies, and the ability to sense neighbours appears to be important for cell survival.
(5) The epigenetic fingerprint of cells can be analysed in a similar manner to the transcriptional identity to build up a global picture of the cell
state. Enhancer and promoter usage result in modification of histones and differential methylation of DNA. These profiles can be compared
between cells. Additionally, the naı̈ve state has additional epigenetic properties, such as global DNA hypomethylation and retention of imprinting
marks which should be found in human naı̈ve cells. (6) A key feature of the naı̈ve state in female mouse cells is the presence of two active
X-chromosomes. While the exact connection between naı̈ve identity and X-chromosome status is still elusive, this is considered a hallmark of the
naı̈ve identity. While aspects of X-chromosome regulation differ between mouse and human, recent embryo work suggests that the human
preimplantation epiblast shares this feature with mouse. (7) Many other elements of the cell are controlled by the cell state. One example is the
switch between aerobic and anaerobic respiration. The naı̈ve compartment of the embryo is considered to be facultatively aerobic, displaying
relatively mature mitochondria, whereas other early embryonic cell states rely on anaerobic glycolysis for most of their energy requirements. While
the cause of this switch is unknown, it is likely to be the result of integrating many other state-specific signals.
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its role in the degradation of b-catenin [17]. However,
these conditions are not optimal and extrinsic signals that
enhance pluripotency and survivability are often added to
the culture. Most common, is the LIFR/GP130 ligand
LIF which activates the JAK/STAT pathway [18,19].
This is typically included with inhibitors of GSK3b
and MEK to give chemically defined 2i LIF medium.
This enhances the efficiency of induced naı̈ve pluripo-
tency [17,20] and maintains mouse naı̈ve PSCs in a state
closely resembling the naı̈ve epiblast of the pre-implan-
tation embryo [1,17,20].
Given the importance of LIF and downstream JAK/
STAT signalling in reprogramming and maintenance of
mouse naı̈ve PSCs [21,22] and its ability to induce human
cells with some naı̈ve-like properties [23,24], it was sur-
prising that Theunissen et al. [3] found hLIF to be
dispensable for culture of their hniPSCs. Indeed their
microarray data (publically accessible on the GEO data-
base, accession GSE59435) indicates that LIFR expres-
sion is fourfold lower in naı̈ve cells than in their parental
primed cells. In addition, Takashima et al. [4] show that
LIFR is expressed at a far lower level in hniPSCs than in
mouse ESCs. While LIF signalling is a key feature of the
mouse blastocyst and is important for survival in diapause
[25], it is also known to be important in the process of
implantation in both mouse and humans [26,27]. Further
work will be required to test whether JAK/STAT signal-
ling is indeed an important component of the human
naı̈ve state.
In mouse, Fgf2 and Activin A are both used to support the
undifferentiated growth of primed EpiSCs [2,28,29],
while Fgf signalling leads to differentiation of naı̈ve
ESCs and Activin signalling is dispensable [17,29–31].
While the current human naı̈ve cells can be maintained in
the absence of FGF and Activin [3,4], Theunissen
et al. identified increased differentiation on their double
inhibition [3]. Notably in mouse, following activation
by LIF stimulation, JAKs activate PI3K and the AKT
signalling pathway [32]. This appears to have a role in
ESC self-renewal, with cells treated with a PI3K or PDK1
inhibitor showing reduced proliferation and increased
multi-lineage differentiation [33,34]. The PI3K/AKT
pathway is known to be activated downstream of both
FGF and Activin A/TGFb signalling in various contexts
[29,35,36], but most interestingly FGF2-induced AKT
activation has been demonstrated in conventional
primed human ESCs, where it is proposed to boost cell
survival [37]; in this manner, FGF/Activin could be
beneficial to the human naı̈ve-like state in the absence
of sufficient LIF signalling to induce the AKT signalling
cascade.
Given the poor survival of hniPSCs Theunissen et al. [3]
found it necessary to maintain these with ROCK inhibi-
tor. While ROCK inhibitor was found not to be strictly
required by Takashima et al. [4], it was used in combi-
nation with their t2iL+Gö in feeder-free culture and
embryo derivation [4,5]. In mouse, poor survival on
single-cell passaging is a more common trait in primed
cells [2], which can be similarly rescued with application
of ROCK inhibitor [38]. The precise manner in which
ROCKi contributes to the enhancement of self-renewal is
not clear. It appears that following single-cell dissociation,
loss of focal adhesions between cells leads to activation of
RHO/ROCK signalling. This results in enhanced actino-
myosin contractility which induces apoptosis [39,40]. The
improved proliferation observed while culturing the
hniPSCs in the presence of ROCKi may suggest that
they are not responding appropriately to cell-cell and cell-
substrate contacts (Figure 1, part 4). In mouse, a switch
from E-cadherin expression in naı̈ve ESCs to N-cadherin
in primed EpiSCs has been observed [41,42]. Examina-
tion of the microarray data from Theunissen et al. reveals a
decrease in N-Cadherin on transition to the naı̈ve state;
however, both N-cadherin and E-cadherin are expressed
in primed human ESCs, and there is no further increase in
E-cadherin in the naı̈ve cells [8]. It could be interesting
to examine other cell contact-sensing pathways such as
YAP/TAZ signalling to see if they are compromised.
Interestingly, it has been suggested that overexpression
of YAP promotes the reprogramming of human primed
cells to a naı̈ve-like identity [43].
Epigenetic fingerprint
Another distinctive feature of most cell states, and par-
ticularly the naı̈ve state, is the epigenetic landscape
(Figure 1, part 5). In mouse ESCs cultured in 2i LIF,
there is a remarkable genome-wide reduction in DNA
methylation which is also observed in vivo [44–46]. It has
been unclear until recently whether this should also be
expected in humans [47,48]. However, recent work sug-
gests that DNA methylation shows the same trend in
human as in mouse [49]. In line with this, Theunissen,
Guo and Takashima all identified a decrease in global
DNA methylation [4,5,8], on the order of that ob-
served in human embryos [49]. Beyond this global de-
crease, however, there are signs that DNA methylation
may not be properly regulated in these cells. Imprinted
loci are specifically marked by methylation on one of
the parental chromosomes. Stable imprints are retained
throughout development and can still be found in differ-
entiated cells. Importantly, they are observed in primed
human ESCs. On conversion to naı̈ve conditions, how-
ever, many of these marks are lost [50], which is an
issue as this is linked to poor differentiation in vitro
and shows links to developmental disorders and tumour-
ogenisis [51].
Another epigenetic property of mouse naı̈ve ESCs is the
absence of a silent X-chromosome in females resulting in
the presence of two active X-chromosomes (Figure 1,
part 6). On fertilisation, the paternal X-chromosome is
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specifically inactivated [52] and is only reactivated in the
naı̈ve epiblast at the blastocyst stage [52–55]. Shortly after
implantation of the embryo a random X-chromosome is
inactivated [56]. There has been some debate over the
state in human blastocysts [57,58], but recent evidence
shows that they do have two active X-chromosomes [9].
In the early human female blastocyst, cells exhibit twice
the amount of X-linked gene expression compared to
counterpart male embryo cells [9]. However, despite
maintaining biallelic expression as the blastocyst devel-
ops further, transcription of X-linked genes is downregu-
lated, a phenomenon termed ‘dampening’ of the X-
chromosome [9].
The status of the X-chromosome in female primed cells
has also been somewhat contentious [59–61]. Primed cells
have undergone X-inactivation, and there is no reactiva-
tion when reprogramming human somatic cells to primed
iPSCs [61]. However, over prolonged culture of primed
pluripotent cells, a phenomenon of erosion of X-inactiva-
tion can be observed [60–62]. It appears that expression of
Xist, the master regulator of X-inactivation, becomes
epigenetically silenced resulting in the subsequent acti-
vation of genes on the formerly inactive chromosome.
This makes the presence of two active X chromosomes in
primed human ESCs an epigenetic abnormality rather
than a molecular feature of biological significance.
Recently, it was shown that in the reprogramming of
human primed cells to a naı̈ve-like state the silent X-
chromosome reactivates [8,63]. Despite exhibiting bial-
lelic expression, it was found that X-linked gene expres-
sion was not twice that of the cells of origin which
contained a silent X chromosome [63]. Instead it resem-
bled the ‘dampening’ phenomenon observed in vivo in
very late human blastocysts [8,9,63]. Upon differentia-
tion there was inactivation of the X chromosome. How-
ever, this was non-random and therefore not reflective of
the process that occurs during development.
Together, these studies indicate that there are epigenetic
differences between current human nPSCs, their in vivo
counterpart, and mouse ESCs.
Conclusion
By the majority of measures, the most up to date culture
systems have produced human pluripotent cells with
similarities to both mouse naı̈ve ESCs and to the human
preimplantation epiblast. Nonetheless, there are still
significant discrepancies. The signalling pathways active
in these cells and the transcription factor network they
support, appear to be very similar to, yet far less stable
than, their equivalents in mouse ESCs. It is currently not
possible to say whether the reduced stability of the
human naı̈ve state is due to interspecies differences,
suboptimal culture conditions, or the possibility that
we have not yet isolated bona fide human nPSCs.
Evidence from Takashima and from Guo show that
their naı̈ve cells have undergone metabolic reprogram-
ming, showing a significant level of mitochondrial respi-
ration (Figure 1, part 7) [4,5]. This is typically
associated with mature blastocysts, with cells before
and after this stage relying more heavily on anaerobic
respiration and displaying less mature mitochondria
[64,65]. Additionally, naı̈ve cells show increased glyco-
lytic metabolism, inhibition of which appears to reduce
their proliferation, demonstrating that the high level of
metabolic activity is important to the maintenance of
these cells [66]. On the other hand, some transcriptional
data suggest that the culture systems may favour a less
mature embryonic state. Finally, several issues such as
reduced viability in single cell passaging and genomic
instability could indicate suboptimal conditions for cell
growth.
Interestingly, recent papers have identified novel hPSCs
with broader chimerism and differentiation potential
than naı̈ve or primed cells. These respectively demon-
strate the ability to form interspecies chimaeras and the
ability to differentiate into both embryonic and extra-
embryonic lineages in vivo [67,68]. The latter cells ex-
press naı̈ve marker genes but show also an expression
signature that is not similar to any embryonic cell type.
Further characterisation of the novel human PSCs is now
needed to ascertain their full properties and molecular
signatures.
The next major hurdles in establishing hnPSCs as the
standard for in vitro studies will require demonstrating
superior differentiation potential and reliability compared
to conventional human ES cultures, and methods to
simplify the generation and culture of these cells. By
identifying cell surface markers specific to hnPSCs, Col-
lier et al. [69] present a step forward in facilitating the
establishment of naı̈ve cultures, as well as potentially
allowing the study of reprogramming intermediates to
dissect this interesting transition.
While the conditions for differentiation protocols may
need to be optimised for these new cells, it will be
important to learn whether the promises of more homo-
geneous, less cell-line dependent differentiation from a
naı̈ve starting population can be delivered. If so, then this
cell state could take over to become the accepted stan-
dard starting point for drug discovery models, in vitro
developmental studies, and possibly advances in cell
therapies.
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